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Chapter 1 
Introduction: a review on CXCR3, small CXCR3 ligands and their 
clinical potential 
Abstract 
The CXCR3 chemokine receptor was discovered in 1996 and has 
been shown to play an important role in several diseases, most of 
which are related to inflammation. This chapter describes in detail 
the development of small CXCR3 ligands and their therapeutic 
potential. Classes of CXCR3 antagonists with strikingly variable core 
structures have emerged. Some of these compounds have confirmed 
the beneficial role of CXCR3 antagonism in animal models of disease. 
One of the compounds, AMG 487, progressed to Phase II clinical 
trials but has been withdrawn due to lack of efficacy. New antagonist 
classes are being developed in order to reveal the full therapeutic 
potential of CXCR3. 
Chapter 1 
Introduction 
Chemokines are peptides of 70 to 90 amino acids in length which exert important 
signaling functions in the body. Chemokines are classified into two main subfamilies 
based on whether the first two of four conserved cysteines are adjacent (CC) or 
separated by one amino acid (CXC).1 The chemokine peptides signal via membrane-
bound chemokine receptors, whose nomenclature is based on the class of chemokines 
they bind, i.e. CC or CXC chemokine receptors (CCR and CXCR, respectively). The first 
chemokine receptor was reported in 1991 after the discovery that the chemokine 
interleukin-8 (now named CXCL8) binds to a class A G protein-coupled receptor 
(GPCR).2,3 Chemokine receptors show less than 30% homology with all other known 
GPCRs and are major modulators in the immune system where they affect e.g. migration 
of leukocytes. Besides their role in inflammatory processes, the role of chemokine 
receptors in organogenesis, angiogenesis and the central nervous system, but also in 
metastasis and growth of tumor cells has become apparent.4,5 Therapeutic interest in 
chemokine receptors boosted in 1996 with the finding that chemokine receptors CXCR4 
and CCR5 are coreceptors for human immunodeficiency virus (HIV).6-9Several chemokine 
receptors have since attracted interest from the drug discovery community.10-12 This 
review will describe one of the promising emerging drug targets of this class, namely the 
CXCR3 receptor, and will outline all CXCR3-associated medicinal chemistry disclosed to 
date in scientific and patent literature. 
CXCR3 and peptidergic ligands 
The CXCR3 chemokine receptor was discovered in 1996 during a search for T 
lymphocyte-specific chemokine receptors. A novel cDNA was isolated from a human 
CD4+ T cell library and the encoded GPCR proved to have affinity for chemokines.13 A 
truncated version of this clone, with an incomplete coding sequence, was already isolated 
in 1995.14 CXCR3 consists of 368 amino acids which, as with all GPCRs, are oriented in a 
typical seven-transmembrane -helical topology. This is illustrated in detail by the 2D 
snakeplot in Figure 1. Typical structural motifs for GPCRs such as the conserved DRY 
motif and the NPxxYx5,6F motif at the cytoplasmatic ends of transmembrane domains 3 
and 7 respectively are present, as well as cysteine residues in the first and second 
extracellular loops.15 Similar to most receptors of the chemokine subfamily of GPCRs,16
CXCR3 has additional cysteine residues in the aminoterminus and third extracellular loop. 
The threonine and serine residues in the intracellular carboxyl-tail are potential sites for 
phosphorylation by receptor kinases.13,17
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Figure 1. Snakeplot of CXCR3. The typical seven-transmembrane -helical topology of 
GPCRs is shown, with an additional proposed helix (helix 8) in the membrane proximal 
part of the intracellular carboxyl-terminus, based on the structure of rhodopsin. Residues 
that are highly conserved between GPCRs of class A are shown as black residues.15 These 
residues are N1.50, D2.50, R3.50 in the DRY motif, W4.50, P5.50, P6.50 in the WxP 
motif and P7.50 in the NPxxYx5,6F motif. In this GPCR numbering according to 
Ballesteros and Weinstein, the first number refers to the transmembrane helix and the 
second number indicates the position of the most conserved residue, which is assigned 
position 50 in that helix. Residues N-terminal from the most conserved residue at 
position 50 are designated with lower numbers, e.g. Asp148 is assigned D3.49 etc. The 
use of this Ballesteros-Weinstein numbering simplifies the identification of residues at 
similar positions between different GPCRs. The presumed disulfide bond between 
cysteines in the first and second extracellular loops is shown, as well as potential 
palmitoylation of the cysteine in the carboxy-terminus that anchors helix 8 to the 
membrane.
Activated Th1 lymphocytes express high levels of CXCR3, but the receptor is also found 
on blood T cells and on a small proportion of B cells and natural killer cells.13,18,19 CXCR3 
binds the endogenous CXC chemokines CXCL9, CXCL10 and CXCL11, which before the 
introduction of the systematic nomenclature1 were called monokine induced by 
interferon-gamma (Mig), interferon-gamma inducible 10-kD protein (IP-10) and 
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interferon-inducible T cell alpha chemoattractant/interferon-gamma-inducible protein 9 
(I-TAC/IP-9), respectively.13,20-23 Additionally, CXCL13 has been reported to bind and, at 
high concentrations, activate CXCR3.24 Chemokine CXCL4 was shown to bind a splice 
variant of CXCR3 with an extended amino-terminus called CXCR3-B25, and recently also 
the original CXCR3 (CXCR3-A) has been reported to mediate CXCL4-induced responses at 
high concentrations.26 CXCR3 activates pertussis toxin-sensitive G proteins of the Gi
class upon activation by chemokines, and mediates chemotaxis, calcium flux and 
activation of kinases such as p44/p42 MAPK and Akt.13,17,27
While it is common for chemokines to bind several chemokine receptors, this promiscuity 
is usually restricted to receptors of the same class, i.e. CXC chemokines generally bind 
only to CXC receptors. An intriguing exception may be found for CXCR3: agonists of 
CCR3, e.g. CCL13 and CCL11, bind with high affinity to CXCR3.21,28 In one study CCL11 
blocked CXCR3 activation,21 although two other studies did not confirm this finding.28,29
This leaves the question open if CCR3 ligands are true endogenous antagonists of CXCR3 
in vivo, or that they may interfere with CXCR3 signalling through other means. 
CXCL9, CXCL10 and CXCL11 are all CXCR3 agonists with CXCL11 having the highest 
potency and efficacy.13,20-23,30 Typically, the NH2-terminus of chemokines is important for 
receptor activation. After binding of a chemokine to the NH2-terminus and extracellular 
loops of a chemokine receptor, the NH2-terminus of the chemokine is believed to interact 
with yet to be identified domains of the receptor, resulting in activation.31,32
Consequently, deletion or addition of only a few NH2-terminal amino acids of the 
chemokine often changes it from an agonist into an antagonist.32-34 Indeed, NH2-terminal 
truncation of CXCL11 (CXCL11 4-73) barely affects CXCR3 binding affinity, but results in 
complete loss of agonist activity.35 Similarly, when the first five amino acids of CXCL10 
are deleted and a methionine is added, a potent CXCR3 antagonist is obtained.36
Interestingly, the endogenous CXCR3 ligands can be processed in vivo by cellular 
proteases to give chemokines with modified activity. After NH2-terminal proteolytic 
processing of CXCL10 and CXCL11 by CD26 (dipeptidyl peptidase IV), the chemokine 
metabolites lose their CXCR3-mediated chemotactic activity and calcium signalling, while 
retaining their ability to bind to CXCR3 albeit with reduced affinity.37,38 CD26-processed 
CXCL10 inhibits chemotactic responses of CXCR3-expressing cells towards intact CXCL10, 
illustrating that NH2-terminal processing of CXCL10 produces a natural CXCR3 
antagonist.38
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CXCR3 as a potential drug target 
The general “druggability” of chemokine receptors remains a subject of discussion. 
Despite the reputation of GPCRs as popular drug targets39 no antagonists targeting any 
chemokine receptors have reached the market yet except for HIV entry inhibitors.11 On 
one hand, this may be due to the relatively recent discovery of chemokine receptors. On 
the other hand, there has been ongoing discussion about the applicability of such 
antagonists considering the redundancy of the chemokine system. The notion that most 
chemokine receptors bind more than one chemokine and most chemokines bind to 
several chemokine receptors clearly complicates the prediction of the therapeutic effects 
of chemokine receptor antagonists. It is therefore encouraging that specific roles for 
various chemokine receptors in disease models are emerging.40 Indeed, based on the 
upregulated expression of CXCR3 and its ligands, CXCR3 has been implicated in a variety 
of inflammatory diseases. These include multiple sclerosis,41 rheumatoid arthritis,18
atherosclerosis,42 chronic obstructive pulmonary disease,43 inflammatory bowel disease,44
inflammatory skin diseases22,45 such as psoriasis,46 hepatitis C infected liver,47
sarcoidosis,48 and SARS.49,50 CXCR3 also appears to be a key factor in the rejection of 
donor organs after transplantation.51,52 Moreover, CXCR3 appears to play an important 
role in metastasis of melanoma and colon cancer cells to the lymph nodes and in 
metastasis of breast cancer cells to the lung.53-55 Last, for certain HIV virus strains and 
isolates, CXCR3 may act as a coreceptor.56
Various preclinical approaches have been used to confirm the therapeutic potential of the 
CXCR3 receptor system: (1) the generation of CXCR3 knockout (KO) mice, (2) targeting 
CXCR3 or its endogenous ligands by antibodies, (3) inhibiting CXCR3 by means of 
protein-based antagonists, and (4) targeting CXCR3 by small molecules. The first three 
approaches will be briefly highlighted below, while approach (4) is the topic of the next 
section.
Use of CXCR3-KO mice 
CXCR3-KO (CXCR3–/–) mice appear phenotypically normal in the unchallenged host,51,57,58
although a deficiency in NK cells in the lung and peripheral blood has been reported. 
Moreover, a reduction of natural killer (NK) and NK T cells in the liver is observed, 
indicating that CXCR3 is required for NK and NK T cell homeostasis.59 In murine models 
of transplant rejection, CXCR3–/– mice showed delayed acute or chronic rejection of 
cardiac allografts51 or pancreatic island allografts.60 In some cases, allografts were even 
maintained chronically in CXCR3–/– mice, especially in combination with the 
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immunosuppressive drug cyclosporine A.51 Using CXCR3–/– mice, it was shown that 
CXCR3 is involved in skin wound healing, although CXCR3 is not a critical factor.57
Antagonism of CXCR3 signalling is suggested to leave less scarring of the skin, whereas 
agonism of CXCR3 may result in more rapid maturation of the skin compartments.57
Studies on CXCR3–/– mice also revealed that CXCR3 plays a critical role in the positioning 
of effector T cells at sites of viral inflammation in the brain58 and in limiting lung fibrosis 
following lung injury.59
Targeting of CXCR3 or its endogenous ligands by antibodies 
CXCL10-antibodies attenuate chronic experimental colitis by blocking cellular trafficking 
and protecting intestinal epithelial cells, a finding relevant in diseases like ulcerative 
colitis.61 Notably, a Phase II clinical trial has been launched to investigate a CXCL10 
antibody (MDX1100) in treating ulcerative colitis.62 In addition, similar to the CXCR3–/–
models mentioned above, the use of an antibody directed against either CXCR3 or 
CXCL10 significantly prolongs allograft survival, sometimes even with administration 
taking place several days after the transplantation.51,60,63-65 Moreover, an antibody 
directed against CXCR3 not only reduced T cell recruitment to inflamed arthritic joints in 
a rat model of arthritis, but also prevented weight loss by the animals and decreased the 
severity of arthritis in general.66 The CXCL10 antibody MDX1100 (vide supra) will also be 
investigated in a Phase II trial for rheumatoid arthritis.62 Last, a CXCL10-antibody 
suppressed metastasis of melanoma cells to the lymph nodes in mice.53
Although targeting of one or more of the CXCR3 ligands with antibodies appeared 
beneficial in certain models,67 targeting CXCR3 appears a more straightforward way to 
treat the condition since this abrogates the effects of all three chemokines at the same 
time. Indeed, deletion of either CXCL9 or CXCL10 alone in a mouse model of obliterative 
bronchiolitis did not affect T-cell recruitment into the allograft, whereas deletion of 
CXCR3 did.68
Targeting of CXCR3 by protein antagonists  
The strategic use of protein-based antagonists (e.g. chemokine analogs) has confirmed 
some of the key roles presented so far. In a mouse model for skin inflammation, 
CXCL11-based antagonists reduced swelling of the skin in response to a sensitizer.69
Such antagonists also inhibited neuroinflammation in mice implanted with the neurotoxic 
CXCR3-binder SDF(5-67).70 Administration of CXCL10-based protein antagonists to mice 
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reduced the progression of autoimmune sialadenitis, which relates to the inflammation of 
the salivary glands as observed in Sjögren’s syndrome.36
Targeting of CXCR3 by non-peptidergic CXCR3-antagonists 
Figure 2 shows that publications on small CXCR3 ligands first emerged around 2002 with 
increases occurring over subsequent years. As there is only a handful of speculative 
therapeutic indications for CXCR3 agonists (vide supra), virtually all the reports deal with 
antagonists. The CXCR3 antagonist area has been reviewed before.71, 72 The current 
review provides the developments in this area up to early 2008. Below, all known classes 
of CXCR3-antagonists will be discussed with accompanying medicinal chemistry and 
available (pre)clinical data. In all cases, affinity or activity numbers are accompanied by 
the reference chemokine and/or the type of assay used (if reported) and, unless 
specified, human CXCR3 was used in these assays. 
Figure 2: The number of 
publications that has appeared on 
structure-activity studies of small 
CXCR3 ligands per year. Numbers 
were obtained by detailed searches 
with SciFinder Scholar and PubMed 
and do not include conference 
reports. Date of acceptance was 
used.
TAK-779 and naturally occurring non-peptidergic antagonists 
Besides the frequently used method of screening corporate collections, two other venues 
have afforded CXCR3 hits. First, the known CCR5-ligand TAK-779 (1)10 attracted some 
interest from the CXCR3 community as it proved to bind mouse CXCR3 as well (IC50=369 
nM,125I-CXCL10).73 However, despite showing efficacy in rodent models involving CXCR3, 
CCR5 and CCR2,74-77 the moderate affinity of TAK-779 for CXCR3 and its poor selectivity 
profile have rendered it only of limited value to CXCR3 research as a whole. Secondly, 
various natural products were found to bind CXCR3. Merck performed a screen (125I-
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CXCL10) on a library consisting of extracts from microbial, plant and marine sources.78 A 
highly diverse set of hits was picked up, including sugar-derivatised steroid 2 (IC50=470 
nM) and dipyridinium salt 3 (IC50=690 nM). 
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Figure 3. Structures of TAK-779 and some naturally occurring binders. 
(Aza)quinazolinones – from bench to clinical trials 
The companies Chemocentryx and Tularik, later acquired by Amgen, teamed up to 
develop small (aza)quinazolinone-based CXCR3 antagonists leading to an array of 
patents with the first one appearing in 2001.79,80 Compound 4 was retrieved as a 
moderate hit (IC50=250 nM, 125I-CXCL10) from a High Throughput Screening (HTS) 
campaign, but it displayed unacceptable pharmacokinetic properties.81 Studies on 4
identified the decanoyl and dimethylamino group as major metabolic culprits.81 However, 
replacement of the decanoyl chain in 4 by other hydrophobic groups initially led to 
compromised affinity.81,82 Later, it was discovered that a biphenylmethylene group (6) or 
an isostere with a p-CF3 (7) or p-OCF3 group (8) could be successfully introduced.81 With 
improved hit 7 in hand, the dimethylamino-group was investigated. Other groups, such 
as a 3-pyridylmethyl (9) and 2-ethoxyethyl (10), served as effective substitutes.81 In 
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many compounds, the 4-F group be successfully exchanged for a 4-CN group.80 For 
example, applying such an exchange on compound 9 gave maintained affinity,81 whereas 
for 4 it was found to give a three-fold boost in affinity (i.e. 5, VUF5834).82 The affinity of 
9 could be improved further by substituting the 4-F atom by a propargyl or ethoxy 
group.80,81 Eventually, the pharmacokinetically more attractive 4-ethoxy substituent was 
combined with the CF3O-substituted phenylacetamide moiety to deliver 11 (IC50=6 nM,
125I-CXCL10). While seeking an increase in polarity of compound 11, an N-atom was 
introduced in the Ph-ring of the quinazolinone to give azaquinazolinone 12 (IC50=8 nM,
125I-CXCL10).80,81 Compound 12, dubbed AMG 487, contains one chiral centre which has 
the (R)-configuration. This configuration is important for affinity, since the (S)-
enantiomer is less efficient.83 AMG 487 is currently the most studied member of the 
azaquinazolinone class. In addition, a more active 4-F,3-CF3 analogue (13, NBI-74330) 
from the same patent80 was independently studied by researchers from Neurocrine and 
UCB (Ki=1.5 nM, 125I-CXCL10).84,85
The (pre)clinical properties of NBI-74330 and AMG 487 have been extensively studied. 
NBI-74330 inhibits CXCL11 in [35S]-GTPS binding (IC50=10.8 nM), Ca2+ mobilization 
(IC50=7 nM) and chemotaxis (IC50=3.9 nM).84 The antagonism of human CXCR3 is non-
competitive, i.e. the maximum signal induced by CXCL11 (Emax) was dose-dependently 
reduced by NBI-74330 with notable reductions already visible at 3 nM ([35S]-GTPS). Our 
group has confirmed non-competitive antagonism on human CXCR3 by NBI-74330, 
amongst other antagonists.86 Non-competitive antagonism for NBI-74330 is also reported 
on murine CXCR3 (pA2=8.35, CXCL11, [35S]-GTPS), but in a less pronounced manner.85
Here, NBI-74330 induced a rightshift in the EC50 at low and high concentrations, but only 
a significant reduction in Emax at high concentrations (1 M).  
Like NBI-74330, the structurally related AMG 487 exhibits non-competitive antagonism.86
It inhibits CXCR3-mediated cell migration (IC50= 15 nM, CXCL11) as well as Ca2+
mobilization (IC50=5 nM, CXCL11).81 Interestingly, in addition to this antagonism of the 
original CXCR3 (CXCR3-A), AMG 487 also inhibits CXCL4 and CXCL11-mediated 
responses through the alternatively spliced variant CXCR3-B.26 The compound displays a 
greater than 1000-fold selectivity for CXCR3 versus a panel of other receptors, including 
11 chemokine receptors.87 Compared to initial HTS hit 4, AMG 487 has lower clearance 
(1.6 and 1.1 L/h/kg, 0.5-1.0 mg/kg i.v. in rats and dogs, respectively) and an improved 
bioavailability (12-57 and 85 %, 2.0-2.5 mg/kg orally in rats and dogs, respectively).81
The safety profile of AMG 487, as assessed by various genotoxicity and cardiotoxicity 
assays, revealed no major concerns.83 The two main metabolic pathways for AMG 487 
involve CYP3A4-mediated oxidation of the pyridine N-atom to the N-oxide (14) and de-
ethylation to phenol 15. Metabolite 14 efficiently binds CXCR3 (IC50=6 nM, 125I-
CXCL10)83 and has also been patented.88 The Area-Under-the-Curve (AUC) ratio of 14 vs 
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AMG 487 varies from 0.03 to 0.6 in various animal studies.83 Recent studies on analogue 
NBI-74330 have shown that this ratio also depends on the mode of administration. 
Higher exposure of NBI-74330 over N-oxide was achieved by oral dosing, while 
subcutaneous (s.c.) dosing led to about equivalent exposures.85 It may be expected that 
similar dependences on administration hold true for AMG 487. 
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Figure 4. Structures of first generation (aza)quinazolinones and some metabolites. 
Studies with NBI-74330 and AMG 487 in animal models reveal that this azaquinazolinone 
class of CXCR3 antagonists bears clinical promise in a variety of diseases. The ability of 
AMG 487 to inhibit inflammatory cell migration in vivo was confirmed in a mouse model 
of bleomycin-induced cellular recruitment, where AMG 487 significantly reduced 
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infiltration of macrophages and lymphocytes into the lungs with infiltration levels being 
as low as in CXCR3-KO mice (3 mg/kg sc).83 In a mouse model for idiopathic pneumonia 
syndrome (IPS), AMG 487 reduced recruitment of donor T cells to the lung after 
allogeneic stem cell transplantation, leading to improved survival rates.89 Likewise, 
reductions in inflammation, pannus formation and cartilage damage were observed upon 
administering AMG 487 at doses up to 50 mg/kg s.c. in mouse collagen-induced arthritis 
models.90 Interestingly, NBI-74330 gave rise to reduction in lesion formation in models 
for atherosclerosis by the inhibition of effector cell migration to the atherosclerotic plaque 
and by regulating the local immune response.91 Last, as outlined earlier, metastasis of 
breast cancer was identified as a possible therapeutic area. This was substantiated by the 
inhibiting effect of AMG 487 on lung metastasis in a murine model for metastatic breast 
cancer.54
The preclinical studies convincingly paved the way for clinical studies on two 
inflammation-related diseases: psoriasis and rheumatoid arthritis. In 2003, results of a 
Phase I trial on AMG 487 were disclosed. The compound was assessed for safety and 
pharmacokinetics in 30 healthy males in a randomized, double blind, placebo-controlled 
dose-escalation study. Generally, the compound was well tolerated and adverse events 
were mild to moderate (25 to 1100 mg doses).92 In a subsequent Phase IIa trial, patients 
suffering from psoriasis received 50 or 200 mg of AMG 487 or placebo orally once a day 
for 28 days. Disappointingly, no significant differences in the endpoints (Psoriasis 
Severity Index or Physician Global Assessment scores) were seen between patient 
groups. It was speculated that this lack of clinical efficacy may result from high variability 
in drug exposure.93 Metabolic studies with healthy humans provided a plausible 
explanation for such variability.94 Of key relevance were the two metabolites 15 and 14, 
the latter being formed through CYP3A4. The studies revealed that 15 was a relatively 
potent (5 M) and time-dependent inhibitor of CYP3A4, leading in turn to variable 
formation of the major metabolite 14. In 2004, it was announced that Phase II trials with 
AMG 487 on patients with rheumatoid arthritis were to be initiated.95 The current status 
of these trials is unknown. 
It comes therefore as no surprise that the latest lead optimisation efforts on AMG 487 
have aimed at replacing the metabolically liable pyridine ring, ethoxy group and 
azaquinazolinone core.96-98 The described N-oxidation can be blocked through 
replacement of the pyridine ring by a sulphone-group. Likewise, metabolic de-ethylation 
can be circumvented by replacing the ethoxy group with a cyano-group.97,98 Changing the 
azaquinazolinone bicyclic core for a wide variety of heterocyclic groups (16) was 
tolerated and sometimes beneficial, leading to the hypothesis that the rigid bicyclic core 
serves as a scaffold to hold the adjacent groups in the correct orientations.98 These 
structural replacements differentially affected binding to plasma proteins and the overall 
11
Chapter 1 
effects had to be balanced. This led to the identification of 17 which compared to AMG 
487 had similar affinity but reduced clearance (0.24 L/h/kg, 0.5 mg/kg i.v. in rat).98
However, compounds in this class of pyrido[1,2-a]pyrimidin-4-ones appear to suffer from 
CYP-induction mediated by the Pregnane X receptor. It was reported that optimisation to 
structure 18 could counteract this unwanted effect.96 Another effective replacement of 
the azaquinazolinone core is an imidazole group (19) substituted at the 4-position (R2)
with a lipophilic group.97 Although affinities could be kept in the low nM range within this 
class, it presented its own metabolic hurdle: substantial addition of glutathione to the 
imidazole ring. This was elegantly overcome by installing electron-withdrawing groups on 
the 5-position of the imidazole ring (R1 in 19) as exemplified by compound 20 (IC50 = 18 
nM, 125I-CXCL10), although clearance levels remained inferior to those of 17 (20: 2.2 
L/h/kg, 0.5 mg/kg i.v. in rat). 
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Piperazinyl piperidines 
Schering-Plough has filed many patents describing a piperazinyl piperidine-scaffold 
flanked by a substituted benzyl unit and a polar headgroup (general structure 21).
Notably, many compounds of this class have subnanomolar affinities (e.g., 22, 23, 24:
Ki=0.2 nM, 125I-CXCL10).99-101 Upon inspection of the best compounds, the (S)-
configuration of the ethyl-substituted carbon is maintained and R1 and/or R2 in 21 are 
often halogens or halogenated groups, suggesting crucial roles for these moieties. No 
functional data has been disclosed. 
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1-Aryl-3-piperidin-4-yl-ureas 
UCB has designed CXCR3 antagonists based on an initial rigid piperidinyl-urea scaffold 
(general structure 25). A HTS campaign using a FLIPR-based calcium flux assay led to 
the identification of hit 26 (Ki=110 nM, [35S]-GTPS). This compound was reported to 
have poor solubility (0.1 g/mL).102  Replacement of the cyclooctenyl ring by a variety of 
highly lipophilic substituents mostly afforded Ki values higher than 10 M. A fortunate 
exception was the naturally occurring (–)myrtenyl group  which  gave  a  compound  with 
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similar affinity as 26.102 With the (–)myrtenyl group in place, extensive structural 
variation of the aromatic group was performed in order to optimise affinity and drug-like 
properties. Several compounds were identified that had better affinities ([35S]-GTPS)
and improved physicochemical properties compared to hit 26. This can be clearly 
illustrated by compound 27 (Ki=16 nM, solubility 23 g/mL). N-Methylation of 27 to a 
quaternary ammonium salt was allowed for CXCR3 interaction while it further increased 
solubility. However, the resulting compounds suffered from reduced membrane 
permeability.102,103 In order to improve the in vivo pharmacokinetic properties of 27, two 
approaches were followed. In the first approach, the urea group was replaced by a 
hydantoin or imidazolinone group as well as by a modelling-inspired switch to a 
benzazole or aryl azole.104 None of these alternative linkers surpassed 27 in affinity, but 
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several gave increased microsomal stability and low CYP inhibition. For example, 28
displayed low clearance (2.8 mL/min/kg) and a long plasma half-life (5.4 h). A second 
and seemingly more successful approach focused on the spacer and (–)myrtenyl group in 
27.105 Hundred compounds with myrtenyl-replacements were prepared, revealing a 
terminal piperidinyl-amide (29) as an entry into pharmacokinetically more favourable 
compounds. Subsequent modelling studies suggested that a homotropenyl-amide would 
spatially better resemble the myrtenyl group in 27 than an unsubstituted piperidinyl-
amide in 29. Concomitant focus was placed on preventing the central amino-piperidine 
unit from being oxidised in vivo. Interestingly, modelling revealed that, once again, a 
tropanyl unit would do just that by bridging the ring. Thus, an exo-tropanyl central core 
and homotropenyl peripheral unit were combined to deliver 30. Compared to 27, this 
compound is slightly more potent (Ki= 7 nM, [35S]-GTPS) but is cleared less rapidly (7 
L/min/mg), boosts a similar solubility (40 g/mL) and has a high bioavailability (70 %). 
Notably, a high selectivity for CXCR3 in a panel of 50 receptors was disclosed for 30.105
With the novel (homo)tropanyl-type structural elements at hand, replacement of the urea 
group was revisited.106 This resulted in the discovery of quinoline-based antagonists 
(31). Compared to 30, one isopropoxy-substituted member (32) has comparable affinity 
(Ki= 5 nM, [35S]-GTPS) and higher solubility (1280 g/mL at pH=6.5), but at the same 
time an increased propensity to bind plasma proteins. Quinoline 32 was tested for its in 
vivo properties where it showed good oral availability (t1/2=7.6 h, 30 mg/kg p.o in mice) 
and dose-related inhibition of CXCR3 internalisation.85 At 100 mg/kg, an effect on CXCR3 
internalisation was observed up to 24 h post-dose. 
4-N-aryl-[1,4]diazepane-ureas 
Pharmacopeia researchers screened over 4 million compounds (90 libraries)107 using a 
FLIPR-based calcium mobilization assay.108,109 This HTS screen led to the discovery of 
various antagonist scaffolds.108 The general structure of one disclosed class is 
represented by 33. The phenethyl substituent benefits from halogen substitutions, most 
particularly a 3,5-dichloro pattern. A similar preference for a 3-chloro (but also 3-fluoro) 
substituent was observed for the benzamide moiety. Replacement of the azepane spacer 
or the urea unit by different groups led to a dramatic drop in affinity. The combined SAR 
studies resulted in the discovery of 34 as a potent CXCR3 antagonist (IC50=60 nM, 
CXCL11, Ca2+).108 The compound was capable of inhibiting chemotaxis (IC50  100 nM, 
CXCL11). No cytotoxicity at 100 M was observed while high selectivity over 14 other 
GPCRs was noted.  
15
Chapter 1 
Figure 8. Structures of 4-N-aryl-[1,4]diazepane-ureas and 2-imino-benzimidazoles.
2-Imino-benzimidazoles 
Researchers from Abbott Laboratories recently disclosed 2-imino-benzimidazoles as 
CXCR3 antagonists.110,111 The initial HTS hit, a substituted 2-acetyl-1H-
benzo[d]imidazole, as well as several first-generation derivatives gave reasonable 
affinities (IC50=2 – 20 M, 125I-CXCL10) but suffered from solubility problems in aqueous 
buffer. This complicated the pharmacology as it gave apparent partial antagonism. A 
strategic substitution of the 2-acetyl-benzimidazole core by a 3-methyl-2-imino-
benzimidazole moiety (general structure 35) afforded not only much improved solubility 
but also higher affinities. Variation of the benzophenone substituent (R2) in this scaffold 
showed that 4-halo substituents gave submicromolar affinities. Upon selection of the 4-Cl 
group, the effect of ring substituents at the benzimidazole core (R3) was investigated. 
The most notable improvements in affinity resulted from installing small, apolar 
substituents at the C4 position (36: IC50=100 nM, 37: IC50=30 nM / 125I-CXCL10).
Whereas this represented an 8- and 27-fold boost in affinity for 36 and 37 compared to 
the unsubstituted counterpart (R=H), the corresponding boost in functional antagonism 
was an interesting 113- and 129-fold, respectively (36: IC50=80 nM, 37: IC50=70 nM / 
CXCL10, Ca2+). Compound 36 was evaluated for its in vivo pharmacokinetic properties, 
where it showed a t1/2 of 4.9 h and a bioavailability of 57 % upon oral dosing in mice (10 
mg/kg). 
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Bipiperidines  
Researchers from Janssen have devised compounds centered around the 3,4’-bipiperidine 
scaffold (38).112,113 One of the N-termini was linked to an amide or urea group (3,4'-
bipiperidine-amides and -ureas), or carbonyl groups were included in one of the 
piperidine rings (3,4'-bipiperidine-2,6-diones). The scaffolds were decorated by Ph-rings, 
with ring halogenation often appearing to be a privileged manipulation. Exemplary 
compounds from all three series are represented by structures (R)-39, 40 and (R)-41
(IC50=79, 50 and 32 nM, CXCL11, [35S]-GTPS). Within this class of compounds, the (R)-
configuration seems generally preferred, which can be deduced from selected affinities of 
(S)-isomers reported in the same patents ((S)-39: IC50=251 nM, (S)-41 IC50=6310 
nM).112,113 Two piperidine rings were also the essence of a patent filed by Amgen, but 
there the connection was established through a spiro-fusion (42). This novel scaffold was 
discovered after a screening of Amgen’s chemical library.114 The compounds were 
decorated with a fused indole and halogenated aromatic rings. Compounds 43-45 all had 
IC50 values < 500 nM as reported in the patent.115
Ergolines 
A rather unusual type of CXCR3 antagonist was patented by Novartis (46).116
Replacement of the N-Me group of LSD by an N-phenylcarbamate moiety afforded 
compound 47. It exerts good binding (IC50=54 nM, 125I-CXCL11) and blocks Ca2+
mobilization (IC50=18 nM, CXCL11) as well as chemotaxis (IC50=74 nM, CXCL11). Slight 
improvements could be achieved by certain replacements of the diethylamide moiety. For 
example, morpholine-containing compound 48 has an IC50 of 23 nM (125I-CXCL11) but 
otherwise similar functional properties as 47. This class of compounds successfully 
reduced vessel wall remodelling after allotransplantation in murine models.116 This is to 
our knowledge the first SAR report on ergoline-type compounds for a chemokine 
receptor, although these are known as promiscuous GPCR ligands, binding on e.g. 
various dopamine-, serotonine- and adreninergic-receptors.117
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Figure 9. Structures of various bipiperidines.
Various 
A handful of additional different scaffolds for CXCR antagonists have been disclosed in 
patents but often with little pharmacological data. As a result, no clear SAR can be 
deduced. To offer the reader the fullest overview possible, we show here the general 
structure of these scaffolds as deduced from inspecting of all structures.  
Charged imidazolium salts (49) were reported by SmithKlineBeecham researchers.118
One such compound (50) has a Ki-value of 251 nM (125I-CXCL10).86 This group also 
disclosed camphor-containing antagonists of structure 51, which had potencies up to 10 
nM (CXCL10, Ca2+).119 Three patents from Merck describe a substituted piperidinylamide 
linked by its C-4 position to a substituted Ph-ring through a heteroaromatic spacer such 
as a thiazole or pyridine (52).120-122 Reported IC50 values were as low as 0.5 nM 
(CXCL10, chemotaxis). 
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Figure 11. Structures of CXCR3 agonists.
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Non-peptidergic CXCR3-agonists 
Intuitively, development of agonists for inflammatory chemokine receptors does not 
seem attractive from a therapeutic point of view.123 However, CXCR3 may offer an 
intriguing exception. One study suggests that CXCR3 agonism is beneficial in skin wound 
healing (vide supra).57 Moreover, the CXCR3 agonists CXCL9,124 CXCL10125 and 
CXCL11126 have been shown to possess anti-tumor activity, which is attributed to the 
recruitment of leukocytes by these chemokines. Therefore, topical application of a CXCR3 
agonist may have beneficial effects in these specific cases. 
In itself the task of designing a small non-peptidergic activator for any chemokine 
receptor seems daunting. Nevertheless, a handful of agonists for chemokine receptors 
other than CXCR3 has already been found in recent years.127-129 CXCR3 agonists were 
disclosed by researchers from Pharmacopeia in 2006. In an HTS screen for antagonists of 
a pool of more than 4 millions compounds, they identified a few CXCR3 agonist 
chemotypes.109 Three exemplary compounds (53-55) were described in detail.109 All 
three show structural similarities: a basic amino acid, a hydrophobic group and an N-
containing bicyclic unit. Notable differences include the lack of a benzopropione unit in 
55 and the opposite stereochemistry of the amino acid in 55 compared to 53 and 54.
Compounds 53-55 activate CXCR3 (EC50=3.3, 1.1 and 1.7 M, respectively / Ca2+ influx) 
with high efficacies (120, 120 and 100 % of that of CXCL11, respectively). Activation by 
the agonists was dose-dependently inhibited by antagonist 34, indicating specific CXCR3-
mediated effects. This was further illustrated by lack of binding to a panel of GPCRs, 
including six chemokine receptors. Importantly, 54 and 55 were able to stimulate 
chemotaxis of T-cells in vitro (no results for 53 disclosed).
Modulation of CXCR3 by non-peptidergic ligands. General considerations. 
Structural elements 
The diversity amongst the CXCR3 antagonists described in this review is quite high and a 
general pharmacophore model seems difficult to construct. Indeed, to date no such 
models have been proposed in the public domain. Basic or charged groups are often 
thought to be beneficial for chemokine receptor affinity. While a good deal of the 
discussed antagonists possesses permanent charges or basic groups poised for 
protonation at pH 7.4, more and more emerging ligands lack a highly basic group (see 
18, 34 and 47). Also of importance is that non-competitive CXCR3 antagonism occurs in 
a structurally diverse set of compounds.84-86 Given the huge structural and spatial 
differences between the small antagonists and large chemokine, their binding sites are 
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likely different. Precedence for such differential binding of chemokine ligands can be 
found for e.g. TAK-779, which was shown to bind CCR5 in a cavity between 
transmembrane helices 1, 2, 3, and 7 rather than at the extracellular domain.130 Lastly, 
CXCR3 antagonists of different structural classes have been shown to act as inverse 
agonists at a constitutively active mutant of CXCR3, namely CXCR3 N3.35A.86
A recurring and highly important issue in drug research is the translation of animal 
models to human studies. Chemokine research represents no exception to this. In fact, 
mouse knock-in models for e.g. CXCR2 have been specifically constructed to circumvent 
problems related to species-differences.131 Another illustration involves TAK-779, which 
has a 100-fold higher affinity for human CCR5 than for mouse CCR5, complicating 
interpretation of the results from murine studies.73,132 A careful inspection of all available 
results on CXCR3 points towards some species differences, caused by differences in the 
protein sequence of CXCR3 from various species. Compound 27 has affinities of 16 and 
227 nM for human and murine CXCR3 ([35S]-GTPS),102 respectively, whereas some 
compounds of the related later-stage tropanyl class reveal a 3-4 fold preference for 
human CXCR3.105 A systematic study on other antagonist classes (AMG 487, NBI-74330, 
5 and 50) shows a similar 4-fold higher affinity for human and rhesus macaque CXCR3 
compared to rat or mouse CXCR3.86 Clearly, there is a slight CXCR3 species difference 
but it is believed that it does not represent a serious hurdle for future CXCR3 drug 
discovery efforts. 
(Pre)clinical effects 
Inhibiting the recruitment of inflammatory cells is at the heart of the clinical rationale for 
developing CXCR3 antagonists. Animal models using AMG 487 and NBI-74330 suggest 
that this rationale bears fruit. That is, CXCR3-related therapeutic effects have been 
observed in a general model for in vivo recruitment of inflammatory cells83 as well as in 
more specific models for idiopathic pneumonia syndrome,89 arthritis90 and 
atherosclerosis.91 Unfortunately, no beneficial effect was observed with AMG 487 in Phase 
IIa trials on psoriasis. This clinical failure may have been due to pharmacokinetic rather 
than pharmacodynamic properties. Clinical promise of CXCR3 antagonism therefore 
remains to be confirmed by newer generations of compounds. 
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Conclusion 
This review has dealt with the different aspects of CXCR3 as a drug target with emphasis 
on the potential of small, non-peptidergic ligands to therapeutically modulate the 
receptor. After a relatively slow start, more and more ligand classes are steadily 
disclosed by the drug discovery community. The structural variability amongst these 
classes is strikingly high. One quest for antagonists has left researchers with the first 
series of small molecule CXCR3 agonists, which will undoubtedly prove useful as research 
tools. For the antagonists, the highest affinities are found for the piperazinyl piperidines 
of Schering-Plough. In contrast, the best described series are the 1-aryl-3-piperidin-4-yl-
ureas from UCB and most notably the Amgen class represented by AMG 487 and NBI-
74330. Positive preclinical results with the latter two CXCR3 antagonists have 
strengthened the therapeutic expectations for CXCR3 antagonism. Unfortunately, a Phase 
IIa clinical trial with AMG 487 has been halted. Since this may have been due to 
unacceptable variability in drug exposure, it is clear that this failure is not a falsification 
of CXCR3 as a drug target per se. Indeed, clinical promise for the CXCR3 system is 
illustrated by the recent announcement of two Phase II clinical trials investigating a 
CXCL10 antibody in treating ulcerative colitis and rheumatoid arthritis.62 In all, CXCR3 
target validation in humans still remains the ultimate and elusive goal and it is expected 
that ongoing medicinal chemistry efforts will soon shed more light on the therapeutic use 
of small CXCR3 ligands.  
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Chapter 2 
Scope of this thesis  
The gene for the chemokine receptor CXCR3 was first cloned in 1996. The protein was 
identified as the endogenous receptor for the chemokines CXCL9, CXCL10 and CXCL11. 
Over the years, potential implications of CXCR3 in a variety of inflammatory diseases and 
in cancer have been studied and clarified to a certain extent. Recently, some controversy 
regarding the role of CXCR3 in transplant rejection has emerged. Nevertheless, it is 
thought that CXCR3 inhibition represents an appealing target for developing new classes 
of compounds that may be used both as pharmacological tools and as potential new 
drugs.
As described in chapter 1, the only compound that is currently known to have progressed 
to Phase II clinical trials (AMG 487) showed a lack of efficacy in that setting and hence 
did not proceed to the next development stages. Therefore, there is a need for new 
antagonist classes that may aid in fully clarifying the therapeutical potential of CXCR3. 
In 2002, at the start of the studies described in this PhD thesis, many publications on the 
role of CXCR3 and its biogenic ligands CXCL9, CXCL10 and CXCL11 were already 
available describing e.g. expression studies. However, very little was disclosed on the 
design and synthesis of small non-peptidergic ligands for CXCR3 (see Figure 2 in Chapter 
1), and the only known information was restricted to a few patent reports. 
The aim of the research described in the following chapters was to synthesize and 
pharmacologically evaluate structurally diverse antagonistic ligands for CXCR3 in order to 
obtain a better understanding of the structural requirements necessary for antagonism 
on this receptor. Several approaches were followed, including classical SAR studies, 
pharmacophore models and the concept of bivalent ligands. 
Chapter 3 describes the synthesis and pharmacological evaluation of a series of 3-
phenyl-3H-quinazolin-4-one derivatives for their action as CXCR3 antagonists. A CXCR3 
antagonist abstracted from a patent was used as the starting point for the development 
of high-affinity CXCR3 antagonists. The use of SAR studies led to the identification of a 
compound with 3 times higher affinity. 
Chapter 4 reports on the synthesis and structure activity relationship of 3H-pyrido[2,3-
d]pyrimidin-4-ones and their link with the 3-phenyl-3H-quinazolin-4-one series described 
in Chapter 3. The evaluation of the afforded class of compounds confirmed NBI-74330 as 
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a highly efficient, nanomolar CXCR3 antagonist and set the stage for a deeper 
pharmacological evaluation of this important tool (Chapter 6). 
In chapter 5, the synthesis of a series of imidazolium compounds and their affinities at 
CXCR3 are reported. This new class of compounds was identified after a pharmacophore 
model development and an optimization of a database screening, followed by a ‘merging’ 
approach with a patented CXCR3 ligand scaffold. 
Chapter 6 deals with the molecular mechanism of action of diverse small molecule 
antagonists at the CXCR3 receptor. Additionally, this chapter reports on the behaviour of 
small CXCR3 ligands at species different from human. Also, a constitutively active mutant 
of CXCR3 was used which led to the identification of inverse agonistic properties of these 
small molecules. 
In chapter 7, preliminary steps towards the use of dimeric ligands for CXCR3 are 
illustrated. This was based on the emerging concept of receptor dimerization. Bivalent 
derivatives of the 3H-pyrido[2,3-d]pyrimidin-4-ones series (Chapter 4) as well as of the 
3-phenyl-3H-quinazolin-4-one series (Chapter 3) have been synthesized and evaluated 
for their affinity and antagonistic activity at CXCR3. 
 
 
Chapter 3 
Synthesis and structure-activity relationship of 3-phenyl-3H-
quinazolin-4-one derivatives as CXCR3 chemokine receptor 
antagonists 
Adapted from:  
Stefania Storelli, Pauline Verdijk, Dennis Verzijl, Henk Timmerman, Andrea C. van de 
Stolpe, Cornelis P. Tensen, Martine J. Smit, Iwan J. P. De Esch and Rob Leurs  
Bioorg. Med. Chem. Lett. 2005, 15, 2910 – 2913 
 
 
 
Abstract 
 
A series of 3-phenyl-3H-quinazolin-4-ones has been synthesized and 
tested for affinity and activity at the chemokine CXCR3 receptor 
using radioligand binding. The most potent compound, decanoic acid 
{1-[3-(4-cyano-phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]-ethyl}-
(2-dimethylamino-ethyl)-amide (1d), has been further evaluated in 
functional assays with CXCR3-expressing cells. Compound 1d 
efficiently inhibited CXCR3 induced phospholipase C activity and 
calcium mobilization. Moreover, in CXCR3 expressing human primary 
T cells, 1d completely abrogated CXCR3-mediated actin 
polymerization and chemotaxis, while migration towards CXCR4-
ligand CXCL12 was not affected. Compound 1d is a useful tool for 
further characterization of the CXCR3 receptor. 
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Introduction 
 
Chemokines constitute a superfamily of small secreted proteins that attract and activate 
a variety of cell types. They are classified by structure according to the number and 
spacing of conserved cysteine residues into four major groups (CC, CXC, CX3C and 
XC).1,2 Chemokine receptors are defined by their ability to signal on binding of one or 
more members of the chemokine superfamily of chemotactic cytokines. All of them 
belong to the family of G protein-coupled receptors (GPCRs).3,4 
The chemokine receptor CXCR3 is mainly expressed on activated T cells and natural killer 
cells and binds CXCL9 (monokine induced by IFN-; Mig), CXCL10 (IFN--inducible 
protein 10; IP10) and CXCL11 (IFN--inducible T cell -chemoattractant; I-TAC/IP9).5-9 
Exposure of cells expressing CXCR3 to CXCL9, CXCL10 and CXCL11 leads to the 
activation of phospholipase C (PLC) followed by an increase of intracellular calcium via 
activation of Gi proteins.10,11 Furthermore the agonists binding to CXCR3 expressed on 
human T cells determines a rapid and transient increase in filamentous actin (F-actin) 
and chemotaxis towards the chemotactic gradient.10,11 Increased expression of CXCR3-
targeting chemokines is observed in chronic inflammatory diseases (rheumatoid 
arthritis,12,13 multiple sclerosis,14 hepatitis C-infected liver,15 atherosclerosis16 and chronic 
skin reactions10,17,18) and is associated with the infiltration of CXCR3-positive T-cells. 
The involvement of CXCR3 in the pathophysiology of the Th1-type diseases suggests that 
CXCR3 may serve as a new molecular target for anti-inflammatory therapies.19,20 
For further characterization of the receptor and for validating CXCR3 as a viable drug 
target, the development of small, non-peptidergic CXCR3 ligands is essential. In patent 
literature, it has been suggested that decanoic acid (2-dimethylamino-ethyl)-{1-[3-(4-
fluoro-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-y]-ethyl}-amide (1c) (Figure 1) is a 
CXCR3 ligand with micromolar affinity.21 
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Figure 1. Structure of decanoic acid (2-dimethylamino-ethyl)-{1-[3-(4-fluoro-phenyl)-4-
oxo-3,4-dihydro-quinazolin-2-y]-ethyl}-amide (1c)  
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We set out to explore the SAR of this compound. More specifically, the role of the nonyl 
chain of lead structure (1c) was investigated. In addition, the 4-phenyl ring substituent 
effect on the biological activity was evaluated.22 
Chemistry 
 
The 3-phenyl-3-H-quinazolin-4-ones 1a-n were prepared according to Scheme 1. 
Reaction of 2-amino-benzoic acid with propionyl chloride gave 2-propionylamino-benzoic 
acid (2) (76% yield). Treatment of this intermediate with phosphorus trichloride and the 
appropriate substituted aniline gave compounds 3a-h in moderate to good yields (35-
75%). Reaction with bromine gave the intermediates 4a-h (60-80% yields) that were 
used for the subsequent reaction with the commercially available N,N-dimethyl-ethylene-
diamine. The crude oils were readily purified by flash chromatography giving the 
corresponding key derivatives 5a-h (5-80% yields). Reaction with decanoyl, 
cyclohexanecarbonyl, benzoyl or naphthalene-1-carbonyl chloride afforded compound 
1a-h and 1j-n (15-85 % yields). The methoxy group of 5b and 1b was converted to a 
hydroxy moiety by treatment with boron tribromide23,24 to give compounds 5i and 1i, 
respectively, in low isolated yields (10-15%). 
 
 
Pharmacology 
 
The affinities of compounds 1a-n, 5a-f and 5i for CXCR3 were assayed by testing their 
ability to displace [125I]CXCL10 from HEK-293 cells expressing the human CXCR3 
receptor.25 Follow-up pharmacological studies on selected compounds were aimed at 
inspecting functional activities on CXCR3 in more detail. Toward this end, antagonistic 
effects of a compound were measured in four different CXCR3-based functional assays: 
(1) CXCL11-induced phospholipase C activity (2) CXCL11-induced increase of intracellular 
[Ca2+] (3) CXCL11-induced actin polymerization (4) CXCL11-induced chemotaxis of 
activated T cells. 
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3a: X=H
3b: X=4-OCH3,
3c: X=4-F
3d: X=4-CN
3e: X=4-CH3
3f : X=4-CF3
3g: X=2-CN
3h: X=3-CN
4a: X=H
4b: X=4-OCH3
4c: X=4-F
4d: X=4-CN
4e: X=4-CH3
4f : X=4-CF3
4g: X=2-CN
4h: X=3-CN
5a: X=H
5b: X=4-OCH3
5c: X=4-F
5d: X=4-CN
5e: X=4-CH3
5f : X=4-CF3
5g: X= 2-CN
5h: X=3-CN
5i : X=4-OH
1a : X=H, R=nonyl
1b : X=4-OCH3,R=nonyl
1c : X=4-F, R=nonyl
1d : X=4-CN, R=nonyl
1e : X=4-CH3,R=nonyl
1f : X=4CF3, R=nonyl
1g : X=2-CN, R=nonyl
1h : X=3-CN, R=nonyl
1i : X=4-OH, R=nonyl
1j : X=4-F, R=cyclohexyl
1k : X=4-CN, R=cyclohexyl
1l : X=4-F, R=phenyl
1m: X=4-CN, R=phenyl
1n : X=4-F, R=naphtyl
vivi
i
 
Scheme 1. Reagents: i) CH3CH2COCl, DMF; ii) PCl3, substituted anilines, toluene; iii) Br2, 
CH3COOH, CH3COONa; iv) H2N(CH2)2N(CH3)2, EtOH, reflux; v) RCOCl, Et3N, 1,4-dioxane, 
vi) BBr3, DCM. 
 
 
Results and conclusions 
 
In patent literature, compound 1c has been reported as CXCR3 antagonist in the 
micromolar range.21 We confirmed this result in our binding assay where 1c showed an 
IC50 value of 3.2 M. The importance of the nonyl chain of 1c was investigated by its 
removal (5a-i) or substitution with different hydrophobic moieties (1j-n). These 
modifications result in a total loss of affinity (Figure 2), suggesting an important role of 
the flexible aliphatic chain. 
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Figure 2. Displacement of [125I]-CXCL10 binding to CXCR3. The binding 
experiments were carried out on HEK-293 cells expressing the human CXCR3 receptor. 
The compounds 1a-n, 5a-f and 5i (10M) were tested for their ability to displace 
[125I]CXCL10. Error bars show standard error of the mean.  
 
The role of the para-fluoro atom of the phenyl ring in the lead compound 1c was also 
studied (Table 1). The presence of appropriate substituents is required for affinity at 
CXCR3, since the unsubstituted analogue (1a) is five times less potent (IC50= 15 M) 
than the lead compound (1c). Substituents with different electronic and lipophilic 
properties resulted in ligands with altered affinities for the CXCR3 receptor. The para-
methoxy and para-methyl derivatives (1b and 1e) showed the same degrees of affinity 
as the prototype, 1c, whereas the para-cyano derivative, 1d, was 3 fold more potent 
than 1c. In fact within this series 1d is the only compound to show submicromolar 
affinity. Shifting the cyano substituent from the para- to the ortho- or meta- position 
caused a large decrease in CXCR3 affinity (IC50=10 M for 1g and 5.8 M for 1h, 
respectively). Replacement of the 4-fluoro atom of 1c by a 4-CF3 (1f) or 4-OH (1i) group 
is not allowed for activity. 
Compound 1d (VUF5834) has the highest affinity for CXCR3 in the [125I]CXCL10 binding 
assay and was therefore tested in different functional assays.  
The effect of 1d on CXCL11- and CXCL10-mediated processes was studied in different 
signaling assays in human CXCR3 expressing cells and its effects were compared to the 
analogue without nonyl chain 5d. Agonist binding to CXCR3 results in the activation of 
phospholipase C (PLC) via Gi proteins.11 The effect of 1d on CXCL11-induced PLC 
activity was determined by  measuring the  production of  [3H]-inositol phosphates ([3H]- 
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Table 1. IC50 values of the compounds 1a-i for their displacement of [125I]CXCL10 
binding to CXCR3 
Compound R X IC50 (M)a
1a
 
nonyl 
 
H 
 
15 (10-20) 
1b nonyl 4-OCH3 3.3 (2.2-4.4) 
1c nonyl 4-F 3.2 (2.3-4.2) 
1d nonyl 4-CN 0.93 (0.74-1.1) 
1e nonyl 4-CH3 3.1 (2.0-4.1) 
1f nonyl 4-CF3  100 
1g nonyl 2-CN 10 (8.6-12) 
1h nonyl 3-CN 5.8 (5.1-6.5) 
1i nonyl 4-OH  100 
 
a The binding experiments were carried out on HEK-293 cells expressing the human 
CXCR3 receptor. The compounds were tested for their ability to displace [125I]CXCL10. 
The values are represented as the mean and the interval of the IC50 (M) values of at 
least three independent experiments 
 
 
IPx) in COS-7-CXCR3 cells. A 10 minute preincubation of COS-7-CXCR3 cells with 1d 
inhibited CXCR3–mediated phosphatidylinositol (PI) turnover in a dose-dependent 
manner (IC50 [10 nM CXCL11]: 6 M), while 5d had no effect on this process (Figure 3). 
Inositol trisphosphate (IP3), one of the products of PLC activity, induces an increase in 
intracellular [Ca2+] concentrations, by mobilizing [Ca2+] from intracellular stores and 
activating the influx of [Ca2+] from the extracellular environment.9,10,26 Stimulation of the 
human CXCR3 receptor with 10 nM CXCL11 resulted in a rapid increase of intracellular 
[Ca2+], which returned thereafter to baseline levels (Figure 4). Pre-incubation of the cells 
with 10 M of 1d, 10 minutes prior to chemokine stimulation completely abrogated the 
CXCL11-induced [Ca2+] increase, while 5d had no effect (Figure 4). These data 
demonstrate that compound 1d can efficiently block CXCL11-induced PI turnover and 
CXCR3-mediated calcium release. 
A consequence of agonist binding to CXCR3 on human T cells is the fast and transient 
increase of F-actin which is therefore considered one of the earliest measurable biological 
response. Neverthless, the following binding of chemoattractants10,11 to their receptor is 
considered as an early sign of lymphocyte migration.27-29  
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Figure 3. Compound 1d 
abrogates CXCR3-mediated 
IP3 production. Effect of 1d 
and 5d on CXCR3-mediated PLC 
activity by CXCL11 (A) and 
CXCL10 (B). PLC activity was 
measured by the production of 
[3H]IPx from radioactive labeled 
inositol in COS-7-CXCR3. 
 
 
 
 
We investigated the effect of 1d on both CXCR3-induced actin polymerization and 
migration of human activated T cells. CXCR3-induced increase in actin filaments was 
completely abrogated in the presence of 1 M of 1d (figure 5) whereas 5d had no effect 
on CXCR3-agonist induced actin polymerization, indicating that inhibition was dependent 
on receptor binding. 
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Figure 4. Compound 1d abrogates CXCR3-mediated [Ca2+] mobilization. Effect of 
compounds 1d and 5d (10 M) on the CXCL11 (10 nM) induced Ca2+ mobilization in 
HEK-293-CXCR3 cells. Compounds were added 10 min prior to chemokine stimulation 
with CXCL11 (indicated by the arrow). The experiment is representative of two 
independent experiments performed in triplicate defines the maximal response as 
maximal Ca2+ concentration induced. Error bars show standard error of the mean. 
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Figure 5. Compound 1d inhibits CXCR3-mediated actin polymerization. Human T 
cells were isolated form peripheral blood and activated with PHA and IL-2. Actin 
polymerization in response to CXCL11 was measured in the presence or absence of 1 M 
of 1d or 5d. Results are representative for 3 donors. Error bars show the standard error 
of the mean. 
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Subsequently we studied the effect of both 1d and 5d on CXCR3-mediated chemotaxis. 
Migration of activated T cells towards CXCR3-ligands CXCL11 and CXCL10 was dose-
dependently inhibited by preincubation with 1d and not by 5d (Figure 6A). Compound 1d 
inhibited T cell migration induced by 30 nM CXCL11 with an IC50 of 0.5 M.  
Furthermore we studied the 1d effect on T cell migration towards CXCR4-ligand CXCL12 
(30 nM). Compound 1d did not affect the migration of activated T cells to CXCR4-agonist 
CXCL12 formerly known as SDF-1 (Figure 6B), indicating that 1d acts specifically on 
CXCR3-mediated migration. Basal migration in the absence of chemoattractants was not 
changed by 1d, demonstrating that motility of the cells was not affected. 
 
 
Conclusions 
 
We have described the SAR of a series of 3-phenyl-3H-quinazolin-4-one derivatives for 
their action as CXCR3 antagonists. Compound 1d has the highest affinity for the human 
CXCR3 receptor and is able to effectively inhibit CXCR3 mediated IP3 production and 
calcium mobilization in cells expressing the human CXCR3. Furthermore compound 1d 
abrogates CXCR3 mediated actin polymerization and chemotaxis of human T cells 
representing therefore a valuable tool for future lead optimization programs.  
 
 
Experimental section 
 
Chemistry 
 
General. All the reactions were performed under an atmosphere of dry nitrogen. 1H NMR 
spectra were recorded on a Bruker AC-200 (200 MHz) spectrometer. Mass spectra were 
recorded on a Finnigan MAT-90 mass spectrometer. Chromatography was performed on 
J.T.Baker silica gel for flash chromatography. THF was freshly distilled from LiAlH4 and 
DMF was dried on molecular sieves. 
 
 
 
 
 
 
 41
Chapter 3 
 
 
 
-11 -10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
5d
1d
A
log[compound]
%
C
X
C
L
11
-i
n
d
u
ce
d
 m
ig
ra
ti
o
n
 
-11 -10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
CXCL11
CXCL10
CXCL12
B
log [1d]
%
ch
em
o
ki
n
e-
in
d
u
ce
d
 m
ig
ra
ti
o
n
 
Figure 6. Compound 1d 
inhibits CXCR3-
mediated chemotaxis 
of human T cells. A) 
Dose-response effect of 
1d and 5d on chemotaxis 
of activated T cells 
induced by 30 nM of 
CXCL11.  
B) Dose-response effect 
of 1d on CXCL11-, 
CXCL10- and CXCL12-
induced chemotaxis (all 
30 nM) of activated T 
cells. Results are 
representative for 3 
donors. Error bars show 
the standard deviation. 
 
 
 
2-Propionylamino-benzoic acid (2) 
Anthranilic acid (68.6 g, 0.50 mol) was dissolved in N,N-dimethylformamide (250 mL). 
Propionyl chloride (47.6 mL, 0.55 mol) was added dropwise at such a rate that the 
temperature of the mixture remained below 40 ºC. The product began to precipitate after 
about one half of the acid chloride was added, and the suspension was stirred vigorously 
at room temperature for an additional three hours after the addition was completed. The 
resulting mixture was poured into water (2.0 L) and stirred for an additional two hours. 
The precipitated product was collected by filtration, washed with water and dried in a 
vacuum oven at 40 ºC under reduced pressure. This afforded 73.03 g (76%) of white 
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crystals. 1H NMR (CDCl3) : 1.25 (t, 3H), 2.55 (q, 2H), 6.75 (brs, 1H), 7.07-7.14 (m, 
1H), 7.55-7.59 (m, 1H), 8.02-8.14 (m, 1H), 8.72-8.76 (m, 1H), 10.98 (s, 1H). 
 
2-Ethyl-3-phenyl-3H-quinazolin-4-one (3a) 
To a suspension of 2-propionylamino-benzoic acid (2) (3.00 g, 12.52 mmol) and aniline 
(1.41 mL, 15.52 mmol) in toluene was added dropwise phosphorus chloride (0.96 mL, 
6.98 mmol). The resulting suspension was heated to reflux for 8 hours. After cooling to 
r.t., a saturated sodium carbonate solution was added and the mixture was stirred 
vigorously until all solid was dissolved. The toluene was removed in vacuo and the 
resulting solid was collected by filtration, rinsed with water, dried and recrystallized from 
isopropyl alcohol. This afforded 2.74 g (71%) of the desired compound as a white solid. 
1H NMR (CDCl3) : 1.21 (t, 3H), 2.43 (q, 2H), 7.10-7.31 (m, 2H), 7.33-7.61 (m, 4H), 
7.62-7.83 (m, 2H), 8.13-8.30 (m, 1H). 
 
2-Ethyl-3-(4-methoxy-phenyl)-3H-quinazolin-4-one (3b) 
The same procedure as for 3a was applied, using 2 (8.00 g, 41.41 mmol) and p-anisidine 
(5.10 g, 41.41 mmol). The desired compound was obtained as a white powder (5.49 g, 
47%). 1H NMR (CDCl3) : 1.18 (t, 3H), 2.44 (q, 2H), 4.38 (s, 3H), 6.96-7.18 (m, 4H),
7.35-7.51 (m, 1H), 7.61-7.82 (m, 2H), 8.19-8.34 (m, 1H). 
 
2-Ethyl-3-(4-fluoro-phenyl)-3H-quinazolin-4-one (3c) 
The same procedure as for 3a was applied, using 4-fluoroaniline (1.72 g, 15.52 mmol). 
The desired compound was  obtained  as a beige powder (3.32 g, 75%). 1H NMR (CDCl3) 
: 1.21 (t, 3H), 2.43 (q, 2H), 7.21-7.24 (m, 4H), 7.41-7.49 (m, 1H), 7.68-7.80 (m, 2H), 
8.22-8.26 (m, 1H). 
 
4-(2-Ethyl-4-oxo-4H-quinazolin-3-yl)benzonitrile (3d) 
The same procedure as for 3a was applied, using 4-aminobenzonitrile (1.83 g, 15.52 
mmol). The desidered compound was obtained as a white powder (1.50 g, 35%). 1H NMR 
(CDCl3) : 1.18 (t, 3H), 2.34 (q, 2H), 7.30-7.55 (m, 3H), 7.60-7.95 (m, 4H), 8.21-8.29 
(m, 1H). 
 
2-Ethyl-3-p-tolyl-3H-quinazolin-4-one (3e) 
The same procedure as for 3a was applied, using p-toluidine (1.66 g, 15.52 mmol). The 
desidered compound was obtained as a yellow oil (2.86 g, 70%). 1H NMR (CDCl3) : 1.23 
(t, 3H), 2.22-2.58 (m= s+q, 5H), 6.88-7.49 (m, 5H), 7.61-7.82 (m, 2H), 8.18-8.29 (m, 
1H). 
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2-Ethyl-3-(4-trifluoromethyl-phenyl)-3H-quinazolin-4-one (3f) 
The same procedure as for 3a was applied, using 4-aminobenzotrifluoride (2.53 mL, 
15.52 mmol). The desired compound was obtained as a white powder (2.22 g, 42%). 1H 
NMR (CDCl3) : 1.16 (t, 3H), 2.39 (q, 2H), 7.25-7.53 (m, 3H), 7.62-7.95 (m, 4H), 8.16-
8.41 (m, 1H). 
2-(2-Ethyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (3g) 
The same procedure as for 3a was applied, using antranilonitrile (1.83 g, 15.52 mmol). 
The desired compound was obtained as a white powder (1.50 g, 35%).1H NMR (CDCl3) :
1.30 (t, 3H), 2.41 (q, 2H), 7.32-7.54 (m, 2H), 7.58-87.99 (m, 5H), 8.27-8.31 (m, 1H). 
 
3-(2-Ethyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (3h) 
The same procedure as for 3a was applied, using 3-aminobenzonitrile (1.83 g, 15.52 
mmol). The desired compound was obtained as a white powder (2.10 g, 50%). 1H NMR 
(CDCl3) d: 1.20 (t, 3H), 2.38 (q, 2H), 7.39-7.87 (m, 7H), 8.28-8.33 (m, 1H). 
 
2-(1-Bromo-ethyl)-3-phenyl-3H-quinazolin-4-one (4a) 
To a mixture of 3a (2.55 g, 10.21 mmol), anhydrous sodium acetate (1.02 g) and glacial 
acetic acid (15 mL) at 40 ºC, a bromine (0.82 mL, 10.21 mmol) solution in acetic acid 
was added over a period of 3 hours. After the addition was completed the mixture was 
poured into water (300 mL) and stirred at room temperature for about 2 hours. The 
precipitate was isolated by filtration, washed with warm water to remove the trace of the 
acetic acid, then rinsed with a small amount of isopropyl alcohol and dried to provide the 
desired compound (1.95 g, 58%) as a yellow solid. 1H NMR (CDCl3) : 2.01 (d, 3H), 4.52 
(q, 1H), 7.00-7.18 (m, 1H), 7.32-7.63, (m, 5H), 7.65-7.82 (m, 2H), 8.22-8.29 (m, 1H). 
 
2-(1-Bromo-ethyl)-3-(4-methoxy-phenyl)-3H-quinazolin-4-one (4b) 
This was carried out analogously to the preparation of 4a, using 3b (5.33 g, 19.00 
mmol). The desired compound was obtained as a pale yellow solid (4.03 g, 59%). 1H 
NMR (CDCl3) : 2.02 (d, 3H), 3.38 (s, 3H), 4.60 (q, 1H), 6.91-7.11 (m, 3H), 7.35-7.57 
(m, 2H), 7.75-7.80 (m, 2H), 8.18-8.23 (m, 1H). 
 
2-(1-Bromo-ethyl)-3-(4-fluoro-phenyl)-3H-quinazolin-4-one (4c) 
This was carried out analogously to the preparation of 4a, using 3c (2.03 g, 7.56 mmol). 
The desired compound was obtained as a pale grey solid (2.20 g, 84%). 1H NMR (CDCl3) 
: 2.04 (d, 3H), 4.53 (q, 1H), 7.15-7.32 (m, 3H), 7.47-7.58 (m, 2H), 7.78-7.80 (m, 2H), 
8.25-8.29 (m, 1H). 
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4-[2-(1-Bromo-ethyl)-4-oxo-4H-quinazolin-3-yl]- benzonitrile (4d) 
This was carried out analogously to the preparation of 4a, using 3d (1.50 g, 5.45 mmol). 
The desired compound was obtained as a pale yellow solid (1.39 g, 72%). 1H NMR 
(CDCl3) : 2.02 (d, 3H), 4.40 (q, 1H), 7.25-7.35 (m, 1H), 7.45-7.65 (m, 1H), 7.70-
7.95(m, 5H), 8.20-8.24 (m, 1H). 
 
2-(1-Bromo-ethyl)-3-p-tolyl-3H-quinazolin-4-one (4e) 
This was carried out analogously to the preparation of 4a, using 3e (2.70 g, 10.21 
mmol). The desired compound was obtained as an off white solid (2.69 g, 77%). 1H NMR 
(CDCl3) : 2.04 (d, 3H), 2.44 (s, 3H), 4.58 (q, 1H), 6.94-7.09 (m, 1H), 7.30-7.58 (m, 
4H), 7.68-7.72 (m, 3H), 8.27-8.31 (d, 1H). 
 
2-(1-Bromo-ethyl)-3-(4-trifluoromethyl-phenyl)-3H-quinazolin-4-one (4f) 
This was carried out analogously to the preparation of 4a, using 3f (2.20 g, 7.56 mmol). 
The desired compound was obtained as a white solid (2.11 g, 70%). 1H NMR (CDCl3) : 
2.09 (d, 3H), 4.49 (q, 1H), 7.28-7.34 (m, 1H), 7.38-7.56 (m, 1H), 7.58-7.89 (m, 5H), 
8.20-8.24 (m, 1H). 
 
2-[2-(1-Bromo-ethyl)-4-oxo-4H-quinazolin-3-yl]-benzonitrile (4g) 
This was carried out analogously to the preparation of 4a, using 3g (1.50 g, 5.45 mmol). 
The desired compound was obtained as a pale yellow solid (1.52 g, 79%). 1H NMR 
(CDCl3) : 1.98-2.18 (m, 3H), 4.35 (q, 0.7H), 4.59 (q, 0.3H), 7.30-7.35 (m, 0.5H), 7.49-
7.98 (m, 6.5H), 8.20-8.25 (m, 1H).
3-[2-(1-Bromo-ethyl)-4-oxo-4H-quinazolin-3-yl]-benzonitrile (4h) 
This was carried out analogously to the preparation of 4a, using 3h (2.00 g, 7.26 mmol). 
The desired compound was obtained as a white solid (2.07 g, 80%). 1H NMR (CDCl3) : 
2.04-2.09 (m, 3H), 4.41 (q, 1H), 7.42-7.58 (m, 2H), 7.63-7.89 (m, 5H), 8.23-8.27 (m, 
1H). 
 
2-[1-(2-Dimethylamino-ethylamino)-ethyl]-3-phenyl-3H-quinazolin-4-one (5a) 
A mixture of compound 4a (1.90 g, 5.77 mmol) and N,N dimetylethylenediamine  (1.01 
mL, 9.23 mmol) in 100 mL ethanol was heated to reflux for 18 hours. The ethanol was 
removed in vacuo and the concentrate dissolved in chloroform and extracted with 
saturated aqueous sodium bicarbonate solution (350 mL). The combined organic 
extracts were dried over sodium sulphate, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography on silica gel eluting with 
methanol/dichloromethane (1:9) to afford the desired compound as a colourless oil (1.23 
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g, 63%). 1H NMR (CDCl3) : 1.17 (d, 3H, CH3CH), 2.09-2.70 (s+m, 10H, (CH3)2N, 
NCH2CH2N), 3.34 (q, 1H, CH3CH), 4.25 (brs, 1H, NH), 7.03-7.19 (m, 2H), 7.23-7.51, (m, 
4H), 7.53-7.72 (m, 2H), 8.09-8.13 (m, 1H); MS(ESI) m/z 337 (M+H)+. The (+)-tartrate 
salt of compound 5a was prepared and subsequently recrystallized from 2-PrOH:EtOH 
(1:1). 1H NMR (DMSO) : 1.18 (d, 3H), 2.46-2.92 (s+m, 10H), 3.18 (s, 1H), 4.15 (s, 
2H), 7.15-7.94 (m, 10H), 8.11-8.13 (m, 1H).  
 
2-[1-(2-Dimethylamino-ethylamino)-ethyl]-3-(4-methoxy-phenyl)-3H-
quinazolin-4-one (5b) 
This procedure was performed analogously to the synthesis of 5a, using 4b (4.00 g, 
11.13 mmol). Compound 5b was obtained as a solid after flash chromatography (2.19 g, 
54%). 1H NMR (CDCl3) : 1.22 (d, 3H, CH3CH), 2.12-2.64 (s+m, 10H, (CH3)2N, 
NCH2CH2N), 2.88 (brs, 1H, NH), 3.52 (q, 1H, CH3CH), 3.80 (s, 3H, CH3O), 6.91-7.18 (m, 
4H), 7.40-7.51, (m, 1H), 7.59-7.68 (m, 2H), 8.18-8.22 (m, 1H); MS(ESI) m/z 367 
(M+H)+. 
 
2-[1-(2-Dimethylamino-ethylamino)-ethyl]-3-(4-fluoro-phenyl)-3H-quinazolin-
4-one (5c) 
This procedure was performed analogously to the synthesis of 5a, using 4c (2.62 g, 7.55 
mmol). Compound 5c was obtained as a solid after flash chromatography (0.99 g, 37%). 
1H NMR (CDCl3) : 1.20 (d, 3H, CH3CH) 2.22-2.80 (s+m, 10H, (CH3)2N, NCH2CH2N), 3.39 
(q, 1H, CH3CH), 4.41 (brs, 1H, NH), 7.00-7.22 (m, 4H), 7.32-7.41 (m, 1H), 7.55-7.77 
(m, 2H), 8.11-8.15 (d, 1H); MS(ESI) m/z 355 (M+H)+. 
 
4-{2-[1-(2-Dimethylamino-ethylamino)-ethyl]-4-oxo-4H-quinazolin-3-yl}-
benzonitrile (5d) 
This procedure was performed analogously to the synthesis of 5a, using 4d (1.30 g, 4.49 
mmol). Compound 5d was obtained as a white solid after flash chromatography (1.11 g, 
68%). 1H NMR (CDCl3) : 1.23 (d, 3H, CH3CH), 2.22 (s, 6H, (CH3)2N), 2.30-2.59 (m, 4H, 
NCH2CH2N), 3.31 (q, 1H, CH3CH), 7.22-7.50, (m, 3H), 7.70-7.86 (m, 4H), 8.20-8,24 (m, 
1H); MS(ESI) m/z 362 (M+H)+. 
 
2-[1-(2-Dimethylamino-ethylamino)-ethy]-3-p-tolyl-3H-quinazolin-4-one (5e) 
This procedure was performed analogously to the synthesis of 5a, using 4e (2.60 g, 7.57 
mmol). Compound 5e was obtained as a pale yellow solid after flash chromatography 
(1.71 g, 64%). 1H NMR (CDCl3) : 1.21 (d, 3H, CH3CH), 2.18 (s, 6H, (CH3)2N), 2.30-2.70 
(s+m, 7H, NCH2CH2N, CH3-Ar), 3.11 (brs, 1H, NH), 3.43 (q, 1H, CH3CH), 6.98-7.17 (m, 
2H), 7.23-7.50 (m, 3H), 7.60-7.79 (m, 2H), 8.19-8.23 (m, 1H); MS(ESI) m/z 351 
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(M+H)+. 
 
2-[1-(2-Dimethylamino-ethylamino)-ethyl]-3-(4-trifluoromethyl-phenyl)-3H-
quinazolin-4-one (5f) 
This procedure was performed analogously to the synthesis of 5a, using 4f (2.00 g, 5.04 
mmol). Compound 5f was obtained as a white powder after flash chromatography (1.59 
g, 78%). 1H NMR (CDCl3) : 1.21 (d, 3H, CH3CH), 2.12 (s, 6H, (CH3)2N), 2.21-2.40 (m, 
4H, NCH2CH2N), 2.81 (brs, 1H, NH), 3.30 (q, 1H, CH3CH), 7.28-7.48 (m, 3H), 7.58-7.82 
(m, 4H), 8.01-8.05 (m, 1H); MS(ESI) m/z 405 (M+H)+. 
 
2-{2-[1-(2-Dimethylamino-ethylamino)-ethyl]-4-oxo-4H-quinazolin-3-yl}-
benzonitrile (5g) 
This procedure was performed analogously to the synthesis of 5a, using 4g (1.50 g, 4.23 
mmol). Compound 5g was obtained as a white powder after flash chromatography (0.07 
g, 5%). 1H NMR (CDCl3) : 1.28 (d, 1.5H, CH3CH), 1.34 (d, 1.5H, CH3CH), 2.18 (s, 3H, 
(CH3)2N), 2.24 (s, 3H,(CH3)2N), 2.35-2.98 (m, 5H, NCH2CH2N+NH), 3.21 (q, 0.5H, 
CH3CH), 3.31 (q, 0.5H, CH3CH), 7.36-7.60 (m, 2H), 7.62-7.88 (m, 5H), 8.22-8.28 (m, 
1H); MS(ESI) m/z 362 (M+H)+. 
 
3-{2-[1-(2-Dimethylamino-ethylamino)-ethyl]-4-oxo-4H-quinazolin-3-yl}-
benzonitrile (5h) 
This procedure was performed analogously to the synthesis of 5a, using 4h (2.00 g, 5.65 
mmol). Compound 5g was obtained as a white powder after flash chromatography (0.09 
g, 4%). 1H NMR (CDCl3) : 1.24 (d, 3H, CH3CH), 2.12 (s, 6H, (CH3)2N), 2.32-2.56 (m, 
4H, NCH2CH2N), 2.62 (brs, 1H, NH), 3.31 (q, 1H, CH3CH), 7.32-7.88 (m, 7H), 8.16-8.20 
(m, 1H); MS(ESI) m/z 362 (M+H)+. 
 
2-[1-(2-Dimethylamino-ethylamino)-ethyl]-3-(4-hydroxy-phenyl)-3H-
quinazolin-4-one (5i) 
A boron tribromide solution (1M in dichloromethane, 5.25 mL, 5.46 mmol) was added to 
a cooled (0°C) solution of 5b (0.50 g, 1.36 mmol) in anhydrous dichloromethane under 
nitrogen atmosphere. An orange precipitate formed immediately. The flask was covered 
with aluminium foil. The mixture was warmed to room temperature and then stirred for 
16 hours. All volatiles were removed under reduced pressure and the resulting residue 
treated with methanol to quench the borate intermediates. The methanol was removed in 
vacuo, the crude material was treated with a sodium carbonate saturated solution and 
then extracted with dichloromethane (3x25 mL). The organic phases were dried over 
magnesium sulphate, filtered and concentrated. The crude material was purified by flash 
 47
Chapter 3 
 
 
chromatography on silica gel eluting with DCM/MeOH (7.5:2.5). Fractions containing 
product were combined to afford 5i as a white solid (0.23 g, 12%). 1H NMR (CDCl3) : 
1.22 (d, 3H, CH3CH), 2.11 (s, 6H, (CH3)2N), 2.30-2.81 (m, 5H, NCH2CH2N+NH), 3.58 (q, 
1H, CH3CH), 5.63 (brs, 1H, Ar-OH, exchangeable with D2O), 6.58-7.08 (m, 4H), 7.29-
7.49 (m, 1H), 7.58-7.79 (m, 2H), 8.12-8.17 (m, 1H); MS(ESI) m/z 353 (M+H)+. 
 
Decanoic acid (2-dimethylamino-ethyl)-[1-(4-oxo-3-phenyl-3,4-dihydro-
quinazolin-2-yl)-ethyl]-amide (1a) 
Compound 5a (0.34 g, 1.00 mmol) and triethylamine (0.14 mL, 1.00 mmol) were 
dissolved in 25 mL dioxane. Decanoyl chloride (0.21 mL, 1.00 mmol) was added to the 
solution. The resulting mixture was stirred at room temperature for 18 hours and then 
concentrated under reduced pressure. The residue was dissolved in dichloromethane (50 
mL) and washed with saturated aqueous Na2CO3 solution (50 mL), then twice with water 
(50 mL). The organic phases were dried over anhydrous Na2SO4, filtered and evaporated. 
The crude material was purified by flash chromatography on silica gel eluting with ethyl 
acetate/methanol (9:1). This afforded the desired compound (0.31 g, 63%) as a 
colourless oil. 1H NMR (CDCl3) : 0.90 (t, 3H), 1.13-1.32 (m, 16H, CH2), 1.36 (d, 1.2H, 
CH3,) 1.51 (d, 1.8H, CH3), 2.01 (s, 2.4H, N(CH3)2), 2.13 (s, 3.6H, N(CH3)2), 2.18-2.21 
(m, 1H, CH2N), 2.38-2.52 (m, 1H, CH2N), 3.32-3.57 (m, 2H, CH2NCO), 4.71 (q, 0.4H, 
CH), 5.37 (q, 0.6H, CH), 7.35-7.90 (m, 8H), 8.25 (d, 1H); MS(ESI) m/z 492 (M+H)+. 
The compound was obtained as a crystalline material after (+)-tartrate salt formation 
followed by recrystallization from isopropyl alcohol.1H NMR (D2O) : 0.92 (t, 3H), 1.00-
1.32 (m, 16H, CH2), 1.61 (d, 3H, CH3), 2.35(s, 5H, N(CH3)2), 2.45 (s, 1H, N(CH3)2), 
3.10-3.18 (m, 2H, CH2N), 3.53-3.56 (m, 2H, CH2NCO), 4.62 (s, 4H, 2(CHOH)2), 5.09 (q, 
1H, CH), 7.15-8.00 (m, 8H), 8.10 (d, 1H). 
 
Decanoic acid (2-dimethylamino-ethyl)-{1-[3-(4-methoxy-phenyl)-4-oxo-3,4-
dihydro-quinazolin-2-y]-ethyl}-amide (1b) 
The same procedure as for 1a was applied using 5b (0.37 g, 1.00 mmol). This afforded 
1b as a colourless oil (0.29 g, 55%). 1H NMR (CDCl3) : 0.75 (t, 3H), 1.08-1.22 (m, 16H, 
CH2), 1.23 (d, 1.2H, CH3) 1.43 (d, 1.8H, CH3), 1.83 (s, 4H, N(CH3)2), 1.92 (s, 2H, 
N(CH3)2), 2.08-2.22 (m, 1H, CH2N), 2.23-2.42 (m, 1H, CH2N), 3.20-3.52 (m, 2H, 
CH2NCO), 3.68 (s, 3H, OCH3) 4.78 (q, 0.4H, CH), 5.25 (q, 0.6H, CH), 7.35-7.90 (m, 7H), 
8.25 (d, 1H);MS(ESI) m/z 522 (M+H)+. The compound was obtained as a crystalline 
material after fumarate salt formation followed by recrystallization from isopropyl alcohol. 
1H NMR (DMSO) : 0.85 (t, 3H), 1.12-1.32 (m, 16H, CH2), 1.34 (d, 1.2H, CH3) 1.46 (d, 
1.8H, CH3), 2.15 (s, 4H, N(CH3)2), 2.30 (s, 2H, N(CH3)2), 3.28-3.32 (m, 2H, CH2N), 3.35 
 48
3-Phenyl-3H-quinazolin-4-one derivatives as CXCR3 receptor antagonists
 
(m, 2H, CH2NCO), 3.80 (s, 3H, OCH3), 4.78 (q, 0.4H, CH), 5.21 (q, 0.6H, CH), 6.55 (s, 
4H, 2(CH=CH)), 6.90-7.90 (m, 7H), 8.25 (d, 1H). 
Decanoic acid (2-dimethylamino-ethyl)-{1-[3-(4-fluoro-phenyl)-4-oxo-3,4-
dihydro-quinazolin-2-y]-ethyl}-amide (1c) 
The same procedure as for 1a was applied using 5c (0.35 g, 1.00 mmol). This afforded 
1c as colourless oil (0.26 g, 51%).1H NMR (CDCl3) : 0.80 (t, 3H), 1.08-1.25 (m, 14H, 
CH2), 1.38 (d, 0.9H, CH3) 1.50 (d, 2.1H, CH3), 1.95 (s, 1.5H, N(CH3)2), 2.16 (s, 4.5H, 
N(CH3)2), 2.18-2.30 (m, 1H, CH2CON), 2.32-2.53 (m, 1H, CH2CON), 3.22-3.52 (m, 4H, 
CH2NCO, CH2N), 4.74 (q, 0.5H, CH), 5.32 (q, 0.5H, CH), 7.13-7.81 (m, 7H), 8.25 (d, 
1H); MS(ESI) m/z 510 (M+H)+. The compound was obtained as a crystalline solid after 
fumarate salt formation followed by recrystallization from isopropyl alcohol. 1H NMR 
(DMSO) : 0.84 (t, 3H), 0.98-1.38 (m, 14H, CH2), 1.43 (d, 3H, CH3), 2.05-2.72 (s+m, 
10H, N(CH3)2, CH2CON, CH2N), 2.98-3.41 (m, 2H, CH2NCO), 5.22 (q, 1H, CH), 7.15-7.90 
(m, 7H), 8.15 (d, 1H). 
Decanoic acid {1-[3-(4-cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-y]-
ethyl}-(2-dimethylamino-ethyl)-amide (1d) 
The same procedure as for 1a was applied using 5d (0.36 g, 1.00 mmol). This afforded 
1d as a white powder (0.33 g, 63%). 1H NMR (CDCl3) : 0.78 (t, 3H), 1.17-1.23 (m, 
16H, CH2), 1.26 (d, 3H, CH3) 1.90 (s, 1H, N(CH3)2), 2.21 (s, 5H, N(CH3)2), 2.29 (m, 2H, 
CH2N), 3.28-3.43 (m, 2H, CH2NCO), 4.66 (q, 0.2H, CH), 5.21 (q, 0.8H, CH), 7.24-7.89 
(m, 7H), 8.20 (d, 1H); MS(ESI) m/z 516 (M+H)+. 
 
Decanoic acid (2-dimethylamino-ethyl)-[1-(4-oxo-3-p-tolyl-3,4-dihydro-
quinazolin-2-yl)-ethyl]-amide (1e) 
The same procedure as for 1a using 5e (0.35 g, 1.00 mmol). This afforded 1e as 
colourless oil (0.28 g, 55%).1H NMR (CDCl3) : 0.78 (t, 3H), 0.99-1.31 (m, 16H, CH2), 
1.32 (d, 1.0H, CH3) 1.48 (d, 2.0H, CH3), 1.95 (s, 3H, N(CH3)2), 2.14 (s, 3H, N(CH3)2), 
2.18-2.22 (m, 2H, CH2N) 2.41 (s, 3H, Ar-CH3), 3.22-3.52 (m, 2H, CH2NCO), 4.78 (q, 
0.5H, CH), 5.33 (q, 0.5H, CH), 6.83-7.83 (m, 7H), 8.25 (d, 1H); MS(ESI) m/z 506 
(M+H)+. The compound was obtained as a crystalline solid after (+)-tartrate salt 
formation followed by recrystallization from isopropyl alcohol.1H NMR (CD3OD) : 0.90 (t, 
3H), 1.15-1.40 (m, 16H, CH2), 1.62 (d, 3H, CH3), 2.40 (s, 3H, Ar-CH3), 2.48-2.52 (m, 
2H, CH2N), 2.80 (s, 6H, N(CH3)2), 3.45 –3.48 (m, 2H, CH2NCO), 4.45(s, 4H, 2(CHOH)2), 
5.10 (q, 1H, CH), 7.10-8.10 (m, 7H), 8.25 (d, 1H). 
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Decanoic acid (2-dimethylamino-ethyl)-{1-[4-oxo-3-(4-trifluoromethyl-
phenyl)-3,4-dihydro-quinazolin-2-yl]-ethyl}-amide (1f) 
The same procedure as for 1a was applied using 5f (0.40 g, 1.00 mmol). This afforded 
1f as a white wax (0.47 g, 84 %).1H NMR (CDCl3) : 0.79 (t, 3H), 1.12-1.32 (m, 16H, 
CH2), 1.35 (d, 1.5H, CH3) 1.52 (d, 1.5H, CH3), 1.90 (s, 2H, N(CH3)2), 2.12 (s, 4H, 
N(CH3)2), 2.20-2.52 (m, 2H, CH2N), 3.20-3.52 (m, 2H, CH2NCO), 4.60 (q, 0.3H, CH), 
5.20 (q, 0.7H, CH), 7.21-7.83 (m, 7H), 8.15 (d, 1H); MS(ESI) m/z 560 (M+H)+. 
 
Decanoic acid {1-[3-(2-cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-
ethyl}-(2-dimethylamino-ethyl)-amide (1g) 
The same procedure as for 1a was applied using 5g (0.36 g, 1.00 mmol). This afforded 
1g as colourless oil (0.10 g, 20%).1H NMR (CDCl3) : 0.80 (t, 3H), 1.08-1.19 (m, 16H, 
CH2), 1.39 (d, 3H, CH3), 2.10 (s, 6H, N(CH3)2), 2.10-2.62 (m, 2H, CH2N), 3.18-3.35 (m, 
1H, CH2NCO), 3.41-3.55 (m, 1H, CH2NCO), 5.23 (q, 0.4H, CH), 5.63 (q, 0.6H, CH), 7.31 
(d, 1H), 7.43-7.62 (m, 3H), 7.68-7.97 (m, 3H), 8.18-8.31 (m, 1H); MS(ESI) m/z 516 
(M+H)+.The compound was obtained as a crystalline solid after (+)-tartrate salt 
formation followed by recrystallization from isopropyl alcohol. 1H NMR (D2O) : 0.88-1.57 
(m, 22H) 2.62 (s, 6H, N(CH3)2), 2.99-3.23 (m, 2H, CH2N), 3.25-3.60 (m, 3H, 
CH2NCO+CH), 4.50 (s, 4H, 2(CHOH)2), 7.30 –8.20 (m, 8H). 
Decanoic acid {1-[3-(3-cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-
ethyl}-(2-dimethylamino-ethyl)-amide (1h) 
The same procedure as for 1a was applied using 5h (0.36 g, 1.00 mmol). This afforded 
1h as colourless oil (0.12g, 26%).1H NMR (CDCl3) : 0.80 (t, 3H), 1.12-1.21 (m, 16H, 
CH2), 1.34 (d, 3H, CH3), 2.04 (s, 3H, N(CH3)2), 2.17 (s, 3H, N(CH3)2), 2.19-2.50 (m, 2H, 
CH2N), 3.22-3.54 (m, 2H, CH2NCO), 5.16 (q, 0.5H, CH), 5.38 (q, 0.5H, CH), 7.32-7.98 
(m, 7H), 8.20 (d, 1H); MS(ESI) m/z 516 (M+H)+. The compound was obtained as a 
crystalline solid after (+)-tartrate salt formation followed by recrystallization from 
isopropyl alcohol. 1H NMR (D2O) : 0.80-1.82 (m, 22H), 2.77 (s, 3H, N(CH3)2), 2.83 (s, 
3H, N(CH3)2), 3.12-3.30 (m, 2H, CH2N), 3.63-3.97 (m, 2H, CH2NCO), 4.45(s, 4H, 
2(CHOH)2), 5.20 (q, 1H, CH), 7.22 -7.89 (m, 8H).
Decanoic acid (2-dimethylamino-ethyl)-{1-[3-(4-hydroxy-phenyl)-4-oxo-3,4-
dihydro-quinazolin-2-yl]-ethyl}-amide (1i) 
The same procedure as for 5i was applied using 1b (0.53 g, 1.00 mmol). This afforded 1i 
as a colorless oil (0.05 g, 10%). 1H NMR (CDCl3) : 0.84 (t, 3H), 1.12-1.33 (m, 16H, 
CH2), 1.38 (d, 1.4H, CH3) 1.62 (d, 1.6H, CH3), 2.00 (s, 2.5H, N(CH3)2), 2.22 (s, 3.5H, 
N(CH3)2), 2.23-2.40 (m, 1H, CH2N), 2.42-2.63 (m, 1H, CH2N), 3.33-3.62 (m, 2H, 
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CH2NCO), 4.92 (q, 0.4H, CH), 5.15 (s, 1H exchangeable with D2O, OH), 5.43 (q, 0.6H, 
CH), 6.68-7.22 (m, 4H), 7.40-7.79 (m, 3H), 8.24 (d, 1H); MS(ESI) m/z 508 (M+H)+. The 
compound was obtained as a crystalline solid after (+)-tartrate salt formation followed by 
recrystallization from isopropyl alcohol. 1H NMR (CD3OD) : 0.92 (t, 3H), 1.10-1.32 (m, 
16H, CH2), 1.57 (d, 3H, CH3) 2.83 (s, 6H, N(CH3)2),3.12-3.62 (m, 4H, CH2N+CH2NCO), 
4.40 (s, 4H, 2(CHOH)2), 5.40 (q, 1H, CH), 6.68-7.23 (m, 4H), 7.37-7.81 (m, 3H), 8.20 
(d, 1H). 
 
Cyclohexanecarboxylic acid (2-dimethylamino-ethyl)-{1-[3-(4-fluoro-phenyl)-
4-oxo-3,4-dihydro-quinazolin-2-yl]-ethyl}-amide (1j) 
The same procedure as for 1a was applied using 5c (0.35 g, 1.00 mmol) and 
cyclohexane carboxylic acid chloride (0.16 mL, 1mmol). This afforded 1j as a white solid 
(0.23 g, 50%). 1H NMR (CDCl3) : 1.12-1.99 (m, 14H), 2.21 (s, 6H, N(CH3)2), 2.22-2.58 
(m, 2H, CH2N), 3.32-3.70 (m, 2H, CH2NCO), 4,81 (q, 0.2H, CH), 5.18 (q, 0.8H, CH), 
7.08-7.80 (m, 7H), 8.20 (d, 1H); MS(ESI) m/z 466 (M+H)+. 
 
Cyclohexanecarboxylic acid {1-[3-(4-cyano-phenyl)-4-oxo-3,4-dihydro-
quinqzolin-2-yl]-ethyl}-(2-dimethylamino-ethyl)-amide (1k) 
The same procedure as for 1a was applied using 5d (0.36 g, 1.00 mmol) and 
cyclohexane carboxylic acid chloride (0.16 mL, 1mmol). This afforded 1k as a white solid 
(0.23 g, 49%). 1H NMR (CDCl3) : 1.11-2.00 (m, 14H), 2.23 (s, 6H, N(CH3)2), 2.18-2.43 
(m, 2H, CH2N), 3.42-3.62 (m, 2H, CH2NCO), 5.18 (q, 1H, CH), 7.26-7.91 (m, 7H), 8.30 
(d, 1H); MS(ESI) m/z 473 (M+H)+. 
N-(2-Dimethylamino-ethyl)-N-{1-[3-(4-fluoro-phenyl)-4-oxo-3,4-dihydro-
quinazolin-2-yl]-ethyl}-benzamide (1l) 
The same procedure as for 1a was applied using 5c (0.36 g, 1.00 mmol) and benzoyl 
chloride (0.12 mL, 1.00 mmol). This afforded 1l as a white solid (0.11 g, 24%). 1H NMR 
(CDCl3) : 1.49 (d, 3H, CH3), 1.81 (s, 6H, N(CH3)2), 2.16-2.30 (m, 2H, CH2N), 3.33-3.45 
(m, 2H, CH2NCO), 5.24 (q, 1H, CH), 7.20-8.01 (m, 12H), 8.30 (d, 1H); MS(ESI) m/z 460 
(M+H)+. 
N-{1-[3-(4-Cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-ethyl}-N-(2-
dimethylamino-ethyl)-benzamide (1m) 
The same procedure as for 1a was applied using 5d (0.36 g, 1.00 mmol) and benzoyl 
chloride (0.12 mL, 1.00 mmol). This afforded 1m as a white solid (0.07 g, 15%). 1H NMR 
(CDCl3) : 1.43 (d, 3H, CH3), 1.92 (s, 6H, N(CH3)2), 2.11-2.37 (m, 2H, CH2N), 3.32-3.55 
(m, 2H, CH2NCO), 5.23 (q, 1H, CH), 6.80-8.11 (m, 12H), 8.20 (d, 1H); MS(ESI) m/z 467 
(M+H)+. 
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Naphthalene-1-carboxylic acid (2-dimethylamino-ethyl)-{1-[3-(4-fluoro-
phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-ethyl}-amide (1n) 
The same procedure as for 1a was applied using 5c (0.36 g, 1.00 mmol) and 1-naphtoyl 
chloride (0.15 mL, 1.00 mmol). This afforded 1n as a white solid (0.17 g, 33%).1H NMR 
(CDCl3) at 100 C :1H NMR (CDCl3) : 1.22 (d, 3H, CH3), 2.00 (s, 6H, N(CH3)2), 2.13-
2.52 (m, 4H, CH2N), 3.23-3.42 (CH2NCO), 5.37 (q, 1H, CH), 7.22-8.25 (m, 15H), 8.88 
(d, 1H); MS(ESI) m/z 510 (M+H)+. 
 
 
Pharmacology 
 
Radioligand binding assay 
HEK293-CXCR3 cells were grown at 5% CO2 at 37°C in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum, 250 mg/mL G-418, 50 IU of 
penicillin per mL, and 50 mg of streptomycin per mL. These cells were seeded in poly-L-
Lysine-coated 48-well plates. After 24h, binding was performed on whole cells for 4h at 
4°C using approximately 70 pM [125I]-labelled CXCL10 (Perkin Elmer Life Science, 
Boston, USA) in binding buffer (50 mM HEPES [pH 7.4], 1 mM CaCl2, 5 mM MgCl2, 0.5% 
BSA) containing increasing concentrations of the indicated compounds. After incubation, 
cells were washed three times with ice-cold binding buffer supplemented with 0.5 M 
NaCl. Subsequently, cells were lysed and counted in a Wallac Compugamma counter. 
 
[Ca2+] measurements 
CXCL11-induced increases in [Ca2+] were quantified by monitoring the fluorescence of 
Fluo-4 AM-loaded HEK293-CXCR3 cells, using an automated NOVOstar microplate reader 
(BMG Labtech GmbH, Offenburg, Germany). . Cells were loaded in Hanks’ balanced salt 
solution containing 20 mM HEPES, 2.5 mM Probenecid, 2 M Fluo-4 AM and 0.02 % 
Pluronic F-127 [pH = 7.4]. Thereafter they were washed three times and fluorescence 
was measured (1 data point/second, excitation 485 nm, emission 520 nm) for 10 
seconds to calculate the mean basal value. Cells were preincubated for 10 min with the 
indicated compounds (10 M). After injection of the agonist CXCL11 (10 nM) fluorescence 
was recorded for 50 seconds. To determine the maximal fluorescence of the system, cells 
were exposed to Triton X-100 (0.25% [v/v]). Basal and maximal values determined for 
each well were used to normalize the data. Cells preincubated with compounds 1d and 
5d show comparable baseline fluorescence to non-treated cells. Results were expressed 
as percentage of the maximal fluorescence induced by Triton X-100. 
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[3H]Inositol phosphate production 
COS-7 cells were transfected with CXCR3 and Gqi5 chimeric protein.30 24 h after 
transfection cells were labeled overnight in inositol free medium (modified Eagle's 
medium with Earle's salts) supplemented with 2 mM L-glutamine, L-cysteine, L-leucine, 
L-methionine, L-arginine, glucose, 0.2% bovine serum albumin, and 2 Ci/mL myo-[2-
3H]inositol (Amersham Pharmacia Biotech, Roosendaal, The Netherlands). Subsequently, 
the labeling medium was aspirated, cells were washed for 10 min with Dulbecco's 
modified Eagle's medium containing 25 mM HEPES (pH 7.4) and 20 mM LiCl. Cells were 
preincubated for 10 minutes with/or without the indicated compounds and incubated for 
2 h in the same medium in the absence or presence of 10 nM CXCL11 or 30 nM CXCL10. 
The incubation was stopped by aspiration of the medium and addition of cold 10 mM 
formic acid. After 90 min of incubation on ice, inositol phosphates were isolated by anion 
exchange chromatography (Dowex AG1-X8 columns, Bio-Rad) and counted by liquid 
scintillation. 
 
Actin polymerization assay 
Cells were resuspended in RPMI-1640 with 0.25% BSA [BSA, fraction V,Sigma] in a 
concentration of 4 × 106 cells/mL. Indicated compounds were added 10 minutes prior to 
the stimulation. Chemokines was added in a concentration of 10 nM. At indicated time 
points, 25 mL of cell suspension was transferred to 25 mL of fixation solution (4 % 
paraformaldehyde; PFA). Cells were fixed for at least 15 minutes. Thereafter, cells were 
washed and resuspended in 50 mL of permeabilization reagent (0.1% Triton-X 100). 
After 10 minutes, cells were washed, blocked with 1% BSA (5 min), washed and 
incubated with 0.5 mM rhodamine-phalloidin (Molecular Probes, Leiden, The Netherlands) 
to visualize filamentous actin (F-actin). After 45 minutes, cells were centrifuged and 
resuspended in PBS with 0.25% BSA. Mean fluorescence intensity was measured by 
FACS analysis. 
 
Chemotaxis assays 
The assay for chemotaxis was performed in 24 well plates (Costar, Cambridge,MA) 
carrying Transwell permeable supports with 5 m pore size polycarbonate membrane. T 
cells were cultured overnight at 4 × 106 cells/mL in RPMI-1640 containing 0.25% BSA. 
Cells were incubated with indicated compounds for 10 minutes. Medium alone or 
supplemented with chemokine and/or indicated compounds was placed in the lower 
compartment, and cells were loaded onto the inserts at 0.4 × 106/100 l. Chambers were 
incubated for 120 minutes in a 5% CO2, humidified incubator at 37°C. After the 
incubation period, numbers of T cells migrating to the lower chamber were counted under 
a microscope using a hemocytometer. Viability was checked with trypan blue exclusion. 
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All conditions were tested in at least in triplicate; statistic evaluation was performed 
using the Student’s test. 
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Abstract 
 
CXC chemokine receptor-3 (CXCR3) is a G-protein coupled receptor 
(GPCR) predominantly expressed on activated T lymphocytes that 
promote Th1 responses. Previously, we described the 3H-quinazolin-
4-one containing VUF 5834 (decanoic acid {1-[3-(4-cyano-phenyl)-
4-oxo-3,4-dihydroquinazolin-2-yl]-ethyl}-(2-dimethylamino-ethyl)-
amide) as a small-molecule CXCR3 antagonist with submicromolar 
affinity and as a lead structure for the development of CXCR3 
antagonists. More recently, the related 3H-pyrido[2,3-d]pyrimidin-4-
one compounds AMG 487 and NBI-74330 have been reported as 
nanomolar CXCR3 antagonists and these ligands are currently under 
clinical investigation. The aim of this study is to link the structure-
activity relationship (SAR) of the previously published class of 3H-
quinazolin-4-one containing CXCR3 ligands with these novel clinical 
candidates. From the modification of the lead structure VUF 5834 
emerged the importance of the (4-fluoro-3-
(trifluoromethyl)phenyl)acetyl and the 3-methylen-pyridine as 
substituents to improve the affinity at the human CXCR3 receptor, 
whereas other features are less important. The described molecules 
serve as tool to investigate the role of the CXCR3 receptor in various 
inflammatory conditions. 
Chapter 4 
 
Introduction 
 
Chemokines are a family of small proteins (70–80 aminoacids) secreted by leukocytes or 
tissue cells that mediate cellular recruitment to sites of inflammation or injury.1 
Depending on the number and spacing of conserved cysteine residues, chemokines are 
classified into four major groups (CC, CXC, CX3C, and XC).2,3 The IFN--inducible CXC 
chemokines, CXCL9, CXCL10, and CXCL11 interact with CXC chemokine receptor-3 
(CXCR3) to exert their functions.4 Like all the chemokine receptors, CXCR3 belongs to 
the superfamily of the G-protein coupled receptors (GPCR).5 Activation of CXCR3 via G-
proteins of the Gi-type leads to an increase of intracellular calcium and cellular 
migration.6,7 Several studies have shown that levels of CXCL9, CXCL10, and CXCL11 are 
elevated in various chronic inflammatory diseases such as rheumatoid arthritis,8,9 
multiple sclerosis,10 transplant rejection,11 hepatitis C infected liver,12 atherosclerosis,13 
chronic skin reactions,6,14,15 and chronic obstructive pulmonary disease16 and are related 
to the infiltration of CXCR3-positive T-cells. Consequently, it is believed that CXCR3 
antagonists provide a therapeutic approach in chronic inflammatory and neoplastic 
diseases.17-19 
Several classes of CXCR3 antagonists have recently been reported in scientific 
literature.20–25 We24 and others26 have previously described VUF 5834, the decanoic acid 
{1-[3-(4-cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-ethyl}-(2-dimethylamino-
ethyl)-amide 1a, as a submicromolar CXCR3 antagonist and we have continued to 
explore the SAR of this series. During our studies, Amgen Inc. announced that the 
structural derivative AMG 487 (2) was under clinical investigation27, while scientists from 
Neurocrine Biosciences Inc. described pharmacological evaluation of patent compound 
NBI-74330 (3).28 These ligands are the most potent CXCR3 ligands reported to date, 
showing affinity values for the human CXCR3 receptor in the nanomolar range. Here, we 
describe a SAR study in which the previously published 3H-quinazolin-4-one scaffold 
(e.g. VUF 5834, 1a) and the novel 3H-pyrido[2,3-d]pyrimidin-4-one scaffold (exemplified 
by ligands 2 and 3) are compared. For the structures of reference compounds VUF 5834 
(1a), AMG 487 (2), and NBI–74330 (3) see Figure 1.  
 
 
Chemistry 
 
The 3-phenyl-3H-quinazolin-4-one scaffold was constructed as reported earlier (Scheme 
1).24 The reaction of 2-amino-benzoic acid with propionyl chloride afforded 2-
propionylamino-benzoic acid 5 and treatment of this intermediate with phosphorus 
trichloride and 4-ethoxyaniline or 4-amino-benzonitrile afforded compounds 6a  and  6b, 
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Figure 1. Structures of reference compounds VUF 5834 (1a), AMG 487 (2) and NBI –
74330 (3). 
 
 
trichloride and 4-ethoxyaniline or 4-amino-benzonitrile afforded compounds 6a and 6b, 
respectively, in moderate yields. Intermediates 7a and 7b were obtained in good yields 
via reaction with bromine and were used for the subsequent reaction with the 
commercially available N,N-dimethylethylene diamine (leading to 9a and 9b) or 3-
picolylamine (leading to 8). Reaction of 9a and 9b with decanoyl, cyclohexanecarbonyl, 
benzoyl, or phenylacetyl chloride afforded compound 1a–d and 1f whereas compounds 
1e and 10 were obtained via coupling of 8 or 9a, respectively, with (4-trifluoromethoxy-
phenyl)-acetic acid and using EDCI as activating agent. 
The 3H-pyrido[2,3-d]pyrimidin-4-one derivatives 11a–f were prepared according to 
Scheme 2.26 Boc-D-alanine was activated with iso-butylchloroformate under basic 
conditions at –20°C and then allowed to react with 2-aminonicotinic acid leading to 13. 
Because of the poor stability of 13,29 the crude material was immediately reacted with 
either 4-ethoxy-phenylamine or 4-iodo-phenylamine leading to compound 14a and 14b, 
respectively. Subsequent ring closure afforded compounds 15a and 15b in a moderate 
yield. 
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Scheme 1. General synthesis of 3H-quinazolin-4-one analogues. Reagents and 
conditions: i) propionyl chloride, DMF, 40 ºC; ii) p-phenetidine or p-amino-benzonitrile, 
PCl3, toluene, reflux; iii) Br2, CH3COONa, CH3COOH, 40 ºC; iv) H2N(CH2)2N(CH3)2, EtOH, 
reflux; v) acid chloride, NEt3, dioxane or carboxylic acid, EDCI, DCM, DMF; vi) 3-
(aminomethyl)pyridine, NEt3, DMF, DMF ; vii) carboxylic acid, EDCI, DCM. 
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15a : X = OEt
15b : X = I
15c : X = CN
i ii iii
iv
v
vivii
17a : X = OEt, R = pyridin-
3-ylmethyl
17b : X = CN, R = pyridin-
3-ylmethyl
12
N R
vii
 
 
Scheme 2. General synthesis of 3H-pyrido[2,3-d]pyrimidin-4-one analogues. Reagents 
and conditions: i) Iso-butylchloroformate, NMM, DCM, -20oC; ii) 4-ethoxy-phenylamine
or 4-iodo-phenylamine, -20oC; iii) Iso-butylchloroformate, NMM, DCM, -20oC; iv) Zn 
(CN)2, Pd(PPh3)4, DMF, 80oC; v) TFA, DCM, rt; vi) 3-pyridinecarboxaldehyde, 
Na(CH3COO)3BH, DCE; vii) acid chloride, NEt3, dioxane or carboxylic acid, EDCI, DCM, 
DMF or carboxylic acid, EDCI, HOBT, DIPEA, DCM.  
 
 
With the aim to obtain the para-cyano analogue (in our hand the best substituent of the 
3-phenyl-3H-quinazolin-4-one series24) of reference compound 2, intermediate 15b was 
treated with zinc cyanide using tetrakis(triphenylphosphine) palladium as catalyst,30 
resulting in 15c in acceptable yield. The Boc protecting group of 15a and 15c was 
cleaved using trifluoroacetic acid and the amines 16a,b were obtained in excellent yield. 
Key intermediates 17a and 17b were obtained via reductive amination with pyridine-3-
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carbaldehyde. Final compounds 11a–c and 11f were obtained by coupling the 
appropriate amine with the corresponding carboxylic acids31 whereas for compounds 11d 
and 11e the corresponding acid chlorides were used.  
Reference ligands 2 and 3 have been reported as enantiopure compounds using a 
synthetic strategy very similar to the one outlined here.32 In our hands, however, the 
synthesis route described in this patent results in racemic mixtures as determined from 
an absence of e.e. in building blocks 16a,b (as judged from chiral HPLC). This means 
that all final compounds 11 are racemic. 
 
 
Pharmacology 
 
The affinity for the human CXCR3 of all compounds was determined by the displacement 
of [125I]CXCL10 binding to membranes from HEK-293 cells stably expressing the human 
CXCR3 receptor. 
 
Results and discussion 
 
In this study, we set out to link the SAR of the previously described 3H-quinazolin-4-one 
and the more recent 3H-pyrido[2,3-d]pyrimidin-4-one CXCR3 ligand classes. In the 
series of the 3H-quinazolin-4-one analogues (1a–f, 9b, 10, Table 1), proper decoration 
of the amide group is required to achieve appreciable affinity for the receptor. Previously, 
we found that the decanoyl chain of 1a was necessary to obtain micromolar affinity 
values at CXCR3. Indeed, the absence of the decanoyl chain as in amine 9b or in the 
presence of alternative lipophilic acetamide moieties such as cyclohexanecarbonyl 1b, 
benzoyl 1c, or phenylacetyl 1d resulted in a complete loss of affinity (Table 1). Inspired 
by the Amgen patent application,32 we subsequently synthesized the 4-trifluoromethoxy-
phenyl-acetyl compound 1e which showed a threefold increase in CXCR3 affinity (Table 
1) compared to our lead structure 1a. Considering that the phenyl-acetyl derivative 1d 
does not have affinity for the CXCR3 receptor, the affinity of the 4-trifluoromethoxy-
phenylacetyl derivative 1e is striking. Clearly, the 4-trifluoromethoxy substituent has an 
enormous effect on the CXCR3 affinity and it seems that this part of the ligands is able to 
have very specific interaction with the binding site of the receptor. 
Next, the influence of the para-substitution on the phenyl ring in position 3 of the 3H-
quinazolin-4-one scaffold was investigated. We previously described the para-cyano 
moiety (as in 1a) as the best substituent for CXCR3 binding and reported it to be 
substantially better than a methoxy group in this position.24 Considering the para-
ethoxyphenyl group in reference compound 2,32 we synthesized the para-ethoxy 
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substituted analogue for the 3H-quinazolin 4-one series and the resulting ligand 1f 
showed a twofold better affinity compared to the para-cyano-substituted lead compound 
1a. The difference in affinity between the para-methoxyphenyl derivative and the 
improved para-ethoxyphenyl derivative, again illustrates the fine optimization work by 
Amgen scientists. The subsequent replacement of the N,N-ethylendiamine group at R1 
with a pyridin-3-ylmethyl afforded the analogue 10. With a pKi value of 7.5, this 
compound is the most potent CXCR3 antagonist belonging to the 3H-quinazolin-4-one 
series. Moreover, the development of 10 nicely illustrates the key role of both the R1 and 
R2 substituents at the amino function. 
 
 
Table 1. pKi values of the 3H-quinazolin-4-one analogues as determined by the 
displacement of [125I]CXCL10 binding to the human CXCR3 receptor. 
 
X
 
  
O
N
N
N
R1 R2
 
Compound no X R1 R2 pKi#
1a CN CH2CH2N(CH3)2 CO(CH2)8CH3 6.26±0.25 
9b CN CH2CH2N(CH3)2 H <5 
1b CN CH2CH2N(CH3)2 cyclohexanecarbonyl <5 
1c CN CH2CH2N(CH3)2 benzoyl <5 
1d CN CH2CH2N(CH3)2 phenyl-acetyl <5 
1e CN CH2CH2N(CH3)2 (4-Trifluoromethoxy-
phenyl)-acetyl 
6.71±0.04 
1f OCH2CH3 CH2CH2N(CH3)2 CO(CH2)8CH3 6.56±0.04 
10 OCH2CH3 pyridin-3-ylmethyl (4-Trifluoromethoxy-
phenyl)-acetyl 
 
7.45±0.13 
#The binding experiments were carried out on cell membranes fractions from  HEK-293 
cells stably expressing the human CXCR3 receptor. The compounds were tested for their 
ability to displace [125I]CXCL10 binding. The values are represented as the mean ± 
S.E.M. of at least three independent experiments. All compounds are racemic. 
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Next, we explored if the SAR of the 3H-quinazolin-4-ones could be transferred to the new 
3H-pyrido[2,3-d]pyrimidin-4-one scaffold. Comparing the two series (Tables 1 and 2) 
shows that the introduction of an additional nitrogen atom in the heterocyclic scaffold did 
not affect the CXCR3 affinity (compare 10 with 11a). However, the different amino 
substituents at R1 and R2 again had dramatic effects on the CXCR3 affinity. Compound 
11d shows that the decanoyl chain is tolerated, as it is for the 3H-quinazolin-4-one 
series, although only a submicromolar affinity is obtained. In addition, the unsubstituted 
phenylacetyl analogue 11e did not have affinity for the CXCR3 receptor, while the 
slightly more functionalized 4-trifluoromethoxy-phenylacetyl group, as in reference 
compound 2, significantly improves affinity. Again, a properly substituted phenyl ring is a 
key determinant for CXCR3 binding. 
 
Table 2. pKi values of the 3H-pyrido[2,3-d]pyrimidin-4-one analogues as determined by 
the displacement of [125I]CXCL10 binding to the human CXCR3 receptor. 
 
X
 
  
O
N
N
N
N
R1 R2
 
Compound no X R1 R2 pKi# 
11a OCH2CH3 pyridin-3-ylmethyl (4-Trifluoromethoxy-
phenyl)-acetyl 
7.39±0.08 
11b CN pyridin-3-ylmethyl (4-Trifluoromethoxy-
phenyl)-acetyl 
7.39±0.05 
11c OCH2CH3 pyridin-3-ylmethyl (4-Fluoro-3-
trifluoromethyl-phenyl)-
acetyl 
8.13±0.12 
11d OCH2CH3 pyridin-3-ylmethyl CO(CH2)8CH3 6.47±0.09 
11e OCH2CH3 pyridin-3-ylmethyl phenyl-acetyl <5 
11f OCH2CH3 H (4-Trifluoromethoxy-
phenyl)-acetylH 
5.34±0.19 
16a OCH2CH3 H H <5 
17a OCH2CH3 pyridin-3-ylmethyl H <5 
#The binding experiments were carried out on cell membranes fractions from HEK-293 
cells stably expressing the human CXCR3 receptor. The compounds were tested for their 
ability to displace [125I]CXCL10 binding. The values are represented as the mean ± S.E.M 
of at least three independent experiments. All compounds are racemic. 
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Compound 11c has a fivefold higher affinity for CXCR3 than 11a, meaning that in this 
subset of 3H-pyrido[2,3-d]pyrimidin-4-ones the (4-fluoro-3-trifluoromethyl-phenyl)-
acetyl is the best substituent at R2. These results validate recent disclosures by Amgen 
Inc. and Neurocrine Biosciences Inc.27,28 The presence of both a proper acetamide 
substituent and the pyridin-3-ylmethyl group are necessary for high CXCR3 affinity. The 
absence of one of the two (compounds 17a and 11f) or both (16a) causes a dramatic 
loss of affinity. Nevertheless, 11f with (4-trifluoromethoxy-phenyl)-acetyl substituent 
retains a micromolar affinity for the receptor. 
Finally, the influence of the para-substituent on the phenyl ring in position 3 of the 3H-
pyrido[2,3-d]pyrimidin-4-ones was investigated. Compound 11b was synthesized to 
determine the effect of para-cyano substitution. For this particular scaffold, the para-
ethoxy derivative 11a and para-cyano derivative 11b do not show significant differences 
in CXCR3 affinity. 
 
 
Conclusions 
 
This study presents the synthesis and initial SAR of CXCR3 antagonists of the 3H-
quinazolin-4-one and 3H-pyrido[2,3-d]pyrimidin-4-one series. These compounds are 
useful as tools for targeting CXCR3 in a variety of inflammatory models. Moreover, the 
structural insights obtained may be used in the design of novel CXCR3 antagonists. 
 
 
Experimental 
 
Chemistry 
 
General procedures. The solvents were dried according to standard procedures. All 
reactions were performed under an atmosphere of dry nitrogen. 1H- and 13C-NMR spectra 
were recorded on a Bruker AC-200 (200 MHz; Bruker Bioscience, Billerica, MA, USA) 
spectrometer. Flash column chromatography was carried out with J. T. Baker silica gel (J. 
T. Baker, Deventer, The Netherlands). Analytical HPLC-MS analyses were conducted 
using a Shimadzu LC-8A preparative liquid chromatograph pump system with a 
Shimadzu SPD-10AV UV-Vis detector set at 254 nm, with the MS detection performed 
with a Shimadzu LCMS-2010 liquid chromatograph mass spectrometer (Shimadzu, 
Tokyo, Japan). The analyses were performed using the following two conditions. 
Condition I: an Xbridge (C18) 5 m column (100 mm × 4.6 mm), with the following two 
solvents: solvent A: 10% buffer pH 8 – 90% H2O; solvent B: 10% aqueous buffer pH 8 – 
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90% acetonitrile. Flow rate = 2.0 mL/min; gradient from 5% to 90% B in 10 min, then 5 
min at 90% B, then 15 min at 5% B. The total run time was 30 min. The buffer-pH 8 is 
prepared with ammonium bicarbonate in H2O (0.4% w/v) adjusted to pH 8 with 
ammonium hydroxide. Condition II: Xbridge (C18) 5 m column (100 mm × 4.6 mm), 
with the following two solvents: solvent A: 0.1% formic acid – 99.9% H2O; solvent B: 
0.1% formic acid/99.9% acetonitrile. Flow rate = 2.0 mL/ min. Gradient from 5% to 90% 
B in 10 min, then 5 min at 90% B, then 15 min at 5% B. The total run time was 30 min. 
Purities calculated are based on RP HPLC-UV peak surface area of the compounds. Chiral 
HPLC analyses were performed with a CHIRAL CEL OD-H column (4.6 mm × 250 mm) 
DAIC 14325, using as eluents 0.05% diethylamine in hexane/isopropyl alcohol (95 : 5). 
Flow rate = 1.1 mL/min, T = 30°C. High Resolution Electron Impact Ion Mass Spectra 
(HREIMS) were recorded on a Finnigan MAT 900 mass spectrometer (Thermo Electron 
Corporation, Bremen, Germany). 
 
2-Propionylamino-benzoic acid (5) 
Anthranilic acid (4) (68.60 g, 0.50 mol) was dissolved in N,N-dimethylformamide (250 
mL). Propionyl chloride (47.60 mL, 0.55 mol) was added drop wise at such a rate that 
the temperature of the mixture remained below 40 ºC. The product began to precipitate 
after about one half of the acid chloride was added, and the suspension was stirred 
vigorously at room temperature for an additional three hours after the addition was 
completed. The resulting mixture was poured into water (2.0 L) and stirred for an 
additional two hours. The precipitated product was collected by filtration, washed with 
water and dried in a vacuum oven at 40 ºC under reduced pressure to afford 73.03 g 
(76%) of white crystals. 1H NMR (CDCl3) : 1.25 (t, J = 7.6 Hz, 3H), 2.55 (q, J = 7.6 Hz, 
2H), 6.75 (brs, 1H), 7.07-7.14 (m, 1H), 7.55-7.59 (m, 1H), 8.02-8.14 (m, 1H), 8.72-
8.76 (m, 1H), 10.98 (s, 1H). 
 
3-(4-ethoxyphenyl)-2-ethylquinazolin-4(3H)-one (6a)  
To a suspension of 2-propionylamino-benzoic acid (3.00 g, 15.52 mmol) and p-
phenetidine (2.41 g, 15.52 mmol) in toluene was added drop wise phosphorus trichloride 
(0.61 mL, 6.98 mmol). The resulting suspension was heated to reflux for 8 hours. After 
cooling to room temperature, a saturated sodium carbonate solution was added and the 
mixture was stirred vigorously until all solid was dissolved. The solvent was removed in 
vacuum and the resulting solid was collected by filtration, rinsed with water, dried and 
recrystallized from isopropyl alcohol to afford the desired compound as a white solid. 
Yield: 2.19 g (48%). 1H NMR (CDCl3) : 1.20 (t, J = 7.4 Hz, 3H), 1.42 (t, J = 7.0 Hz, 
3H), 2.44 (q, J = 7.4 Hz, 2H), 4.10 (q, J = 7.0 Hz, 2H), 7.01-7.23 (m, 4H), 7.39-7.58 
(m, 1H), 7.62-7.89 (m, 2H), 8.22-8.26 (m, 1H).  
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4-(2-Ethyl-4-oxoquinazolin-3(4H)-yl)benzonitrile (6b) 
This was performed analogously to the preparation of 6a, using p-amino-benzonitrile 
(2.22 g, 15.52 mmol). Yield: 1.50 g (35%). 1H NMR (CDCl3) : 1.18 (t, J = 7.4 Hz, 3H), 
2.34 (q, J = 7.4 Hz, 2H), 7.30-7.55 (m, 3H), 7.60-7.95 (m, 4H), 8.21-8.29 (m, 1H). 
2-(1-Bromo-ethyl)-3-(4-ethoxy-phenyl)-3H-quinazolin-4-one (7a)  
A mixture of 6a (2.23 g, 7.56 mmol), anhydrous sodium acetate (756 mg) and glacial 
acetic acid (10 mL) was warmed 40 ºC. A solution of bromine (7.56 mmol) in acetic acid 
(2 mL) was added over a period of 3 hours. After the addition was completed the mixture 
was poured into water (150 mL) and stirred at room temperature for about 2 hours. The 
precipitate product was isolated by filtration, washed with warm water to remove the 
trace of the acetic acid, then rinsed with a small amount of isopropyl alcohol and dried to 
provide the desired compound 7a as a solid. Yield: 2,71 g (96%). 1H NMR (CDCl3) : 
1.44 (t, J = 7.0 Hz, 3H), 2.02 (d, J = 6.7 Hz, 3H), 4.08 (q, J = 7.0 Hz, 2H), 4.61 (q, J = 
6.7 Hz, 1H), 6.90-7.25 (m, 3H), 7.30-7.55 (m, 2H), 7.75-7.80 (m, 2H), 8.24-8.28 (m, 
1H).  
 
4-[2-(1-Bromo-ethyl)-4-oxo-4H-quinazolin-3-yl]-benzonitrile (7b) 
This was performed analogously to the preparation of 7a, using 6b (2.08 g, 7.56 mmol). 
Yield: 2.34 g (88%). 1H NMR (CDCl3) : 2.02 (d, J = 6.6 Hz, 3H), 4.40 (q, 1H, J = 6.6 
Hz), 7.25-7.35 (m, 1H), 7.45-7.65 (m, 1H), 7.70-7.95(m, 5H), 8.20-8.24 (m, 1H). 
 
2-[1-(2-Dimethylamino-ethylamino)-ethyl]-3-(4-ethoxy-phenyl)-3H-quinazolin-
4-one (9a)  
A mixture of 7a (2.82 g, 7.57 mmol) and N,N-dimetylethylendiamine (1.31 mL, 12.11 
mmol) in ethanol (100 mL) was heated to reflux for 18 hours. The ethanol was removed 
in vacuo and the concentrate dissolved in chloroform and washed with saturated aqueous 
sodium bicarbonate (3  50 mL) and the combined organic extracts dried over sodium 
sulfate, filtered and concentrated. The crude material was purified by flash 
chromatography on silica gel eluting with methanol/dichloromethane (1:9) to afford the 
desired compound as white solid. Yield: 1.48 g (52%). 1H NMR (CDCl3) : 1.24 (d, J = 
6.4 Hz, 3H), 1.43 (t, J = 6.9 Hz, 3H), 2.20 (s, 6H), 2.35-2.75 (m, 4H), 3.48 (q, J = 6.4 
Hz, 1H), 4.07 (q, J = 6.9 Hz, 2H), 7.15-7.25, (m, 4H), 7.40-7.55 (m, 1H), 7.55-7.80 (m, 
2H), 8.22-8.26 (m, 1H).  
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4-{2-[1-(2-Dimethylamino-ethylamino)-ethyl]-4-oxo-4H-quinazolin-3-yl}-
benzonitrile (9b) 
This was performed analogously to the preparation of 9a, using 7b (2.68 g, 7.56 mmol).
Yield: 1.28 g (47%). 1H NMR (CDCl3) : 1.23 (d, J = 6.6 Hz, 3H), 2.22 (s, 6H), 2.30-2.59 
(m, 4H), 3.31 (q, J = 6.6 Hz, 1H), 7.22-7.50, (m, 3H), 7.70-7.86 (m, 4H), 8.20-8,24 (m, 
1H). 13C NMR (CDCl3) : 20.87, 44.69, 45.12 (2 C), 54.93, 58.83, 113.55, 117.52, 
120.42, 126.88, 127.04, 127.22 (2C), 129.71, 133.60, 133.66, 134.87, 140.66, 147.13, 
158.59, 161.92. HREIMS m/z 361.18876 (calcd for C21H23N5O, 361.1903). Anal. RP-HPLC 
I: tR = 10.86 min (purity 100%), II: tR = min 9.57 (purity 97%),  
 
3-(4-Ethoxy-phenyl)-2-{1-[(pyridin-3-ylmethyl)-amino]-ethyl}-3H-quinazolin-
4-one (8) 
A solution of 3-(aminomethyl)pyridine (0.11 mL, 1.07 mmol) and triethylamine (0.15 mL, 
1.07 mmol) in DMF (50 mL) was stirred for 0.5 h at room temperature. Then 7a (0.40 g, 
1.07 mmol) was added and the solution was stirred overnight. The reaction mixture was 
concentrated, dissolved in water and extracted with DCM. The organic layer was washed 
with water and a saturated aqueous sodium carbonate, then dried, concentrated and 
purified via flash chromatography (DCM/MeOH, 9.5:0.5) to afford the desired compound 
as 170 mg (40%) of pale yellow oil.1H NMR (CDCl3) : 1.23 (d, J = 6.6 Hz, 3H), 1.40 (t, J 
= 7.0 Hz, 3H), 3.48 (q, J = 6.6 Hz, 1H), 3.40-3.80 (m, 2H), 4.00 (q, J = 7.00 Hz, 2H), 
6.75-7.25, (m, 5H), 7.45 (m, 1H), 7.55-7.80 (m, 3H), 8.22-8.26 (m, 1H), 8.35-8.50 (m, 
2H). 
 
[1-(4-Oxo-4H-pyrido[2,3-d][1,3]oxazin-2-yl)-ethyl]-carbamic acid tert-butyl 
ester (13) 
N-(tert-butoxycarbonyl)-D-alanine (Boc-D-Ala) (5.00 g, 26.43 mmol) was dissolved in 
dry DCM (350 mL). N-methylmorpholine (7.30 mL, 66.07 mmol) was added and the 
reaction mixture was allowed to stir for 20 min. Iso-butylchloroformate (6.9 ml, 52.85 
mmol) was added and the reaction flask was cooled to -20oC. Next, 2-aminonicotinic acid 
(3.65 g, 26.43 mmol) was added and the reaction mixture was allowed to warm up to 
room temperature, stirred overnight and then refluxed for 2.5h. The suspension was 
cooled to room temperature, filtrated and concentrated under reduced pressure. The 
crude product was used for the next step without any purification.  
 
{1-[3-(4-Ethoxy-phenylcarbamoyl)-pyridin-2-ylcarbamoyl]-ethyl}-carbamic 
acid tert-butyl ester (14a)  
Compound 13 (7.70 g, 26.43 mmol) as crude material was dissolved in dry DCM (250 
mL) cooled to -20oC. 4-Ethoxy-phenylamine (3.27 mL, 26.43 mmol) was added and 
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stirred for 3h. The reaction mixture was allowed to warm up to room temperature 
overnight, and then washed with 1.0 N hydrochloric acid, saturated aqueous sodium 
bicarbonate and brine. The organic phase was dried over sodium sulphate, filtered and 
concentrated in vacuum. The crude product was used for the next step without further 
purification. 
 
{1-[3-(4-Iodo-phenylcarbamoyl)-pyridin-2-ylcarbamoyl]-ethyl}-carbamic acid 
tert-butyl ester (14b) 
This was performed analogously to the preparation of 14a, using 4-iodo-phenylamine 
(5.79 g, 26.43 mmol). The crude product was used for the next step without further 
purification. 
 
{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-
ethyl}-carbamic acid tert-butyl ester (15a)  
A solution containing the crude 14a (6.69 g, 15.62 mmol) in 50 mL DCM and N-
methylmorpholine (0.86 mL, 7.81 mmol) was stirred for 20 min at room temperature, 
then cooled to -20oC. Iso-butylchloroformate (1.01 mL, 7.81 mmol) was added drop 
wise. The solution was stirred for 3 h and subsequently allowed to warm to room 
temperature overnight. The reaction mixture was washed with 1.0 N hydrochloric acid, 
saturated aqueous sodium bicarbonate and brine. The organic phase was dried over 
sodium sulphate, filtered, concentrated in vacuum to give a dark-yellow oil. This material 
was dissolved in a small amount of DCM. While stirring, petroleum ether was added. The 
resulting precipitate was collected by filtration, washed with petroleum ether and dried to 
afford 15a as a pale yellow solid. Yield: 3.47 g (64%). 1H NMR (CDCl3) : 1.17 (d, J = 
7.00 Hz, 3H), 1.29-1.50 (m, 12H), 4.06 (q, J = 7.00 Hz, 2H), 4.61-4.66 (m, 1H), 5.75-
5.79 (m, 1H), 7.01-7.44 (m, 5H ), 8.56-8.58 (m, 1H), 8.93-8.95 (m, 1H).  
 
{1-[3-(4-Iodo-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-
carbamic acid tert-butyl ester (15b) 
This was performed analogously to the preparation of 15a, using 14b (6.40 g, 15.62 
mmol). Yield: 3.80 g (59%) of a pale yellow solid. 1H NMR (CDCl3) : 1.28 (d, J = 6.77 
Hz, 3H), 1.36 (s, 9H), 4.45-4.54 (m, 1H), 5.60-5.73 (m, 1H), 6.97-7.01 (m, 2H), 7.40-
7.47 (m, 1H), 7.86-7.96 (m, 1H), 8.56-8.58 (m, 1H), 8.96-8.97 (m, 1H). 
 
{1-[3-(4-Cyano-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-
ethyl}-carbamic acid tert-butyl ester (15c) 
To a solution containing 15b (0.50 g, 1.02 mmol) and zinc cyanide (0.17 g, 1.52 mmol) 
in DMF (30 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.24 g, 0.2 mmol). 
 69
Chapter 4 
 
The reaction mixture was heated to 80oC for five hours, diluted with ethyl acetate and 
filtered trough a pad of celite. The filtrate was concentrated under reduced pressure. The 
residue was diluted with ethyl acetate and washed with saturated aquous sodium 
bicarbonate (1×50 mL). The aqueous layer was extracted with ethyl acetate (3×50 mL) 
and the combined organic layers were concentrated. 
The crude material was purified by flash chromatography (ethyl acetate/hexane, 1:1) to 
afford 15c as white solid. Yield: 0.24 g (60%). 1H NMR (CDCl3) : 1.25 (d, J = 6.8 Hz, 
3H), 1.31 (s, 9H), 4.42-4.44 (m, 1H), 5.53-5.56 (m, 1H), 7.34-7.94 (m, 5H), 8.53-8.55 
(m, 1H), 8.93-8.95 (m, 1H) 
 
2-(1-Amino-ethyl)-3-(4-ethoxy-phenyl)-3H-pyrido[2,3-d]pyrimidin-4-one (16a) 
Compound 15a (2.16 g, 5.27 mmol) in DCM (25 mL) was treated with trifluoroacetic acid 
(8.50 mL) and stirred for four hours at room temperature. The reaction was extracted 
with hydrochloric acid 1M (3×50 mL), combined water layers were made basic with 
aqueous NH4OH solution (25%, pH 9-10) and extracted with DCM (3×150 mL). The 
combined organic layers were dried over Na2SO4 and concentrated to afford 1.64 g of 
16a in quantitative yield as a white solid. 1H NMR (CDCl3) : 1.31 (d, J = 6.6 Hz, 3H), 
1.44 (t, J =7.0 Hz, 3H), 1.81 (s, 2H), 3.78 (q, J = 6.6 Hz, 1H), 4.07 (q, J = 7.0 Hz, 2H), 
7.00-7.17 (m, 4H), 7.40-7.42 (m, 1H), 8.55-8.57 (m, 1H), 8.95-8.97 (m, 1H). 13C NMR 
(CDCl3) : 14.61, 22.77, 49.57, 63.71, 115.65, 115.86, 123.55, 124.27, 128.58, 129.03, 
132.35, 140.65, 152.15, 156.50, 159.56, 164.54. HREIMS m/z 310.14254 (calcd for 
C17H18N4O2, 310.1430). Anal. RP-HPLC I: tR = 10.08 min (purity 99%), II: tR = min 10.44 
(purity 100%). Chiral HPLC: R-enantiomer: tR = 14.91 min, S-enantiomer: tR = 21.78 
min. E.e. = 0 %.  
 
4-[2-(1-Amino-ethyl)-4-oxo-4H-pyrido[2,3-d]pyrimidin-3-yl]-benzonitrile (16b) 
This was performed analogously to the preparation of 16a, using 15c (2.06 g, 5.27 
mmol). Yield: 1.53 g (100%) of a white solid. 1H NMR (CDCl3) : 1.31 (d, J = 6.6 Hz, 
3H), 2.39 (brs, 2H), 3.62 (q, J = 6.6 Hz, 1H), 7.23-7.70 (m, 3H), 7.70-7.87 (m, 2H), 
8.51-8.53 (m, 1H), 8.96-8.98 (m, 1H). E.e. = 0 %. 
 
3-(4-Ethoxy-phenyl)-2-{1-[(pyridin-3-ylmethyl)-amino]-ethyl}-3H-pyrido[2,3-
d]pyrimidin-4-one (17a)  
To a solution containing 16a (3.60 g, 11.60 mmol) in dichloroethane (150 mL) was 
added 3-pyridinecarboxaldehyde (1.21 mL, 12.76 mmol) followed by sodium 
triacetoxyborohydride (3.69 g, 17.40 mmol). The reaction was allowed to stir at room 
temperature overnight. The mixture was diluted with DCM and washed with 1.0 M 
ammonium hydroxide (1 × 150 mL). The organic phase was dried over magnesium 
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sulfate , filtered and concentrated to afford an yellow oil that was purified by flash 
chromatography (DCM/MeOH, 9.5:0.5). A white powder was isolated. Yield: 3.58 g 
(77%). 1H NMR (CDCl3) : 1.29 (d, J = 6.6 Hz, 3H), 1.41 (t, J = 7.0 Hz, 3H), 2.53 (brs, 
1H), 3.42-3.80 (q, J = 6.6 Hz, 1H), 3.42-3.80 (m, 2H), 4.02 (q, J = 7.0 Hz, 2H), 6.80-
7.24 (m, 5H), 7.41-7.43 (m, 1H), 7.61-7.63 (m, 1H), 8.41-8.43 (m, 2H), 8.59-8.61 (m, 
1H), 8.97-8.99 (m, 1H). 13C NMR (CDCl3) : 14.56, 21.32, 48.77, 53.27, 63.68, 115.45, 
115.58, 115.99, 122.28, 123.19, 127.46, 128.62, 128.88, 134.83, 135.52, 136.77, 
148.36, 149.44, 156.12, 157.51, 159.53, 162.67, 164.66. HREIMS m/z 368.16152 (calcd 
for C23H23N5O2 – CH3, 368.1617 ). Anal. RP-HPLC I: tR = 10.75 min (purity 97%), II: tR = 
min 10.63 (purity 97%).  
 
4-(4-Oxo-2-{1-[(pyridin-3-ylmethyl)-amino]-ethyl}-4H-pyrido[2,3-d]pyrimidin-
3-yl)-benzonitrile (17b) 
This was performed analogously to the preparation of 17a, using 16b (3.38 g, 11.60 
mmol) Yield: 2.52 g (57%) of a white powder. 1H NMR (CDCl3) : 1.34 (d, J = 6.61 Hz, 
3H), 3.35 (q, J = 6.61 Hz, 1H), 3.62-3.88 (m, 2H), 7.15-7.32 (m, 2H ), 7.33-7.35 (m, 
1H), 7.54-7.56 (m, 1H), 7.69-7.71 (m, 2H), 7.84-7.86 (m, 1H), 8.49-8.51 (m, 2H), 
8.59-8.61 (m, 1H), 9.00-9.02 (m, 1H). 
 
Decanoic acid {1-[3-(4-cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-
ethyl}-(2-dimethylamino-ethyl)-amide (1a)  
To one equivalent of 9b (0.36 mg, 1.00 mmol) and one equivalent of triethylamine (0.14 
mL, 1.00 mmol) dissolved in 25 mL dioxane was added one equivalent of decanoyl-
chloride (0.21 mL, 1.00 mmol). The resulting mixture was stirred at room temperature 
for 18 hours and concentrated under reduced pressure. The residue was dissolved in 
dichloromethane and washed with saturated aqueous Na2CO3 solution, then twice with 
water. The organic phases were dried over anydrous Na2SO4 and evaporated. The crude 
material was purified by flash chromatography with ethyl acetate/methanol (9/1) to 
afford the desired compound as free bases. Yield 0.18 g (35%). 1H NMR (CDCl3) : 0.83-
0.85 (m, 3H), 1.20-1.22 (m, 16H), 1.34 (d, J = 6.9 Hz, 3H), 1.37-1.49 (m, 2H), 1.86-
2.19 (m, 7H), 3.30-3.50 (m, 2H), 4.65 (q, 0.2H), 5.18 (q, J = 6.9 Hz, 0.8H), 7.33-7.83 
(m, 7H), 8.19-8.22 (m, 1H). 13C NMR (CDCl3) : 13.94, 16.35, 22.48, 22.23, 29.10, 
29.27(2C), 31.67, 30.09, 41.141, 45.33, 45.61(2C), 50.58, 59.69, 113.36, 117.76, 
120.66, 126.87, 127.27, 127.44, 129.33, 130.10, 133.28, 133.38, 134.66, 140.14, 
146.78, 155.28, 161.89. HREIMS m/z 515.32438 (calcd for C31H41N5O2, 515.3260). Anal. 
RP-HPLC I: tR = 15.80 min (purity 95%), II: tR = min 15.43 (purity 100%), tailing due to 
the decanoic acid moiety.  
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Cyclohexanecarboxylic acid {1-[3-(4-cyano-phenyl)-4-oxo-3,4-dihydro-
quinazolin-2-yl]-ethyl}-(2-dimethylamino-ethyl)-amide (1b)  
This was performed analogously to the preparation of 1a, using 9b and 
cyclohexanoylchloride (0.13 mL, 1.00 mmol). Yield 0.36 g (77%). 1H NMR (CDCl3) : 
1.21-1.56 (m, 6H), 1.63-1.89 (m, 8H), 2.12-2.36 (m, 8H), 3.41-3.59 (m, 2H), 1.86-2.19 
(m, 7H), 5.24 (q, J = 6.7 Hz, 1H), 7.34-7.83 (m, 7H), 8.19-8.22 (m, 1H).13C NMR 
(CDCl3) : 16.23, 25.40, 25.52 (2C), 25.61, 41.21, 41.64, 45.66 (2C), 50.18, 60.28, 
113.31, 117.84, 120.67, 126.89, 127.40, 129.50, 130.13, 133.26, 133.60, 134.69, 
140.10, 146.85, 155.35, 161.88, 176.36. HREIMS m/z 471.26212 (calcd for C28H33N5O2, 
471.2634). Anal. RP-HPLC I: tR = 13.19 min (purity 99%), II: tR = min 11.22 (purity 
100%).  
 
N-{1-[3-(4-Cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-ethyl}-N-(2-
dimethylamino-ethyl)-benzamide (1c) 
This was performed analogously to the preparation of 1a, using 9b and benzoylchloride 
(0.12 mL, 1.00 mmol). Yield: 0.10 g (22%). 1H NMR (CDCl3) : 1.47 (d, J = 6.8 Hz, 3H), 
1.87 (s, 6H), 2.01-2.45 (m, 2H), 3.42-3.57 (m, 2H), 5.21-5.25 (m, 1H), 6.75-7.14 (m, 
8H), 7.15-7.95 (m, 4H), 8.12-8.25 (m, 1H). 13C NMR (CDCl3) :18.66, 44.33 (2C), 57.13, 
52.35 58.40, 114.85 (2C), 119.75, 122.05, 127.87, 128.93 (2C), 129.92, 130.28, 
130.32, 130.67, 131.64, 133.32, 133.81, 134.33, 134.71, 136.57, 141.03, 147.72, 
156.22, 177.85 HREIMS: the compound is not eligible for detecting the mass ion peak. 
Anal. RP-HPLC I: tR = 12.39 min (purity 100%), II: tR = min 12.09 (purity 100%).  
 
N-{1-[3-(4-Cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-ethyl}-N-(2-
dimethylamino-ethyl)-2-phenyl-acetamide (1d) 
This was performed analogously to the preparation of 1a, using 9b and 
phenylacetylchloride (0.13 mL, 1.00 mmol).  
Yield: 0.19 g (40%). 1H NMR (CDCl3) : 1.37 (d, J = 7.0 Hz, 3H), 1.77-2.62 (m, 9H), 
3.33-4.66 (m, 3H), 5.18 (q, J = 7.0 Hz, 1H), 7.12-7.97 (m, 7H), 8.21-8.23 (m, 1H). 13C 
NMR (CDCl3) : 16.23, 40.14, 42.52, 45.64 (2C), 51.01, 59.73, 113.31, 117.76, 120.70, 
126.88, 127.02, 127.35, 127.90, 128.03, 128.62, 128.76, 129.30, 130.06, 133.32, 
133.81, 134.33, 134.71, 140.00, 146.72, 155.10, 161.85, 171.20. HREIMS m/z 
479.23178 (calcd for C29H29N5O2, 479.2321). Anal. RP-HPLC I: tR = 12.83 min (purity 
98%), II: tR = min 12.31 (purity 99%).  
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Decanoic acid (2-dimethylamino-ethyl)-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-
dihydro-quinazolin-2-yl]-ethyl}-amide (1f) 
This was performed analogously to the preparation of 1a, using 9a (0.38 g, 1.00 mmol) 
and decanoylchloride (0.21 mL, 1.00 mmol). Yield: 0.23 g (42%). 1H NMR (CDCl3) at 
27oC : 0.78-0.81 (m, 3H), 1.05-1.29 (m, 18H), 1.33-1.50 (m, 4H), 2.11-2.38 (m, 8H), 
3.10-3.17 (m, 0.4H), 3.53-3.57 (m, 1.6H), 3.98 (q, J = 7.0 Hz, 2H), 4.80 (q, J = 7.2 Hz, 
0.8H), 5.13 (q, J = 7.2 Hz, 0.2H), 6.84-7.15 (m, 3H), 7.25-7.77 (m, 4H), 8.05-8.28 (m, 
1H). Peak splitting due to the presence of rotamers, as confirmed by 1H NMR (DMSO) 
measurements at 90oC. HREIMS m/z 534.35434 (calcd for C32H46N4O3, 534.3570). Anal. 
RP-HPLC I: tR = 16.67 min (purity 74%), II: tR = min 16.44 (purity 98%), tailing due to 
the decanoic acid moiety.  
 
Decanoic acid {1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-
d]pyrimidin-2-yl]-ethyl}-pyridin-3-ylmethyl-amide (11d)  
This was performed analogously to the preparation of 1a, using 17a (0.40 g, 1.00 mmol) 
and decanoylchloride (0.21 mL, 1.00 mmol). Yield: 0.22 g (40%). 1H NMR (CDCl3) at 
27oC : 0.80-0.82 (m, 3H), 1.10-1.97 (m, 20H), 2.23-2.30 (m, 2H), 4.01 (q, J = 7.0 Hz, 
2H), 4.78-5.22 (m, 2.4H), 5.30 (q, J = 7.2 Hz, 0.6H), 6.54-6.59 (m, 0.3H), 6.90-8.19 
(m, 8H), 8.42-8.55 (m, 1.7H), 8.90-9.01 (m, 1H). Peak splitting due to the presence of 
rotamers, as confirmed by 1H NMR (DMSO) measurements at 90oC. HREIMS Not eligible 
for detecting the ion peak mass. Anal. RP-HPLC I: tR = 15.06 min (purity 96%), II: tR = 
min 16.28 (purity 96%), tailing due to the decanoic acid moiety.  
 
N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-
ethyl}-2-phenyl-N-pyridin-3-ylmethyl-acetamide (11e)  
This was performed analogously to the preparation of 1a, using 17a and 
phenylacetylchloride (0.13 mL, 1.00 mmol). Yield: 0.04 g (8%). 1H NMR (CDCl3) at 27oC 
: 1.20 (d, J = 7.2.Hz, 2H), 1.40 (t, J = 6.9 Hz, 3H), 2.40-2.99 (m, 0.4H), 3.45-3.55 (m, 
1.6H), 4.03 (q, J = 6.9 Hz, 2H), 4.35-5.17 (m, 2H ), 5.35 (q, J = 7.2 Hz, 1H), 6.85-7.50 
(m, 11H), 7.50-7.75 (m, 1H), 8.25-8.60 (m, 3H), 8.75- 8.92-9.04 (m, 1H). Peak splitting 
due to the presence of rotamers, as confirmed by 1H NMR (DMSO) measurements at 
90oC. HREIMS m/z 519.22551 (calcd for C31H29N5O3, 519.2270). Anal. RP-HPLC I: tR = 
12.16 min (purity 100%), II: tR = min 13.22 (purity 100%). 
 
N-{1-[3-(4-Cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-ethyl}-N-(2-
dimethylamino-ethyl)-2-(4-trifluoromethoxy-phenyl)-acetamide (1e) 
To one equivalent 9b (0.36 mg, 1.00 mmol), and one equivalent (4-trifluoromethoxy-
phenyl)-acetic acid (0.22 g, 1.00 mmol) dissolved in 25 mL dichloromethane and two 
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drops N,N-dimethylformamide, one equivalent of 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDCI) (0.19 g, 1.00 mmol) was added. The reaction 
mixture was stirred overnight, then basified with sodium bicarbonate solution and 
extracted with dicloromethane (3×50 mL). The organic layers were collected, dried over 
sodium sulfate concentrated and purified by flash chromatography (DCM/methanol, 9.5 : 
0.5) to afford the desired compound as free base. Yield: 0.26 g (47%). 1H NMR (CDCl3) 
: 1.36 (d, J = 7.0 Hz, 3H), 1.88-2.48 (m, 9H), 3.34-4.74 (m, 3H), 5.13 (q, J = 7.0 Hz, 
1H), 7.07-7.40 (m, 4H), 7.44-7.91 (m, 7H), 8.21-8.23 (m, 1H) 13C NMR (CDCl3) : 
16.22, 39.39, 42.80, 45.66 (2C), 51.25, 59.93, 113.41, 117.67, 120.69, 121.01, 126.95, 
127.29, 128.12, 129.49, 130.26, 131.61 (2C), 132.18, 133.10, 133.32, 133.42, 133.81, 
134.75, 135.04, 140.68, 148.00, 155.41, 161.80, 170.96. HREIMS m/z 563.21360 (calcd 
for C30H28F3N5O3, 563.2144). Anal. RP-HPLC I: tR = 14.01 min (purity 100%), II: tR = min 
13.73 (purity 100%). 
 
N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-ethyl}-N-
pyridin-3-ylmethyl-2-(4-trifluoromethoxy-phenyl)-acetamide (10) 
This was performed analogously to the preparation of 1e, using 8 (0.40 g, 1.00 mmol) 
and (4-trifluoromethoxy-phenyl)-acetic acid. Yield: 0.35 g (59%). 1H NMR (CDCl3) at 27 
oC : 1.16 (d, J = 7.1.Hz, 2H), 1.32-1.41 (m, 5H), 2.56 (dd, J1 = 16.1 Hz, J2= 40.0 Hz, 
0.8H), 3.21-3.78 (m, 1.2H ), 3.53-4.06 (m, 2.5H), 4.48 (dd, J1 = 14.8 Hz, J2 = 46.4 Hz, 
0.6H), 4.79-5.02 (m, 1.6H), 5.34 (q, J = 7.1 Hz, 0.3H), 6.55-5.85 (m, 0.5H), 6.91-7.21 
(m, 9H), 7.33-7.56 (m, 3H), 7.64-7.83 (m, 1.5H), 8.11-8.46 (m, 2H). Peak splitting due 
to the presence of rotamers, as confirmed by 1H NMR (DMSO) measurements at 90oC. 
HREIMS m/z 602.21506 (calcd for C33H29F3N4O4, 602.2141). Anal. RP-HPLC I: tR = 14.53 
min (purity 100%), II: tR = min 15.36 (purity 100%). 
 
N-{1-[3-(4-Cyano-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-
ethyl}-N-pyridin-3-ylmethyl-2-(4-trifluoromethoxy-phenyl)-acetamide (11b) 
This was performed analogously to the preparation of 1e, using 17b (0.40 g, 1.00 mmol) 
and (4-trifluoromethoxy-phenyl)-acetic acid. Yield: 0.42 g (72%). 1H NMR (CDCl3) : 
1.27 (d, 3H, J = 7.2 Hz), 3.50-3.72 (m, 2H), 5.03-5.13 (m, 3H), 7.00-7.19 (m, 5H), 
7.23-7.49 (m, 3H), 7.85-7.99 (m, 3H), 8.48-8.56 (m, 3H), 8.99-9.02 (m, 1H). 13C NMR 
(CDCl3) : 16.23, 39.81, 46.69, 52.39, 114.13, 116.24, 117.47, 121.05, 122.77, 
123.54(2C), 129.39, 130.15(3C), 130.35(2C), 132.41, 132.98, 133.20, 133.77, 134.10, 
136.81, 139.34, 147.20, 148.87, 156.40, 157.07, 161.48, 161.88, 172.77. HREIMS m/z 
584.17947 (calcd for C31H23F3N6O3, 584.1784). Anal. RP-HPLC I: tR = 12.77 min (purity 
100%), II: tR = min 13.70 (purity 100%). 
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N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-
ethyl}-N-pyridin-3-ylmethyl-2-(4-trifluoromethoxy-phenyl)-acetamide (11a) 
4-(Trifluoromethoxy-pheny)l-acetic acid (0.44 g, 2.00 mmol), 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (0.38 g, 2.00 mmol), 1-
hydroxybenzotriazole hydrate (HOBT) (0.27g, 2.00 mmol) and diisopropylethylamine 
(DIPEA) (2.27 mL) were stirred in DCM (70 mL). After 30 min 17a (0.40 g, 1.00 mmol) 
was added and the reaction mixture was stirred overnight, then extracted with HCl 1M 
(3×50 mL), basified with ammonia hydroxide 25% solution and extracted with DCM 
(3×200 mL). The combined organic layers were dried over Na2SO4 and concentrated to 
obtain the crude material that was purified by flash chromatography (EtOAc/EtOH, 
9.5:0.5) to afford the desired compounds as free base. Yield: 0.33 g (54%).1H NMR 
(CDCl3) at 27oC : 1.25 (d, J = 7.2 Hz, 0.9H), 1.36 (t, J = 6.9 Hz, 3H), 1.43 (d, J =7.2 
Hz, 2.1H), 2.70 (dd, J1 = 16.0 Hz, J2= 33.6, 0.6H), 3.59 (dd, J1= 15.7 Hz, J2= 13.5H, 
1.4H), 4.03 (q, J = 6.9 Hz, 2H), 4.57 (dd, J1 = 14.8 Hz, J2 = 107.3Hz, 0.6H ), 5.05-5.12 
(m, 0.3H), 5.18 (dd, J1 = 18.4 Hz, J2 = 2.9 Hz, 1.4H), 5.37 (q, J = 7.2 Hz, 0.7H), 6.70-
6.74 (m, 0.3H), 6.85-7.24 (m, 8.5H), 7.36-7.47 (m, 2H), 7.61-7.66 (m, 0.6H), 8.17-
8.23 (m, 0.6H), 8.42-8.56 (m, 2H), 8.93-9.04 (m, 1H). Peak splitting due to the 
presence of rotamers, as confirmed by 1H NMR (DMSO) measurements at 90 oC. HREIMS 
m/z 603.20902 (calcd for C32H28F3N5O4, 603.2093). Anal. RP-HPLC I: tR = 13.38 min 
(purity 99%), II: tR = min 14.65 (purity 99%). 
 
N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-
ethyl}-2-(4-trifluoromethoxy-phenyl)-acetamide (11f) 
This was performed analogously to the preparation of 11a, using 16a (0.31 g, 1.00 
mmol) and (4-trifluoromethoxy-phenyl)-acetic acid. Yield: 1.64 g (27%). 1H NMR (CDCl3) 
: 1.31 (d, J = 6.8 Hz, 3H), 1.43 (t, J = 7.0 Hz, 3H), 3.53 (s, 2H), 4.04 (q, J = 7.0 Hz, 
2H), 4.88 (q, J = 6.8 Hz, 1H), 6.84 (d, J = 7.94 Hz, 1H), 6.99-7.46 (m, 8H), 8.58-8.61 
(m, 1H), 8.94-8.97 (m, 1H).13C NMR (CDCl3) : 14.60, 20.01, 42.21, 46.84, 63.67, 
115.63, 115.69, 116.27 (2C), 121.01, 122.47, 127.07, 129.04, 129.26 (2C), 130.48, 
133.18, 137.02, 155.85, 156.96, 159.79, 162.33, 162.43, 169.74. HREIMS m/z 
512.16459 (calcd for C26H23F3N4O4, 512.1671). Anal. RP-HPLC I: tR = 13.30 min (purity 
99%), II: tR = min 14.87 (purity 98%). 
 
N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-
ethyl}-2-(4-fluoro-3-trifluoromethyl-phenyl)-acetamide (11c) 
This was performed analogously to the preparation of 11a, using 17a (0.40 g, 1.00 
mmol) and (4-fluoro-3-trifluoromethyl-phenyl)-acetic acid (0.44 g, 2.00 mmol). Yield: 
0.11 g (19%).1H NMR (CDCl3) at 27 oC : 1.25 (d, J = 7.2 Hz, 2H), 1.39 (t, J = 7.0 Hz, 
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3H), 1.57 (d, J = 7.2 Hz, 1H), 2.30-2.95 (m, 0.6H), 3.57 (dd, J1 = 16.1 Hz, J2 = 17.9 Hz, 
1.4H), 4.03 (q, J = 7.0 Hz, 2H), 4.20-5.23 (m, 2H), 5.05-5.12 (m, 0.3H), 5.33 (q, J = 
7.2 Hz, 1H), 6.94-7.61 (m, 10H), 8.18-8.57 (m, 3H), 8.20-8.95(m, 1H). Peak splitting 
due to the presence of rotamers, as confirmed by 1H NMR (DMSO) measurements at 90 
oC. HREIMS m/z 605.20450 (calcd for C32H27F4N5O3, 605.2050). Anal. RP-HPLC I: tR = 
13.26 min (purity 99%), II: tR = min 14.45 (purity 99%). 
[125I]CXCL10 binding to human CXCR3 receptor 
Cell membranes from HEK293 cells stably expressing the human CXCR3 receptor were 
prepared as follows. Cells were washed with cold PBS, detached using cold PBS 
containing 1 mM EDTA and centrifuged twice at 1500 g for 10 min at 4C. The pellet was 
resuspended in cold membrane buffer (15 mM Tris pH 7.5, 1 mM EGTA, 0.3 mM EDTA, 2 
mM MgCl2) and homogenized by 10 strokes at 1100-1200 rpm using a Teflon-glass 
homogenizer. The membranes were subjected to two freeze thaw cycles using liquid 
nitrogen and centrifuged at 40 000 g for 25 min at 4C. The pellet was rinsed with cold 
Tris-sucrose buffer (20 mM Tris pH 7.4, 250 mM sucrose), resuspended in the same 
buffer and frozen in liquid nitrogen. Protein concentration was determined using a Bio-
Rad protein assay. Membranes were incubated in 96 well plates in binding buffer (50 mM 
HEPES pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 100 mM NaCl, 0.5% BSA) with approximately 
50 pM 125I-CXCL10 (PerkinElmer Life and Analytical Sciences, Boston, MA) and increasing 
concentrations of antagonists for 2 h at RT. Subsequently, membranes were harvested 
via filtration through Unifilter GF/C plates (PerkinElmer Life and Analytical Sciences) 
pretreated with 1% polyethylenimine and washed three times with wash buffer (50 mM 
HEPES pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 500 mM NaCl). Radioactivity was measured 
using a MicroBeta (PerkinElmer Life and Analytical Sciences) counter. Binding data were 
analyzed using Graphpad Prism. 
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Chapter 5 
Imidazolium compounds as CXCR3 ligands 
 
 
Abstract 
 
In our quest to identify new ligands for CXCR3, we created a 
pharmacophore model based on reported CXCR3 ligands and 
subsequentely screened our in house database. Several imidazole-
containing compounds were retrieved as low-affinity hits. A merger 
approach was then pursued, in which the imidazole-hits were 
merged with imidazolium salts known from patent literature as 
CXCR3 binders. Accordingly, we synthesised a series of imidazolium 
analogues and identified 1-(2-(4-amino-3,5-dichlorophenyl)-2-
oxoethyl)-3-(2-(3,4-dichlorophenyl)-2-oxoethyl)-1H-imidazol-3-ium 
bromide (1m) having a pKi value in the submicromolar range as an 
interesting tool for CXCR3 pharmacological investigations. 
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Introduction 
 
Chemokines, a group of small (8-14 kDa) proteins belonging to the family of chemotactic 
cytokines, are known to play an important role in leucocyte activation and migration 
occurring in various immunomediated diseases1. These proteins are structurally divided 
in four groups (CC, CXC, CX3C and XC chemokines) by the number of the conserved 
cysteine residues. Chemokines exert activity through binding to a subfamily of the 
GPCRs, the so called chemokine receptor subgroup2. 
CXCR3, one of the chemokine receptors belonging to the GPCR superfamily, is expressed 
by epithelial, endothelial and lymphoid cells3. It is very well recognized that CXCR3 is 
overexpressed on the T helper 1 cells. Also, its ligands are upregulated in various chronic 
inflammatory diseases (rheumatoid arthritis 4,5, inflammatory bowel disease6, multiple 
sclerosis 7, transplant rejection 8, hepatitis C-infected liver 9, atherosclerosis 10, chronic 
skin reactions 11-13 and chronic obstructive pulmonary disease 14) compared to normal 
physiologic conditions. Therefore, CXCR3 represents an attractive target for the 
treatment of inflammatory and autoimmune diseases. Evidence also suggests that CXCR3 
may be a worthwhile target to treat cancer.15-17 
While the knowledge of CXCR3 biology has increased in the last decade, the public 
domain contained relatively little information about small CXCR3 antagonists at the time 
the work for this thesis started.18-23 The discovery of new CXCR3 ligands was needed to 
address both developments of pharmacological tools as well as of lead compounds for 
new potential drug classes.  
This chapter will describe our efforts in the search of novel CXCR3 ligands. At the time of 
initiation of this work, structural diversity of the known CXCR3 ligands was limited and 
the known compounds had only moderate affinity for the CXCR3 receptor. Although both 
issues complicate successful model generation and in silico screening efforts, we set out 
to try rational drug design approaches using the available dataset, nevertheless. To reach 
our goal, we developed a 3D pharmacophore model based on the lowest energy 
conformation of VUF 10085/AMG 487 (Figure 1). Using the pharmacophore model, we 
performed an in silico query of our in-house database. The selected compounds were 
screened in vitro for their affinity at CXCR3. Some low-affinity hits were subsequently 
‘merged’ with a scaffold extracted from the patent literature. This led to imidazolium salts 
showing potential for targeting CXCR3.24 
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Figure 1. VUF 10085/AMG 487 lowest energy conformation and structure. 
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Figure 2. Overlapping of the 20 lowest energy VUF 10085/AMG 487 conformations.  
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VUF 10085 Conformational Search 
 
Flexible molecules like the CXCR3 reference compound VUF 10085 can adopt many 
different conformations, but only one (or a selected few) low energy conformer(s) that 
brings all the important pharmacophoric features in the correct spatial orientation will be 
responsible for the biological activity.  
To assess the conformational space, a stochastic conformational search was performed to 
generate the different conformers of VUF 10085. Using a stochastic search algorithm was 
preferred in order to avoid the enormous number of starting conformations generated 
during a systematic method for conformational analysis. During the conformational 
analysis, an energy cut off of 7 Kcal/mol was used to prevent the formation of too high-
energy conformers. With this method, 53 conformers were generated. As illustrated by 
the superimposition of the aromatic heterocycles of the 20 lowest energy conformers 
(Figure 2), the flexibility of VUF 10085 is considerable. For example, key pharmacophoric 
features (as deduced by the SAR studies that are described in chapter 4) like the pyridine 
ring and trifluoromethoxybenzene can be positioned in a wide variety of space. Altough 
any of these conformers would serve as a reasonable template for pharmacophore 
modeling, we selected the lowest energy conformer of VUF 10085 (Figure 1) to define a 
hypothesis for a pharmacophore model. 
 
 
 
 
 Figure 3. Pharmacophore model generated from the VUF 10085/AMG 487 lowest 
energy conformations.
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Figure 4. Derivatives resulting from the in silico screen of the in-house database. Chiral 
compounds are racemic and (where applicable) of unknown diastereomeric ratios. 
Compound 15 is a 20/80 mixture of cis/trans isomers. 
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Pharmacophore query, database screening and chemical modifications 
 
The lowest energy conformation of VUF 10085 was used to generate a pharmacophore 
query. A total of 14 pharmacophoric points (Figure 3) were selected based on SAR 
considerations (chapter 4). Starting from this basic “naïve” pharmacophore model, the in 
silico screening of our in-house database (BS/GBR database) did not afford any hit that 
was able to fullfil all 14 pharmacophoric points, whereas enabling partial match of at 
least 8 and 7 pharmacophoric points resulted in 13 and 178 hits, respectively. In total, 
140 of the 178 selected molecules from the the in-house database were readily available. 
These were therefore tested at 10–5 M concentration for the [125I]CXCL10 displacement at 
human CXCR3 receptors on HEK-293 cells membranes stably expressing the receptor. 
Unfortunately, none of these compounds matched VUF 10085 in terms of affinity, with all 
showing only a slight affinity or no affinity at all for CXCR3 (data not shown). However, it 
was observed that most of the hits that showed a slight affinity (1-15) contained an 
imidazole core (Figure 4). Reasoning that the imidazole moieties should be substantially 
protonated at physiological pH, we noticed a general similarity with compounds from a 
recent patent application by Smithkline Beecham.24 This patent describes CXCR3 
inhibitors with a permanently charged imidazolium core as seen in e.g. 3-benzyl-1-[2-
(3,4-dichloro-phenyl)-2-oxo-ethyl]-2-methyl-3H-imidazol-1-ium bromide (16a) and 1,3-
bis-[2-(3,4-dichloro-phenyl)-2-oxo-ethyl]-3H-imidazol-1-ium bromide (16b). Given that 
permanently charged compounds are not uncommon binders for CXCR3,25,26 we decided 
to synthesize a small series of compounds in which the patented central imidazolium core 
was merged with the imidazole compounds identified from our in silico screen.
Essentially, this opportunistic approach is currently one of the more common fragment 
optimization strategies in fragment-based drug discovery, as reviewed recently.27 
Accordingly, selected imidazole-containing compounds (1, 8, 15, see Figure 4 for 
compound structures) belonging to the in-house database were further functionalized 
with 2-bromo-1-(3,4-dichloro-phenyl)-ethanone or 2-bromo-1-(4-chloro-phenyl)-
ethanone moieties. The obtained derivatives (16e-g, i) were compared for affinity at 
human CXCR3 to VUF 10085. Salts 16a and 16b were used as references. 
Furthermore, the importance of the N1 substituent in imidazolium reference compounds 
16a and 16b has been investigated by its removal (16j), substitution with different 
hydrophobic moieties (16c, 16d, 16k-m) or substitution with a more polar group (16h). 
Lastly, the pyridine N-oxide analogue (16n) was prepared. This was based on the 
observation that the main metabolite of VUF 10085, i.e. a pyridine-N-oxide, has high 
activity.28,29 
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Chemistry 
 
The synthetic route for compounds 16a-n is highlighted in Scheme 1. 2-Bromo-1-(3,4-
dichloro-phenyl)-ethanone (18a) and 2-bromo-1-(4-chloro-phenyl)-ethanone (18b) were 
obtained by bromination of 1-(3,4-dichloro-phenyl)-ethanone (17a) and 1-(4-chloro-
phenyl)-ethanone (17b), respectively, in acetic acid. Compounds 19b-d were 
synthesized through substitution on imidazole by 18a, 18b and 2-bromo-4-
phenylacetophenone, respectively. The addition of 18a or 18b to the appropriate 
imidazole derivative (1,8,15,19a-d,19h,19j-m) afforded final compounds (16a-m). 
Yields varied from from high to low (90-30%). Intermediate 18c was obtained by 
bromination of acetylpyridine N-oxide (17c). The addition of 3-(2-bromoacetyl)pyridine-
1-oxide hydrobromide (18c) to 1-(3,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone 
(19b) in the presence of base resulted in final compound 16n.
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Scheme 1. Synthesis of compounds 16a-n. Reagent and conditions. (i) Br2, 
CH3COOH; (ii) CH3CN or DMF, rt; (iii) Br2, CHCl3, reflux. (iv) CH3CN, DIPEA, rt.
 
 
Pharmacology 
 
The affinity for human CXCR3 of compounds was determined by the displacement of 
[125I]CXCL10 binding to membranes from HEK-293 cells stably expressing the human 
CXCR3 receptor. Affinity was measured either in a single-point test or in a full-
concentration curve.
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Results and Discussion 
Aiming to obtain a new class of CXCR3 inhibitors different from the 3H-quinazolin-4-ones 
and 3H-pyrido[2,3-d]pyrimidin-4-ones CXCR3 described in Chapters 3 and 419, we 
developed a pharmacophore model based on the most active compound known at the 
time, VUF 10085. According to this model, we performed a screening of the in-house 
database. A total of 140 compounds were tested at a single concentration of 10 M for 
their affinities at human CXCR3 by assessing the [125I] CXCL10 displacement. Although 
none of the screened compounds showed encouraging affinities for CXCR3, it was noted 
that an imidazole was a commonly found moiety amongst the low-affinity hits. Inspired 
by a Smithkline Beecham patent on imidazolium salts, 24 we decided to perform a merger 
and further expand some of our imidazole hits to imidazolium compounds. Together with 
a subsequent exploratory SAR study, these efforts led to 16a-n. These compounds were 
tested on human CXCR3. The pKi values for 16a-n are summarized in Table 1. 
Compounds 16a and 16b were previously disclosed in a patent as CXCR3 antagonists.24 
In our hands, these compounds showed affinity values in the micromolar range (pKi = 
5.81 and 6.35 respectively). The affinity value of VUF 10085 is in the nanomolar range 
(pKi = 7.39)19. Comparing 16b to 16a, the presence of a 1-(3,4-dichloro-phenyl)-
ethanone unit instead of a benzyl in N1 and the removal of the methyl in position 2 of the 
imidazole ring afforded a compound (16b), three times higher than 16a in terms of 
affinity but ten times lower than VUF 10085. 
Removal of the 3-chloro (16c) or substitution of the 4-chloro with a phenyl (16d) in the 
1-(3,4-dichloro-phenyl)-ethanone moiety in N1 of compound 16b is allowed without any 
dramatic change in the affinity at CXCR3. 
Compounds 16e-i, having various substituents at N1 position of the imidazole ring, all 
revealed low affinity values suggesting that a proper substitution at the N1 position is 
responsible for the interaction with the receptor. Compounds like 16f and 16i with a 
more rigid structure are generally slightly more tolerated than more flexible compounds 
such as 16e, 16g and 16k. For the tricyclic analogues (16f, 16i) the removal of the 3-
chloro substituent (16i) in the 1-(3,4-dichloro-phenyl)-ethanone moiety at N3 of 
compound 16f led to a small drop in affinity. However a deeper SAR study of the 
substituent at N3 would better clarify its role for the affinity at CXCR3. The imidazolium 
derivative 16h bearing a flexible polar substituent at N1 has a comparable affinity to 
compound 16i. A complete removal of a substituent (16j) at N1 of the imidazole ring led 
to a dramatic decrease in the affinity. Also, compound 16l having a benzyl acetamide 
substituent showed a poor affinity, once again underscoring the importance of a proper 
substitution at N1 for the affinity. 
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Table 1. pKi values of the imidazolium analogues as determined by the displacement of 
[125I]CXCL10 binding to the human CXCR3 receptor. 
 
Cl  
 
 
N+
N
R
X
Br-
O
Y
 
 
compd X Y R pKi# 
VUF 10085 - - - 7.39 ± 0.0819 
16a  
VUF 10131
Cl CH3 
 
5.81 ± 0.10 
16b 
VUF 10132
Cl H 
 
6.35 ± 0.03 
16c 
VUF 10616
Cl H 
O
Cl  
6.25 ± 0.01## 
16d 
VUF 10617
Cl H 
O
 
6.33 ± 0.01## 
16e 
VUF 10133
Cl H O
NCl
Cl
Cl  
4.98 ± 0.10 
16f  
VUF 10134
Cl H 
 
5.36 ± 0.03 
16g  
VUF 10141
Cl H 
 
4.83 ± 0.05 
#The binding experiments were carried out on cell membranes fractions from  HEK-293 cells stably 
expressing the human CXCR3 receptor. The compounds were tested for their ability to displace 
[125I]CXCL10 binding. The values are represented as the mean ± S.E.M. of at least three 
independent experiments. 
##Tested twice 
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Table 1. pKi values of the imidazolium analogues as determined by the displacement of 
[125I]CXCL10 binding to the human CXCR3 receptor. 
 
Cl  
 
 
R
X
Br-
O
Y
 
 
compd X Y R pKi# 
16i 
VUF 10205
H H 
O
 
5.02 ± 0.14 
16j 
VUF10713
Cl H CH3 4.35 ± 0.33## 
16k 
VUF 10618
Cl H 
O
Cl  
4.86 ± 0.06## 
16l 
VUF 10611
Cl H 
O
HN
 
4.29 ± 0.12## 
16m 
VUF 10612
Cl H 
 
6.79 ± 0.05## 
16n 
VUF 10639
Cl H 
 
4.57 ± 0.11## 
O
N+
O-
#The binding experiments were carried out on cell membranes fractions from  HEK-293 cells stably 
expressing the human CXCR3 receptor. The compounds were tested for their ability to displace 
[125I]CXCL10 binding. The values are represented as the mean ± S.E.M. of at least three 
independent experiments.  
##Tested twice. 
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Interestingly, the replacement of the 1-(3,4-dichloro-phenyl)-ethanone moiety in the N1 
of 16b by a 1-(4-amino-3,5-dichloro-phenyl)-ethanone unit (16m) afforded the most 
active compound in this series. It has a three times higher affinity value for CXCR3 (pKi  
= 6.79) than the reference compound 16b. The compound bears an aniline flanked by 
two chlorine atoms. Future SAR studies could address the elucidation of the exact roles of 
these three functional groups.  
Last, compound 16n bearing an N-oxide substituent showed a loss of affinity suggesting 
that a pyridine-N-oxide is not necessarily a preferred CXCR3 moiety. 
 
 
Conclusions 
 
In this study, we used a modeling approach with the aim to identify CXCR3 ligands that 
are structurally different from the ones already known. Using the 3H-pyrido[2,3-
d]pyrimidin-4-one scaffold as starting point we developed a pharmacophore model and 
subsequently screened our in-house database. We combined the information obtained 
from the screening exercise with data extracted from patent literature. As such, we were 
able to obtain a series of permanently charged imidazolium derivatives that has been 
tested for binding affinity by displacement of [125I]CXCL10. Compound 16m (pKi=6.79) 
has been identified as the most potent compound in this series, approximately three 
times better than the reference compound 16b. It may represent an interesting tool 
compound for future CXCR3 research. 
Experimental section 
Pharmacophore Model 
In an attempt to find a new scaffold for CXCR3 antagonism, a 3D pharmacophore model 
was developed using the MOE software. The “Pharmacophore from a single active 
molecules” approach has been chosen and VUF 10085 has been used as starting point 
being the most active molecule known at the time of the study (pki = 7.39)19. As source 
for new small molecules our in-house (BS/GBR) database was screened. 
 
General synthetic 
The solvents were dried according to standard procedures. All the reactions were 
performed under an atmosphere of dry nitrogen. 1H NMR and 13C spectra were recorded 
on a Bruker AC-200 (200 MHz) spectrometer. Melting points were measured on an 
Electrothermal IA 9200 apparatus. 
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Building blocks 
Building blocks 19a, 19j and 17a,b were commercially available (Sigma-Aldrich). The 
synthesis of 17c has been described by others.30 Compounds 1, 8, 15 and 19h,k,l,m 
belong to our in-house database. The structures of all these building blocks are depicted 
in Figure 5. 
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Figure 5. Building blocks structures.
2-Bromo-1-(3,4-dichloro-phenyl)-ethanone (18a) 
To a stirred solution of 1-(3,4-dichloro-phenyl)-ethanone 17a (10.00 g, 59.2 mmol) in 
acetic acid (100 mL) a solution of bromine (2.71 mL, 59.2 mmol) in acetic acid (30 mL) 
was added dropwise at 20-25 °C. After 6 hrs the mixture was poured in water (250 mL) 
and stirred overnight at rt. The biphasic solution was diluted in ether (150 mL) and the 
organic layer separated from water and washed again (3200mL). The organic phases 
were dried over sodium sulphate and concentrated to afford 18a as a green oil. Yield: 
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13.28 g (84%). 1H NMR (CDCl3) : 4.33 (s, 2H), 7.42-7.64 (m, 1H), 7.70-7.83 (m, 1H), 
8.03 (s, 1H).
 
2-Bromo-1-(4-chloro-phenyl)-ethanone (18b)  
Analogous to the preparation of 18a, using 1-(4-chloro-phenyl)-ethanone 17b (8.40 mL, 
64.7 mmol). Yield: 7.80 g (78%). 1H NMR (CDCl3) : 4.40 (s, 2H), 7.25-7.44 (m, 2H), 
7.73-7.90 (m, 2H). 
 
3-(2-Bromoacetyl)pyridine 1-oxide hydrobromide (18c) 
Bromine (0.21 mL, 4.08 mmol) was added to a solution of acetylpyridine N-oxide 17c 
(0.56 g, 4.08 mmol) in CHCl3 (10 mL).30 The resulting mixture was gently refluxed under 
argon for 1h. The precipitate was filtered off, washed several times with diethylether and 
dried at rt. Yield: 0.75 g (62 %) as white solid. 1H NMR (DMSO) : 5.0 (s, 2H), 7.7 (t, 
1H), 8.0 (d, 1H), 8.5 (d, 1H), 8.8 (s, 1H).  
 
1-(3,4-Dichloro-phenyl)-2-imidazol-1-yl-ethanone (19b) 
Imidazole (0.13 g, 1.87 mmol) was dissolved in acetonitrile (50 mL). After 10 min, a 
solution of 18a (0.50 g, 1.87 mmol) in acetonitrile (10 mL) was added dropwise. The 
mixture was stirred overnight at rt. A precipitate was formed and fitrated. The solution 
was concentrated, dissolved in dichlorometane (50 mL) basified with sodium bicarbonate 
saturated solution (50 mL) and extracted with dichlorometane (350mL). The organic 
layers were dried over sodium sulphate and concentrated. The crude material was 
purified by flash chromatography on silica gel eluting with ethanol/dichloromethane (1:9) 
to afford the desired compound as pale yellow solid. Yield: 0.15 g (31%). 1H NMR (CDCl3) 
: 5.30 (s, 2H), 6.89 (s, 1H), 7.10 (brs, 1H), 7.45 (brs, 1H), 7.50-7.82 (m, 2H), 7.99 (s, 
1H). 
 
1-(4-Chlorophenyl)-2-(1H-imidazol-1-yl) ethanone (19c) 
This procedure was carried out analogously to the preparation of 19b using 2-bromo-1-
(4-chlorophenyl)ethanone 18b (0.50 g, 2.14 mmol) and imidazole (0.15 g, 2.14 mmol). 
The product was obtained as a off white powder. Yield: 110 mg (23 %) 1H NMR (CDCl3) 
: 5.36 (s, 2H), 6.92 (s, 1H), 7.12 (s, 1H), 7.49 (d, 2H), 7.50 (s, 1H), 7.89 (d, 2H).
 
1-(Biphenyl-4-yl)-2-(1H-imidazol-1-yl) ethanone (19d) 
This procedure was carried out analogously to the preparation of 19b, using 2-bromo-4-
phenylacetophenone (0.44 g, 1.60 mmol) and imidazole (0.11g, 1.60 mmol). The 
product was obtained as a yellow powder. Yield: 148 mg (35 %); 1H NMR (CDCl3) : 5.42 
(s, 2H), 6.96 (s, 1H), 7.40-7.65 (m, 7H), 7.73 (d, 2H), 8.03 (d, 2H) 
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3-Benzyl-1-[2-(3,4-dichloro-phenyl)-2-oxo-ethyl]-2-methyl-3H-imidazol-1-ium 
bromide (16a) VUF10131 
Compound 18a (0.20 g, 0.75 mmol) and 1-benzyl-2-methyl-1H-imidazole 19a (0.13 g, 
0.75 mmol) were stirred overnight at rt in acetonitrile (50 mL). The mixture was diluted 
with ether. The solid product was filtered, washed with ether and dried to afford 16a as 
white solid. Yield: 0.23 g (85%). 1H NMR (DMSO) : 2.56 (s, 3H), 5.54 (s, 2H), 6.03 (s, 
2H), 7.24-7.55 (m, 5H), 7.60-7.63 (m, 1H), 7.82-7.90 (m, 1H), 7.92-8.07 (m, 2H), 
8.33-8.35 (m, 1H). M.p. 240.6-241.8	C. 
 
1,3-Bis-[2-(3,4-dichloro-phenyl)-2-oxo-ethyl]-3H-imidazol-1-ium bromide 
(16b) VUF10132 
This procedure was carried out analogously to the preparation of 16a using 19b (0.19 g, 
0.75 mmol) and 18a (0.20 g, 0.75 mmol). Yield: 0.31 g (78%) of a white solid. 1H NMR 
(DMSO) : 6.20 (s, 4H), 7.67-7.80 (m, 4H), 7.88-8.12 (m, 3H), 8.23-8.25 (m, 2H), 9.12 
(s, 1H). 13C NMR (50 MHz, DMSO) : 54.67, 55.45, 119.92, 122.65, 127.70, 128.45, 
130.15, 131.16, 131.26, 131.98, 132.34, 133.76, 137.83, 138.15, 188.55, 189.74. M.p. 
238.2-239.6 	C. 
(2-(4-Chlorophenyl)-2-oxoethyl)-1-(2-(3,4-dichlorophenyl)-2-oxoethyl)-1H-
imidazol-3-ium bromide (16c) VUF10616 
This procedure was carried out analogously to the preparation of 16a using 19c (0.10 g, 
0.44 mmol) and 18a (0.09 g, 0.35 mmol). The desired product was obtained as white 
solid. Yield: 0.14 g, (67 %) ; 1H NMR (DMSO) : 6.14 (s, 4H), 7.75 (d, 2H), 7.77-8.11 
(m, 6H), 8.31 (s, 1H), 9.06 (s, 1H); 13C NMR (50 MHz, DMSO) : 55.42, 55.47, 123.48, 
123.62, 127.91, 129.05, 129.83, 131.29, 131.92, 132.24, 133.77, 136.98, 138.30, 
139.15, 189.64, 190.22. M.p. 239.1-240.4	C.  
 
3-(2-(Biphenyl-4-yl)-2-oxoethyl)-1-(2-(3,4-dichlorophenyl)-2-oxoethyl)-1H-
imidazol-3-ium bromide (16d) VUF10617 
This procedure was carried out analogously to the preparation of 16a using 19d (0.13 g, 
0.50 mmol) and 18a (0.11g, 0.40 mmol). The product 16d was obtained as a white 
powder. Yield: 0.15 g (55 %); 1H NMR (DMSO) : 6.16 (s, 2H), 6.20 (s, 2H), 7.46-8.33 
(m, 14H), 9.09 (s, 1H); 13C NMR (50 MHz, DMSO): 55.48, 123.46, 123.67, 126.87, 
126.95, 127.92, 128.68, 128.96, 129.85, 131.30, 131.91, 132.29, 133.78, 136.99, 
138.28, 138.34, 145.47, 189.66, 190.62 M.p. 240.8-242.1	C. 
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3-[2-[(E)-4-Chloro-benzyloxyimino]-2-(2,4-dichloro-phenyl)-ethyl]-1-[2-(3,4-
dichloro-phenyl)-2-oxo-ethyl]-3H-imidazol-1-ium bromide (16e) VUF10133 
This procedure was performed analogously to the preparation of 16a using 15 (0.24 g, 
0.60 mmol) and 18a (0.15 g, 0.60 mmol). The product 16e was obtained as a white 
powder. Yield: 0.13 g (32%). 1H NMR (DMSO) : 5.07 (s, 2H), 5.49 (s, 2H), 6.06 (s, 2H), 
7.27-7.40 (m, 2H), 7.41-7.49 (m, 4H), 7.56-7.61 (m, 3H), 7.71-8.05 (m,2H), 8.28-8.30 
(m, 1H), 9.11 (s, 1H). M.p. 202.4-206.1	C. 
1-[2-(3,4-Dichloro-phenyl)-2-oxo-ethyl]-3-[2-(10,11-dihydro-5H-
dibenzo[a,d]cyclohepten-5-yloxy)-ethyl]-3H-imidazol-1-ium bromide (16f) 
VUF10134 
This procedure was performed analogously to the preparation of 16a using 8 free base 
(0.15 g, 0.49 mmol) and 18a (0.13 g, 0.49 mmol). The product 16f was obtained as a 
white solid. Yield: 0.23 g (83%). 1H NMR (DMSO) : 2.80-3.08 (m, 2H), 3.10-3.22 (m, 
2H), 3.62-3.83 (m, 2H), 4.53-4.67 (m, 2H), 5.60 (s, 1H), 6.05 (s, 2H), 7.18-7.32 (m, 
8H), 7.69-8.01 (m, 4H), 8.31-8.32 (m, 1H), 9.11 (s, 1H). M.p. 200.2-201.5	C. 
 
3-{2-[Bis-(2,4-dichloro-phenyl)-methoxy]-ethyl}-1-[2-(3,4-dichloro-phenyl)-2-
oxo-ethyl]-3H-imidazol-1-ium bromide (16g) VUF10141 
This procedure was performed analogously to the preparation of 16a using 1 free base 
(0.16 g, 0.38 mmol) and 18a (0.10 g, 0.38 mmol). The product 16g was obtained as a 
white solid. Yield: 0.19 g (77%). 1H NMR (DMSO) : 3.78-3.90 (m, 2H), 4.45-5.54 (m, 
2H), 5.96 (s, 1H), 6.05 (s, 2H), 7.13-7.18 (m, 2H), 7.42-7.47 (m, 2H), 7.68-7.70 (m, 
3H), 7.80-8.02 (m, 3H), 8.32 (s, 1H), 9.10 (s, 1H). M.p. 241.2-241.9	C. 
 
3-{2-[3-Chloro-4-(3-methyl-ureido)-phenyl]-2-oxo-ethyl}-1-[2-(3,4-dichloro-
phenyl)-2-oxo-ethyl]-3H-imidazol-1-ium bromide (16h) VUF10142 
This procedure was performed analogously to the preparation of 16a using 19h (35 mg, 
0.12 mmol) and 18a (32 mg, 0.12 mmol). The compound 16h was obtained as a white 
solid. Yield: 0.03g (48%)1H NMR (DMSO) : 2.68-2.71 (m, 3H), 6.07 (s, 2H), 6.13 (s, 
2H), 7.22-7.33 (m, 1H), 7.76-8.10 (m, 5H), 8.30-8.32 (m, 1H), 8.48-8.52 (m, 2H), 9.04 
(s, 1H). M.p. 202.6-204.3	C. 
1-[2-(4-Chloro-phenyl)-2-oxo-ethyl]-3-[2-(10,11-dihydro-5H-
dibenzo[a,d]cyclohepten-5-yloxy)-ethyl]-3H-imidazol-1-ium; bromide (16i) 
VUF10205 
This procedure was performed analogously to the preparation of 16a using 8 free base 
(85 mg, 0.28 mmol) and 18b (65 mg, 0.28 mmol). The compound 16i was obtained as a 
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white solid. Yield: 0.13 g (85%). 1H NMR (DMSO) : 2.50-3.18 (m, 2H), 3.34-3.40 (m, 
2H), 3.71-3.81 (m, 2H), 4.51-4.57 (m, 2H), 5.61 (s, 1H), 6.06 (s, 2H), 7.18-7.29 (m, 
2H), 7.69-7.85 (m, 5H), 7.89-8.11 (m, 2H), 9.12 (s, 1H). M.p. 201.2-201.8	C. 
 
1-[2-(3,4-Dichloro-phenyl)-2-oxo-ethyl]-3-methyl-3H-imidazol-1-ium bromide 
(16j) VUF10713 
This procedure was performed analogously to the preparation of 16a using N-methyl 
imidazole 19j (0.12 g, 1.49 mmol) and 18a (0.40 g, 1.49 mmol). The product 16j was 
obtained as red oil. Yield: 0.46 g (88%). 1H NMR (DMSO) : 3.96 (s, 3H), 6.06 (s, 2H), 
7.67-7.68 (m, 1H), 7.70-7.78 (m, 1H), 7.80-8.04 (m, 2H), 8.29-3.31 (m, 1H), 9.05 (s, 
1H). 
 
3-(2-( (4-chlorophenyl) (phenyl) methoxy) -2- oxoethyl) -1- (2 -(3, 4-
dichlorophenyl) -2-oxoethyl)- 1H-imidazol-3-ium bromide (16k) VUF10618 
This procedure was performed analogously to the preparation of 16a using 19k (100 
mg, 0.26 mmol) and 18a (56 mg, 0.21 mmol). The product 16k was obtained as yellow 
foam. Yield: 0.10 g (65 %); 1H NMR (DMSO) : 8.0 (s, 1H), 7.9 (dd, 1H), 7.6 (s, 1H), 7.5 
(d, 1H), 7.4 (s, 1H), 7.3 (m, 10H), 6.8 (s, 1H), 6.3 (s, 2H), 5.4 (dd, 2H). 
 
1-(2-(benzylamino)-2-oxoethyl)-3-(2-(3,4-dichlorophenyl)-2-oxoethyl)-1H-
imidazol-3-ium bromide (16l) VUF10611 
This procedure was performed analogously to the preparation of 16a, using 19l (0.10 g, 
0.46 mmol) and 18a (100 mg, 0.37 mmol). The product 16l was obtained as a white 
powder. Yield: 0.14 g (63 %) 1H NMR (DMSO) : 4.35 (d, 2H), 5.20 (s, 2H), 6.11 (s, 2H), 
7.26-7.39 (m, 5H), 7.70 (s, 1H), 7.81 (s, 1H), 7.92 (d, 1H), 7.99 (d, 1H), 8.30 (s, 1H), 
9.02 (t, 1H), 9.10 (s, 1H); 13C NMR (50 MHz, DMSO) 42.26, 50.46, 55.32, 123.11, 
123.49, 126.84, 127.24, 127.91, 128.14, 129.84, 131.28, 131.89, 133.74, 136.92, 
138.28, 138.33, 164.66, 189.62. M.p. 204.9-206.8	C. 
 
1-(2-(4-amino-3,5-dichlorophenyl)-2-oxoethyl)-3-(2-(3,4-dichlorophenyl)-2-
oxoethyl)-1H-imidazol-3-ium bromide (16m) VUF10612 
This procedure was performed analogously to the preparation of 16a, using 19m (0.10 
g, 0.33 mmol) and 18a (71 mg, 0.26 mmol). The product 16m was obtained as a white 
powder. Yield: 0.12 g (68 %) 1H NMR (DMSO) : 6.03 (s, 2H), 6.13 (s, 2H), 6.78 (s, 2H), 
7.75 (s, 2H), 7.93-8.05 (m, 4H), 8.31 (s, 1H), 9.04 (s, 1H); 13C NMR (50 MHz, DMSO)
54.65, 55.43, 117.20, 121.62, 123.43, 123.59, 127.90, 128.34, 129.83, 131.29, 131.90, 
133.76, 138.27, 146.35, 187.22, 189.64. M.p. 202.0-204.1	C. 
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3-(2-(3-(2-(3,4-dichlorophenyl)-2-oxoethyl)-1H-imidazol-3-ium-1-
yl)acetyl)pyridine 1-oxide bromide (16n) VUF10639 
Compound 18c (50 mg, 0.17 mmol) was suspended in acetonitrile (10 mL) and N,N-
diisopropylethylamine (0.03 mL, 0.17 mmol) was added to liberate the free N-oxide by 
stirring for 15 min at r.t. This gave a red solution. Intermediate 19b (43 mg, 0.17 mmol) 
was added and the solution was stirred overnight at r.t. The desired product precipitated 
and was filtered to give a red powder (44 mg, 56 %).1H NMR (DMSO) : 6.0 (s, 2H), 6.1 
(s, 2H), 7.6 - 7.8 (m, 3H), 7.8 – 8.0 (3H), 8.3 (s, 1H), 8.5 (d, 1H), 8.9 (s, 1H), 9.1 (s, 
1H). 13C NMR (50 MHz, DMSO) 55.49, 55.60, 123.52, 123.62, 123.79, 126.90, 127.89, 
129.81, 131.29, 131.92, 132.79, 133.75, 137.00, 138.15, 138.32, 142.81, 188.98, 
189.57. M.p. 196.2 – 197.8 	C. 
 
 
[125I]CXCL10 binding to human CXCR3 receptor  
Cell membranes from HEK293 cells stably expressing the human CXCR3 receptor were 
prepared as follows. Cells were washed with cold PBS, detached using cold PBS containing 
1 mM EDTA and centrifuged twice at 1500 g for 10 min at 4C. The pellet was 
resuspended in cold membrane buffer (15 mM Tris pH 7.5, 1 mM EGTA, 0.3 mM EDTA, 2 
mM MgCl2) and homogenized by 10 strokes at 1100-1200 rpm using a Teflon-glass 
homogenizer. The membranes were subjected to two freeze thaw cycles using liquid 
nitrogen and centrifuged at 40,000 g for 25 min at 4C. The pellet was rinsed with cold 
Tris-sucrose buffer (20 mM Tris pH 7.4, 250 mM sucrose), resuspended in the same buffer 
and frozen in liquid nitrogen. Protein concentration was determined using a Bio-Rad 
protein assay. Membranes were incubated in 96 well plates in binding buffer (50 mM 
HEPES pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 100 mM NaCl, 0.5% BSA) with approximately 50 
pM 125I-CXCL10 (PerkinElmer Life and Analytical Sciences, Boston, MA) and increasing 
concentrations of ligands for 2 h at RT. Subsequently, membranes were harvested via 
filtration through Unifilter GF/C plates (PerkinElmer Life and Analytical Sciences) 
pretreated with 1% polyethylenimine and washed three times with wash buffer (50 mM 
HEPES pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 500 mM NaCl). Radioactivity was measured 
using a MicroBeta (PerkinElmer Life and Analytical Sciences) counter. Binding data were 
analyzed using Graphpad Prism. 
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Abstract 
 
The chemokine receptor CXCR3 is involved in various inflammatory 
diseases, such as rheumatoid arthritis, multiple sclerosis, psoriasis 
and allograft rejection in transplantation patients. The CXCR3 ligands 
CXCL9, CXCL10 and CXCL11 are expressed at sites of inflammation 
and attract CXCR3-bearing lymphocytes, thus contributing to the 
inflammatory process. Here, we characterize 5 non-peptidergic 
compounds of three different chemical classes that block the action 
of CXCL10 and CXCL11 at the human CXCR3, i.e. the 3H-pyrido[2,3-
d]pyrimidin-4-one derivatives VUF10472/NBI-74330 and 
VUF10085/AMG 487, the 3H-quinazolin-4-one VUF5834, the 
imidazolium compound VUF10132 and the quaternary ammonium 
salt TAK-779. In order to understand the action of these CXCR3 
antagonists in various animal models of disease, the compounds 
were also tested at rat and mouse CXCR3, as well as at CXCR3 from 
rhesus macaque, cloned and characterized for the first time in this 
study. Except for TAK-779, all compounds show slightly lower affinity 
for rodent CXCR3 than for primate CXCR3. Additionally, we have 
characterized the molecular mechanism of action of the various 
antagonists at the human CXCR3 receptor. All tested compounds act 
as noncompetitive antagonists at CXCR3. Moreover, this non-
competitive behavior is accompanied by inverse agonistic properties 
of all 5 compounds as determined on an identified constitutively 
active mutant of CXCR3, CXCR3 N3.35A. Interestingly, all 
compounds except TAK-779 act as full inverse agonists at CXCR3 
N3.35A. TAK-779 shows weak partial inverse agonism at CXCR3 
N3.35A, and likely has a different mode of interaction with CXCR3 
than the other two classes of small-molecule inverse agonists.
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Introduction 
 
Chemokines are secreted peptides that are important mediators in inflammation. They 
are classified into four families based on the number and position of conserved N-
terminal cysteine residues, i.e. CC, CXC, CX3C and XC chemokines.1 Chemokines bind to 
a subset of G protein-coupled receptors (GPCRs) of class A, which are named based on 
their specific chemokine preferences.1 The chemokine receptor CXCR3 is mainly 
expressed on activated Th1 cells, but also on B cells and natural killer cells.2 CXCR3 is 
activated by the interferon-gamma-inducible chemokines CXCL9, CXCL10 and CXCL11, 
with CXCL11 having the highest affinity.3,4 Upon activation, CXCR3 activates pertussis 
toxin-sensitive G proteins of the Gi class and mediates e.g. chemotaxis, calcium flux and 
activation of kinases such as p44/p42 MAPK and Akt.5  
CXCR3 and its ligands are upregulated in a wide variety of inflammatory diseases, 
implying a role for CXCR3 in e.g. rheumatoid arthritis,2 multiple sclerosis,6 transplant 
rejection,7 atherosclerosis8 and inflammatory skin diseases.9 The role of CXCR3 in cancer 
is two-fold: on one hand CXCR3 may be involved in the metastasis of CXCR3-expressing 
cancer cells,10 while on the other hand expression of CXCL1011 or CXCL1112 at tumor 
sites may attract CXCR3-expressing immune cells, that help control tumor growth and 
metastasis. 
Several animal models have been developed for CXCR3, among which a murine model of 
metastatic breast cancer,10 a murine model of renal cell carcinoma (RENCA)13 and an 
arthritis model in Lewis rats.14 In a mouse rheumatoid arthritis model TAK-779, a small-
molecule antagonist with affinity for CCR5, CCR2b and CXCR3, inhibits the development 
of arthritis by downregulating T cell migration, indicating that targeting chemokine 
receptors in models of inflammation is feasible and effective.15-17 
Several classes of non-peptidergic compounds targeting CXCR3 have recently been 
described, including 4-N-aryl-[1,4]diazepane ureas,18 1-aryl-3-piperidin-4-yl-urea 
derivatives,19 quinazolin-4-one and 3H-pyrido[2,3-d]pyrimidin-4-one derivatives20-23 and 
the above mentioned quaternary ammonium salt TAK-779.16 So far, no detailed 
information is available on the molecular mechanism of action of these antagonists at the 
CXCR3 receptor, despite the general notion that small-molecule ligands most likely will 
not have overlapping binding sites with the chemokines, which are supposed to bind 
mainly to the N-terminus and extracellular receptor loops.1 Moreover, although most 
compounds have been tested on human CXCR3 using in vitro assays, little or no 
information on their affinity for CXCR3 of other species is available. Especially in view of 
rodent models of inflammatory diseases it is important to know the relative affinities of 
the compounds for the receptors of different species.  
 102
Mechanism of action of CXCR3 antagonists 
 
Here, we report on the molecular characterization of the 3H-pyrido[2,3-d]pyrimidin-4-
one derivatives VUF10472 (NBI-74330)21,22 and VUF10085 (AMG 487)21,23, the 3H-
quinazolin-4-one VUF583420,23 the imidazolium compound VUF1013224 and the 
quaternary ammonium salt TAK-77915 at CXCR3 of human,3 rat25 and mouse.26 
Additionally, CXCR3 from rhesus macaque was cloned, characterized and subjected to a 
detailed pharmacological analysis using the non-peptidergic compounds. Moreover, we 
constructed and characterized a constitutively active mutant (CAM) of CXCR3, which was 
used to further determine the inverse agonistic properties of the non-peptidergic ligands.
 
 
Methods 
Materials. Dulbecco’s modified Eagle’s medium (DMEM) and trypsin were purchased 
from PAA Laboratories GmbH (Paschen, Austria), RPMI 1640 with glutamax-I and 25 mM 
HEPES, non essential amino acids, sodium pyruvate and 2-mercaptoethanol were from 
Sigma-Aldrich, penicillin and streptomycin were obtained from Cambrex, fetal bovine 
serum (FBS) was purchased from Integro B.V. (Dieren, The Netherlands), certified FBS 
was from Invitrogen. myo-[2-3H]inositol (10-20 Ci/mmol) was bought from GE 
Healthcare. [125I]-CXCL10 (2200 Ci/mmol) and [125I]-CXCL11 (2000 Ci/mmol) were 
obtained from PerkinElmer Life and Analytical Sciences. Chemokines were obtained from 
PeproTech (Rocky Hill, N.J.). TAK-779 was obtained from the NIH AIDS research and 
reference reagent program. 
 
DNA constructs. The cDNA of human CXCR3 inserted in pcDNA33 was amplified by PCR 
and inserted into pcDEF3 (a gift from Dr. Langer).  
A cDNA containing the rhesus macaque (Macaca mulatta, GenBank accession number 
EU313340) CXCR3 open-reading frame was obtained from rhesus macaque peripheral 
blood mononuclear cells (PBMCs) stimulated overnight with phytohemagglutinin-P plus 
phorbol myristate acetate. Total RNA was extracted using Trizol (Life Technologies) and 
cDNA was generated by reverse transcription (RT) with avian myeloblastosis virus RT 
(Promega) and oligo(dT) primer. PCR was then performed with Taq polymerase 
(Promega) and primers TRCXCR3F2 (5’-AGCCCAGCCATGGTCCTTG-3’) and TRCXCR3R2 
(5’-CCTCACAAGCCCGAGTAGGA-3’). The resulting PCR product was spin-column purified 
(Qiagen) and ligated to pGEM-T vector (Promega). Subsequently the cDNA was 
subcloned into pcDEF3.  
A cDNA containing the rattus norvegicus CXCR3 open-reading frame was cloned from an 
F344 heart allograft that was transplanted into a Lewis rat at 28 days post-
transplantation.27 Total RNA was prepared from 0.25 g of rat tissue using the Trizol 
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method. First strand cDNA was synthesized from 2 μg of total RNA using 1.0 μM oligo dT-
T7 primer (GGCCAGTGAATTGTAATACGACTCACTATAGGG(A)24) and 200 U Superscript III 
reverse transcriptase (Invitrogen). Doubled-stranded cDNA was generated by the 
addition of second strand buffer (Invitrogen) according to the manufacturer’s protocol 
and purified by phenol/chloroform extraction. PCR was performed with Taq DNA 
polymerase and primers ratCXCR3Fwd: ATAGGATTCATGTACCTTGAGGTCAGTGAACGTCA 
and ratCXCR3Rev: ATAGAATTCTTACAAGCCCAAGTAGGAGGCCTCAGT. The resulting PCR 
fragment was cloned into pGEM-Teasy (Promega), and subcloned into pcDEF3. 
The cDNA of mouse CXCR3 was a kind gift from Dr. Luster26 and was subcloned into 
pcDEF3. The chimeric G protein Gqi5 (pcDNA1-HA-mGqi5) was a gift from Dr. Conklin.28 
Other plasmids that were used are pcDNA3.1-CXCR1, pcDEF3-CXCR2, pcDNA3-CXCR4, 
pcDEF3-CCR1, pcDNA3.1-CCR2, pcDEF3-H1, pCIneo-H3(445).  
 
Synthesis of non-peptidergic ligands. Synthesis of VUF5834,20 VUF10472 and 
VUF1008521 has been described previously.  
Synthesis of VUF10132 was adapted from the procedure described by Axten et al.24 
Briefly, 1-(3,4-dichloro-phenyl)-2-imidazol-1-yl-ethanone (0.19 g, 0.75 mmol) and 2-
bromo-1-(3,4-dichloro-phenyl)-ethanone (0.20 g, 0.75 mmol) were stirred in acetonitrile 
(50 mL) overnight at rt. The mixture was diluted with ether. The solid product was 
filtered, washed with ether and dried to afford VUF10132 as white solid. Yield: 0.31 g 
(78%). 1H NMR (DMSO) : 6.20 (s, 4H), 7.67-7.80 (m, 4H), 7.88-8.12 (m, 3H), 8.23-
8.25 (m, 2H), 9.12 (s, 1H). 13C NMR (50 MHz, DMSO) : 54.67, 55.45, 119.92, 122.65, 
127.70, 128.45, 130.15, 131.16, 131.26, 131.98, 132.34, 133.76, 137.83, 138.15, 
188.55, 189.74. M.p. 238.2-239.6 	C. 
 
Cell culture and transfection. HEK293T cells were grown at 5% CO2 at 37 ºC in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum, penicillin and streptomycin. HEK293T cells were transfected with 2.5 μg cDNA 
encoding CXCR3 supplemented with 2.5 μg pcDNA1-HA-mGqi5 (for PLC activation 
experiments and ELISA) or 2.5 μg pcDEF3 using linear polyethyleneimine (PEI) (MW 
25,000; Polysciences Inc, Warrington, PA, USA). The total amount of DNA in gene-dosing 
experiments was kept constant at 5 μg by addition of pcDEF3. Briefly, a total of 5 μg 
DNA was diluted in 250 μl 150 mM NaCl. Subsequently 30 μg PEI in 250 μl 150 mM NaCl 
was added to the DNA solution and incubated for 10 min at RT. The mixture was added 
to adherent HEK293T cells in 100 mM tissue culture dishes. Next day, cells were 
trypsinized, resuspended into culture medium and plated in the appropriate poly-L-lysine 
(Sigma) coated assay plates. For membrane preparation, cells were harvested 48 h after 
transfection from the tissue culture dishes in which they were transfected. 
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Murine pre-B L1.2 cells were grown in RPMI 1640 medium with glutamax-I and 25 mM 
HEPES, supplemented with 10% heat-inactivated certified FBS, penicillin, streptomycin, 
glutamine, non-essential amino acids, 2-mercaptoethanol and sodium pyruvate. L1.2 
cells were transfected with 10 μg per 20 million cells using a BioRad Gene Pulser II (330V 
and 975 F) and grown in culture medium supplemented with 10 mM sodium butyrate.  
 
Chemokine binding. Cell membrane fractions from transiently transfected HEK293T 
(CXCR3 and CXCR4) or COS-7 (CXCR2) cells were prepared as follows. Cells were 
washed with cold PBS, detached using cold PBS containing 1 mM EDTA and centrifuged at 
1500 g for 10 min at 4 ºC. Subsequently, cells were washed with PBS and centrifuged at 
1500 g for 10 min at 4 ºC. The pellet was resuspended in cold membrane buffer (15 mM 
Tris pH 7.5, 1 mM EGTA, 0.3 mM EDTA, 2 mM MgCl2) and homogenized by 10 strokes at 
1100-1200 rpm using a teflon-glass homogenizer and rotor. The membranes were 
subjected to two freeze thaw cycles using liquid nitrogen and centrifuged at 40,000 g for 
25 min at 4 ºC. The pellet was rinsed with cold Tris-sucrose buffer (20 mM Tris pH 7.4, 
250 mM sucrose), resuspended in the same buffer and frozen in liquid nitrogen. Protein 
concentration was determined using a Bio-Rad protein assay. Membranes were incubated 
in 96 well plates in binding buffer (50 mM HEPES pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 100 
mM NaCl, 0.5% BSA for CXCR3 and CXCR4 radioligand binding assays and 50 mM Na2/K-
phosphate buffer, pH 7.4, 0.5% BSA for CXCR2 radioligand binding assay) with 
approximately 50 pM 125I-chemokine and displacer for 2 h at RT. Subsequently, 
membranes were harvested via filtration through Unifilter GF/C plates (PerkinElmer Life 
and Analytical Sciences) pretreated with 1% polyethylenimine and washed three times 
with ice-cold wash buffer (50 mM HEPES pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 500 mM NaCl 
for CXCR3 and CXCR4 and 50 mM Na2/K-phosphate buffer, pH 7.4 for CXCR2). 
Radioactivity was measured using a MicroBeta (PerkinElmer Life and Analytical Sciences). 
 
Histamine H1 receptor binding. Cell homogenates from COS-7 cells transiently 
transfected with cDNA encoding the human histamine H1 receptor were incubated with 7 
nM [3H]-mepyramine and 10 M CXCR3 antagonist in H1 buffer (50 mM Na2/K-phosphate 
buffer, pH 7.4) for 30 min at RT and harvested via filtration using ice-cold H1 buffer as 
described above. 
 
Phospholipase C activation. Twenty-four hours after transfection, HEK293T cells were 
labeled overnight in Earle’s inositol-free minimal essential medium (Invitrogen) 
supplemented with 10% fetal bovine serum, penicillin and streptomycin and myo-[2-
3H]inositol (1 Ci/ml). Cells were washed with InsP assay buffer (20 mM HEPES pH 7.4, 
140 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 10 mM glucose and 0.05% (w/v) 
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BSA) and incubated for 2 h in InsP assay buffer supplemented with 10 mM LiCl in the 
presence or absence of indicated ligands. The incubation was stopped by aspiration of the 
assay buffer and addition of ice-cold 10 mM formic acid. After incubation for 90 min at 4 
ºC, [3H]-InsP were isolated by anion-exchange chromatography (Dowex AG1-X8 
columns, Bio-Rad) and counted by liquid scintillation. 
Chemotaxis. Twenty-four h after transfection, chemotaxis of L1.2 cells towards CXCL10 
(10 nM) was determined in the presence or absence of compounds, using 5 μM pore 
ChemoTx 96 well plates (Neuroprobe Inc, MD, USA). Briefly, ChemoTx plates were 
blocked using RPMI 1640 with glutamax-I and 25 mM Hepes supplemented with 1% 
(w/v) BSA. Chemokine and compound dilutions were made in RPMI 1640 with glutamax-I 
and 25 mM Hepes supplemented with 0.1% (w/v) BSA and added to the wells. L1.2 cells 
were added on top of the membrane and incubated for 5 h in a humidified chamber at 37 
ºC. The number of migrated cells per well was determined using a haemocytometer. 
ELISA. Forty-eight hours after transfection, HEK293T cells were washed with TBS and 
fixed with 4% paraformaldehyde in PBS. After blocking with 1% skim milk in 0.1 M 
NaHCO3 (pH 8.6), cells were incubated with mouse monoclonal anti-CXCR3 antibody 
(MAB160, R&D Systems, Inc) in TBS containing 0.1% BSA, washed three times with TBS 
and incubated with goat anti-mouse horseradish peroxidase-conjugated secondary 
antibody (Bio-Rad). Subsequently, cells were incubated with substrate buffer containing 
2mM o-phenylenediamine (Sigma, St. Louis, Mo), 35 mM citric acid, 66 mM Na2HPO4, 
0.015% H2O2 (pH 5.6). The reaction was stopped with 1 M H2SO4 and absorption at 490 
nm was determined. 
Data analysis. Nonlinear regression analysis of the data and calculation of Kd and Ki 
values was performed using Prism 4.03. The pKb values in the PLC activation assay were 
calculated using the Cheng-Prusoff equation pKb = IC50 / (1+[agonist]/EC50).29 
 
 
Results 
Non-peptidergic CXCR3 antagonists 
A selection of CXCR3-targeting small-molecule antagonists from two different structural 
classes was synthesized as previously described and subjected to detailed 
pharmacological analysis, including the quinazolinone-derived 3H-pyrido[2,3-d]pyrimidin-
4-one compounds VUF10472 (NBI-74330)21,22 and VUF10085 (AMG 487),21,23 the 3H-
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quinazolin-4-one VUF5834,20,23 and the imidazolium compound VUF1013224 (Fig. 1). The 
well described CCR5 antagonist TAK-77915 has been reported to show affinity for mouse 
CXCR316 and was therefore included in our set of non-peptidergic ligands as well (Figure 
1).  
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Figure 1. Structures of small non-peptidergic compounds targeting CXCR3. The 
structures of VUF10472 (NBI-74330; N-1R-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-
pyrido[2,3-d]pyrimidin-2-yl]-ethyl-N-pyridin-3-ylmethyl-2-(4-fluoro-3-trifluoromethyl-
phenyl)-acetamide), VUF10085 (AMG 487; N-1R-[3-(4-ethoxy-phenyl)-4-oxo-3,4-
dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl-N-pyridin-3-ylmethyl-2-(4-trifluoromethoxy-
phenyl)-acetamide), VUF5834 (decanoic acid (1-[3-(4-cyano-phenyl)-4-oxo-3,4-dihydro-
quinazolin-2-yl]-ethyl)-(2-dimethylamino-ethyl)-amide), VUF10132 (1,3-Bis-[2-(3,4-
dichloro-phenyl)-2-oxo-ethyl]-3H-imidazol-1-ium bromide) and TAK-779 (N,N-dimethyl-
N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-
yl]carbonyl]amino]benzyl] tetrahydro-2H-pyran-4-aminium chloride) are shown.
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Characterization of human CXCR3 
Binding studies were performed with radiolabeled CXCL10 and CXCL11 on membranes 
prepared from HEK293T cells transiently transfected with cDNA encoding human CXCR3.3 
Homologous displacement of the radioligands with unlabeled chemokines resulted in pKd 
values ± SEM of 9.8 ± 0.1 for CXCL10 and 10.6 ± 0.1 for CXCL11 (Figure 2A, Table 1), 
in accordance with the values and rank-order for these chemokines reported in 
literature.4, 22 
 
 
 
 
Figure 2. Characterization of human CXCR3. A) Homologous displacement binding at 
human CXCR3. Binding experiments were performed with approximately 50 pM 125I-
CXCL10 () or 125I-CXCL11 () and increasing concentrations of homologous unlabeled 
chemokine on membranes from HEK293T cells transfected with cDNA encoding human 
CXCR3. Data are presented as percentage of total binding. pKd values for CXCL10 and 
CXCL11 were 9.8 ± 0.1 (n=11) and 10.6 ± 0.1 (n=7) respectively. B) Activation of PLC 
by human CXCR3. HEK293T cells were transfected with cDNA encoding human CXCR3 
and Gqi5. After 48 h, 3H-InsP accumulation was determined in the presence of increasing 
concentrations of CXCL10 () or CXCL11 (). Data are presented as percentage of the 
maximal response obtained with CXCL11 (100 nM). pEC50 values for CXCL10 and CXCL11 
were 7.5 ± 0.1 (n=8) and 8.5 ± 0.1 (n=12) respectively.
 
 
In HEK293 cells human CXCR3 does not couple efficiently to the phospholipase C (PLC)-
inositolphosphates (InsP) pathway.25 Therefore, CXCR3 was transiently co-transfected 
with cDNA encoding the chimeric G protein Gqi5,28 after which robust PLC activation 
could be observed upon stimulation with CXCL10 and CXCL11. Using this functional 
assay, pEC50 values of 7.5 ± 0.1 and 8.5 ± 0.1 were obtained for respectively CXCL10 
and CXCL11 (Figure 2B, Table 1). CXCL10 acted as a partial agonist, with an intrinsic 
activity of 0.48 ± 0.8 compared to the full agonist CXCL11 (Figure 2B, n=5). 
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Characterization of rhesus macaque, rat and mouse CXCR3 
 
Since the affinities of non-peptidergic ligands targeting chemokine receptors may differ 
among species, e.g. for TAK-779 at human and mouse CCR515,16 and significant 
differences between the amino acid sequences of human and rodent CXCR3 are apparent 
(Figure 3), we set out to characterize CXCR3 of rhesus macaque, mouse and rat. CXCR3 
of mouse26 and rat25 have previously been cloned and described. Here, we report the 
cloning and characterization of rhesus macaque CXCR3 from PBMCs (GenBank accession 
number EU313340, see experimental procedures). The deduced amino acid sequence of 
rhesus macaque CXCR3 was found to be 99% identical to human CXCR3. The Thr83 
residue in the first intracellular loop of human CXCR3 is Ala83 in rhesus macaque CXCR3, 
and Val259 at position 6.391 in TM6 of human CXCR3 is Ala259 in rhesus macaque CXCR3 
(Figure 3). 
Table 1. Properties of chemokine ligands at CXCR3.  
species 
human CXCL10 
pKd n Bmax n pEC50 n
human 9.8 ± 0.1 11 358 ± 53 6 7.5 ± 0.1 8 
N3.35A 10.2 ± 0.2 4 327 ± 91 4 7.5 ± 0.0 2 
rhesus 10.0 ± 0.1 3 163 ± 7 2 7.4 ± 0.1 3 
rat 10.2 ± 0.2 7 631 ±141 7 8.8 ± 0.1 3 
mouse 10.1 ± 0.1 3 658 ± 127 3 8.3 ± 0.1 5 
 
species 
human CXCL11 
pKd n Bmax n pEC50 n
human 10.6 ± 0.1 7 407 ± 126 4 8.5 ± 0.1 12 
N3.35A 11.3 ± 0.3 3 564 ± 242 3 8.7 ± 0.1 4 
rhesus 10.8 ± 0.3 3 255 ± 114 4 8.5 ± 0.1 3 
rat 10.7 ± 0.2 4 1170 ± 644 3 9.5 ± 0.1 3 
mouse 10.7 ± 0.3 4 1882 ± 858 4 9.2 ± 0.2 3 
Shown are pKd values and Bmax values ± SEM for human CXCL10 and human CXCL11 at 
the various CXCR3, calculated from homologous radioligand binding experiments. pEC50 
values ± SEM were obtained using the PLC activation assay. 
 
 
After expression in HEK293T cells, CXCR3 from rhesus, rat and mouse showed similar 
binding affinities for human CXCL10 and CXCL11 as human CXCR3 (Table 1). Bmax values 
of rodent CXCR3 were increased compared to human CXCR3, approximately 2-fold higher 
for CXCL10 and 3 to 4-fold higher for CXCL11 (Table 1) when equal amounts of cDNA 
were transfected. The Bmax for CXCL10 at rhesus CXCR3 was 2-fold lower than for human 
CXCR3, whereas human and rhesus CXCR3 had comparable Bmax values for CXCL11 
(Table 1). Rhesus CXCR3 stimulated PLC with similar maximum effect (Emax) and similar 
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EC50 values for human CXCL10 and CXCL11 as human CXCR3 (Figure 4A and 4B, Table 
1). In contrast, the rodent CXCR3 species had approximately 10-fold higher potencies 
and showed increased Emax for human CXCL10 compared to human CXCR3 (Figure 4A 
and 4B, Table 1). The Emax for human CXCL11 at rat CXCR3 was also increased compared 
to the effect of CXCL11 at CXCR3 of the other species (Figure 4B). 
 
 
 
 
 
 
Figure 3. Snakeplot of CXCR3. Amino acids that were mutated in order to generate 
constitutively active mutants (T2.56, N3.35 and D3.49) are indicated as bold circled 
residues. Amino acids that differ between human and rhesus macaque CXCR3 (T83 in 
intracellular loop 1 and V6.39 are both Ala in rhesus macaque CXCR3) are shown as grey 
circles. Residues which are different between primate and rodent (i.e. rat and/or mouse) 
CXCR3 are indicated as black circles. Human and rhesus macaque CXCR3 have an 
additional Cys (C37) in their amino-terminus compared to rat and mouse CXCR3. Helix 8 
at the membrane proximal part of the carboxy-terminus and potential palmitoylation of 
Cys338 are shown as well.
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Figure 4. Activation of PLC by primate and rodent CXCR3. A) CXCL10-induced 
activation of PLC. HEK293T cells were transfected with cDNA encoding human, rhesus, 
rat or mouse CXCR3 and Gqi5. After 48 h, [3H]-InsP accumulation was determined in the 
presence of increasing concentrations human CXCL10. pEC50 values for CXCL10 were 7.5 
± 0.1 (human CXCR3, n=8), 7.4 ± 0.1 (rhesus CXCR3, n=3), 8.8 ± 0.1 (rat CXCR3, 
n=3) and 8.3 ± 0.1 (mouse CXCR3, n=5). B) CXCL11-induced activation of PLC. 
HEK293T cells were transfected with cDNA encoding human, rhesus, rat or mouse CXCR3 
and Gqi5. After 48 h, [3H]-InsP accumulation was determined in the presence of 
increasing concentrations human CXCL11. pEC50 values for CXCL11 were 8.5 ± 0.1 
(human CXCR3, n=12), 8.5 ± 0.1 (rhesus CXCR3, n=3), 9.5 ± 0.1 (rat CXCR3, n=3) and 
9.2 ± 0.2 (mouse CXCR3, n=3). Data are presented per receptor as percentage of 3H-
InsP accumulation in the absence of chemokine.
 
 
Behavior of non-peptidergic compounds at CXCR3 
The panel of non-peptidergic ligands inhibited [125I]-CXCL10 binding to human CXCR3 
with Ki values ranging between 4 nM for VUF10472 and 1.3 μM for TAK-779 (Figure 5A 
and Table 2). VUF10085, VUF5834 and VUF10132 showed intermediate Ki values of 20 
nM, 158 nM and 251 nM respectively (Figure 5A and Table 2). Subsequently, the ability 
of the small molecules to inhibit CXCL10-induced PLC activation through human CXCR3 
was determined. All compounds reduced CXCL10-mediated (10-50 nM) PLC activation 
with Kb values ranging from 6 nM for VUF10472 to 800 nM for TAK-779 (Figure 5B, Table 
2). A good correlation (r2 = 0.997) was observed between the measured pKi values and 
pKb values determined against CXCL10 (Figure 5C). For the most potent compound, 
VUF10472, inhibition of CXCL11-induced (5 nM) PLC activation was also determined, 
resulting in a Kb value of 12.6 nM (Figure 5D). This value corresponds well to the value 
obtained against CXCL10 (Figure 5D and Table 2). Finally, the ability of the non-
peptidergic ligands to inhibit chemotaxis was investigated. The murine pre-B cell line 
L1.2 was transiently transfected with cDNA encoding human CXCR3 and migration of 
cells towards CXCL10 in the presence or absence of VUF10085 and VUF5834 was 
determined. CXCR3-transfected L1.2 cells did not migrate in the absence of CXCL10, 
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whereas 10.3 ± 0.8 % (n=3) of the cells migrated to CXCL10 (10 nM) in the absence of 
inhibitors (Figure 5E, inset). Both compounds completely inhibited CXCL10-induced (10 
nM) migration at a concentration of 10 μM, with pIC50 values of 6.8 ± 0.2 (n=2) and 5.8 
± 0.1 (n=3) for VUF10085 and VUF5834 respectively (Figure 5E).  
Next, the affinity of the non-peptidergic ligands for CXCR3 of the different species was 
determined using [125I]-CXCL10. The pKi values of the compounds tested at rhesus 
CXCR3 were identical to the values found for human CXCR3 (Table 2). Similarly, the 
affinities of the compounds tested at rat and mouse CXCR3 were identical to each other. 
However, VUF10472, VUF10085, VUF5834 and VUF10132 showed an approximately 4-
fold lower affinity for the rodent CXCR3 (mouse and rat) compared to the primate CXCR3 
(human and rhesus). Only for TAK-779 no difference in affinity between CXCR3 from the 
different species was observed. 
Since the non-peptidergic compounds showed slightly lower affinity for rodent CXCR3 and 
the previous experiments were performed with human chemokines, we also determined 
the ability of the antagonists to inhibit mouse CXCL10-induced signaling at mouse 
CXCR3. The pEC50 of mouse CXCL10 at mouse CXCR3 (8.4 ± 0.1, n=3) was comparable 
with the pEC50 of human CXCL10 at mouse CXCR3 (8.3 ± 0.1, n=5). The different 
antagonists inhibited mouse CXCL10-induced activation of mouse CXCR3 (measured as 
PLC stimulation) with Kb values ranging from 4 nM for VUF10472 to 400 nM for TAK-779. 
The Kb values obtained under these conditions are within two-fold of the Kb values for 
inhibition of human CXCL10 at human CXCR3 (Figure 5F, Table 2). 
In order to determine whether the antagonists show competitive or non-competitive 
behavior, a Schild analysis was performed. HEK293T cells expressing human CXCR3 and 
Gqi5 were incubated with increasing concentrations of CXCL10 (Figure 6A) or CXCL11 
(Figure 6B) in the absence or presence of different concentrations of VUF10472. A 
decreased maximal effect combined with a rightward shift of the curves was observed in 
the presence of VUF10472, indicating non-competitive antagonist behavior. The 
mechanism of antagonism of the other classes of non-peptidergic ligands was 
investigated using only CXCL11. VUF10132 (Figure 6C) and TAK-779 (Figure 6D) both 
clearly showed non-competitive antagonistic behavior similar to that of VUF10472. 
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Figure 5. Characterization of small non-peptidergic compounds at human CXCR3 
A) Displacement of 125I-CXCL10. Binding experiments were performed with 
approximately 50 pM 125I-CXCL10 and increasing concentrations of VUF10472 (), 
VUF10085 (), VUF5834 (), VUF10132 () or TAK-779 () on membranes from 
HEK293T cells transfected with cDNA encoding human CXCR3. Data are presented as 
percentage of total binding. pKi values were 8.4 ± 0.1 (VUF10472, n=7), 7.7 ± 0.0 
(VUF10085, n=18), 6.8 ± 0.1 (VUF5834, n=3), 6.6 ± 0.0 (VUF10132, n=4) and 5.9 ± 
0.0 (n=6).  
B) Inhibition of CXCL10-induced PLC activation. HEK293T cells were transfected with 
cDNA encoding human CXCR3 and Gqi5. After 48 h, CXCL10-induced (10-50 nM) 3H- 
InsP accumulation was determined in the presence of increasing concentrations of 
VUF10472 (), VUF10085 (), VUF5834 (), VUF10132 () or TAK-779 (). pKb values 
were 8.2 ± 0.1 (VUF10472, n=5), 7.7 ± 0.1 (VUF10085, n=9), 7.0 ± 0.1 (VUF5834, 
n=5), 6.7 ± 0.1 (VUF10132, n=5) and 6.1 ± 0.1 (TAK-779, n=4).  
C) Relationship between pKi and pKb of non-peptidergic ligands. pKb values obtained 
using CXCL10 were plotted against pKi values obtained against 125I-CXCL10 (r2 = 0.997). 
D) Inhibition of CXCL11-induced PLC activation by VUF10472. HEK293T cells were 
transfected with cDNA encoding human CXCR3 and Gqi5. After 48 h, CXCL11-induced (5 
nM) 3H-InsP accumulation was determined in the presence of increasing concentrations 
of VUF10472 (). The pKb value of VUF10472 was 7.9 ± 0.0 (n=3). For comparison, 
inhibition of CXCL10-induced (50 nM) PLC activation by VUF10472 is shown as well ().  
Data are represented as percentage stimulation in the absence of antagonist. pKb values 
were calculated using the Cheng-Prusoff equation 29.  
E) Inhibition of CXCL10-induced chemotaxis. L1.2 cells were transfected with cDNA 
encoding human CXCR3. After 24 h, inhibition of CXCL10-induced (10 nM) chemotaxis 
was determined. pIC50 values were 6.8 ± 0.2 (VUF10085, n=2) and 5.8 ± 0.1 (VUF5834, 
n=3).  Data are presented as percentage of migrated cells in the absence of antagonist. 
Inset, CXCL10-induced chemotaxis of L1.2 cells. Data are presented as percentage of 
total L1.2 cells that migrated to CXCL10 (10 nM) in the absence of antagonist (n=3). 
F) Inhibition of mouse CXCL10-induced PLC activation through mouse CXCR3. HEK293T 
cells were transfected with cDNA encoding mouse CXCR3 and Gqi5. After 48 h, mouse 
CXCL10-induced (20 nM) 3H- InsP accumulation was determined in the presence of 
increasing concentrations of VUF10472 (), VUF10085 (), VUF5834 (), VUF10132 () 
or TAK-779 (). pKb values were 8.4 ± 0.1 (VUF10472, n=4), 7.7 ± 0.1 (VUF10085, 
n=4), 7.4 ± 0.2 (VUF5834, n=3), 6.6 ± 0.1 (VUF10132, n=4) and 6.4 ± 0.1 (TAK-779, 
n=4).
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Figure 6. Non-competitive behavior of non-peptidergic compounds at human 
CXCR3. A) Schild analysis of VUF10472 using CXCL10 as agonist. HEK293T cells were 
transfected with cDNA encoding human CXCR3 and Gqi5. After 48 h, CXCL10-induced 3H-
InsP accumulation was determined in the absence () or in the presence of 10 nM () or 
30 nM () VUF10472 (n=2-3). B-D) Schild analysis using CXCL11 as agonist. HEK293T 
cells were transfected with cDNA encoding human CXCR3 and Gqi5. After 48 h, CXCL11-
induced 3H-InsP accumulation was determined in the absence () or in the presence of 
30 nM (), 100 nM (), 1 μM (), 10 μM () or 100 μM () VUF10472 (Fig. 6B, n=6), 
VUF10132 (Fig. 6C, n=6) or TAK-779 (Fig. 6D, n=7). Data are presented as percentage 
of chemokine-induced (1 M) stimulation in the absence of non-peptidergic ligand.
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Fig. 7. Characterization of the constitutively active mutant CXCR3 N3.35A 
A) Expression of CXCR3 WT and CXCR3 N3.35A. HEK293T cells were transfected with 
cDNA encoding Gqi5 and increasing amounts of cDNA encoding human CXCR3 WT or 
CXCR3 N3.35A. Mock cells were transfected with cDNA encoding Gqi5 and pcDEF3 empty 
vector. After 48 h, CXCR3 expression was determined in an ELISA assay. Data are 
presented as percentage signal obtained in mock-transfected cells (n=2-3). 
B) Constitutive activity of CXCR3 N3.35A. HEK293T cells were transfected with cDNA 
encoding Gqi5 and increasing amounts of cDNA encoding human CXCR3 WT or CXCR3 
N3.35A. Mock cells were transfected with cDNA encoding Gqi5 and pcDEF3 empty vector. 
After 48 h, 3H-InsP accumulation was determined in the absence of chemokines. Data are 
presented as percentage 3H-InsP in mock-transfected cells (n=3). 
C) Chemokine-induced PLC activation by CXCR3 N3.35A. HEK293T cells were transfected 
with cDNA encoding CXCR3 N3.35A and Gqi5. After 48 h, 3H-InsP accumulation was 
determined in the presence of increasing concentrations CXCL10 or CXCL11. pEC50 values 
for CXCL10 and CXCL11 were 7.5 ± 0.0 (n=2) and 8.7 ± 0.1 (n=4) respectively. Data 
are presented as percentage of the maximal response obtained with CXCL11 (100 nM). 
D) Inverse agonism at CXCR3 N3.35A. HEK293T cells were transfected with cDNA 
encoding CXCR3 N3.35A and Gqi5. After 48 h, 3H-InsP accumulation was determined in 
the presence of increasing concentrations VUF10472 (), VUF10085 (), VUF5834 (), 
VUF10132 () or TAK-779 (). pIC50 values (n=3) were 8.1 ± 0.1 (VUF10472), 8.0 ± 
0.1 (VUF10085), 7.3 ± 0.0 (VUF5834), 6.6 ± 0.1 (VUF10132) and 5.9 ± 0.1 (TAK-779). 
Data are presented as percentage of CXCR3 N3.35A-mediated constitutive 3H-InsP 
accumulation.  
 117
Chapter 6 
 
 
Specificity of the non-peptidergic CXCR3 antagonists 
 
The CXCR3 antagonists were tested against a small panel of chemokine and histamine 
receptors to determine their specificity. HEK293T cells expressing the different GPCRs 
were incubated with their respective agonists in the presence or absence of CXCR3 
antagonists and activation of PLC was determined. The percentage inhibition of agonist-
induced PLC activation by the CXCR3 antagonists is shown in Table 3. As expected, the 
CXCR3 antagonists (10 M) showed 50-100 % inhibition of CXCL11-induced (100 nM) 
PLC activation through CXCR3 and the CCR5/CCR2/CXCR3 antagonist TAK-779 inhibited 
CCL2-induced activation of CCR2 with 95%. Unexpectedly, VUF10132 inhibited CCL5-
induced CCR1 activation with 61%, compared to 71% inhibition of CXCR3-mediated 
response. The other CXCR3 antagonists did not significantly inhibit the tested chemokine 
or histamine receptors (Table 3). Additionally, the compounds were tested in radioligand 
binding studies on membranes expressing CXCR2, CXCR4 or the histamine H1 receptor. 
At the tested concentration (10 M), the CXCR3 antagonists typically inhibit [125I]-
CXCL10 binding to CXCR3 with 80-100% (Figure 5A). Besides TAK-779, which inhibited 
binding of [3H]-mepyramine to the histamine H1 receptor with only 41% at 10 M, no 
significant inhibition of radioligand binding to CXCR2, CXCR4 or the H1 receptor by the 
other CXCR3 antagonists was observed. 
 
Non-peptidergic antagonists are inverse agonists at a constitutively active 
mutant of CXCR3 
 
Inverse agonism has recently been shown to be an important molecular mechanism of 
action of small-molecule antagonists at a variety of GPCR family members.30 Human 
chemokine receptors generally do not show high levels of constitutive activity. However, 
constitutively active chemokine receptor mutants have been described that signal in the 
absence of ligands. Examples are CXCR2 D3.49V,31 mutation of N3.35 of CXCR4,32 and 
mutation of T2.56 in CCR2 and CCR5.33 To determine if the studied CXCR3 antagonists 
act as neutral antagonists or inverse agonists at CXCR3, analogous CAMs of CXCR3 were 
constructed (Figure 3). Upon expression of the CXCR3 mutants N3.35A, N3.35S and 
T2.56P significant constitutive activity was shown, whereas no constitutive activity was 
found for the CXCR3 D3.49V mutant (data not shown). In view of the signal to noise 
ratio we choose CXCR3 N3.35A for further characterization. Upon transfection of 
HEK293T cells with increasing amounts of cDNA encoding CXCR3 WT or CXCR3 N3.35A 
an increase in receptor expression was detected in ELISA experiments (Figure 7A). When 
similar amounts of cDNA were transfected, CXCR3 WT was expressed at higher levels 
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than CXCR3 N3.35A (Figure 7A). As expected, CXCR3 WT did not activate PLC in the 
absence of ligands (Figure 7B). Even though CXCR3 N3.35A was expressed at lower 
levels than CXCR3 WT, CXCR3 N3.35A showed a marked increase of PLC activation upon 
transfection of increasing amounts of cDNA (Figure 7B).  
The affinities of CXCL10 (pKd 10.2 ± 0.2) and CXCL11 (pKd, 11.3 ± 0.3) for CXCR3 
N3.35A were slightly higher than for CXCR3 WT (Table 1). CXCL10 and CXCL11 activated 
CXCR3 N3.35A over basal levels in a similar manner as CXCR3 WT, with pEC50 values of 
7.5 ± 0.0 (n=2) and 8.7 ± 0.1 (n=4) respectively (Figure 7C, Table 1). Subsequently, 
the affinity of the antagonists at CXCR3 N3.35A was determined using [125I]-CXCL10. The 
affinity of all compounds, except TAK-779, was slightly reduced for CXCR3 N3.35A 
compared to CXCR3 WT (Table 2). Finally, the effect of the  antagonists on the 
constitutive activation of PLC was investigated. VUF10472, VUF10085, VUF5834 and 
VUF10132 all acted as full inverse agonists, with IC50 values ranging between 8 nM for 
VUF10472 and 251 nM for VUF10132 (Figure 7D, Table 2). In contrast, TAK-779 acted as 
a partial inverse agonist with an intrinsic activity of -0.42 ± 0.0 and an IC50 of 1.3 μM 
(n=3) (Figure 7D, Table 2). 
 
Discussion 
 
CXCR3 has attracted considerable attention as a new drug target due to its involvement 
in a variety of serious disorders, including cancer,10 atherosclerosis,8 inflammatory 
disorders like rheumatoid arthritis,2 skin diseases9 and transplant rejection.7 Following 
the recognition of CXCR3 as a potential attractive drug target, several small molecule 
CXCR3 antagonists have recently been identified.16,18-23 In this study, we have selected 
five non-peptidergic antagonists from three different structural classes and studied their 
mechanism of action at the human CXCR3. In addition, the interaction of these 
antagonists with human, rhesus macaque, rat and mouse CXCR3 was investigated.  
All tested non-peptidergic antagonists inhibited CXCL10-induced activation of PLC with 
pKb values that correlated very well with their affinity, with a rank order VUF10472 > 
VUF10085 > VUF5834 > VUF10132 > TAK-779 (Table 2). Subsequently, the mechanism 
of action of the antagonists was explored using Schild analysis. The dose-response 
curves for CXCL10 and CXCL11 did not reach the maximal response in the presence of 
VUF10472 (Figure 6), as has been previously shown by others for human and mouse 
CXCR3.22,34 Antagonists from other structural classes also decreased the maximum 
response of CXCL11, in a manner that follows the rank-order of their affinities. This 
indicates that all tested non-peptidergic antagonists behave as non-competitive 
antagonists for the PLC activation by the endogenous agonists of CXCR3. 
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Antagonists of GPCRs can be classified as neutral antagonists or (partial) inverse 
agonists.30,35 Although both antagonist classes are able to block an agonist-induced 
response by occupying the receptor, there is an ongoing debate about the exact clinical 
benefits or disadvantages of each class.30 Treatment with inverse agonists may be 
beneficial when a constitutively active receptor underlies the pathogenesis. To date, 
there are no reports about constitutive activity of CXCR3 and there are only few 
examples of constitutive activity of chemokine receptors. Constitutive activity is a 
function of the relative stoichiometry of receptors and G proteins35 and chemokine 
receptors, including CXCR3, are often upregulated under inflammatory conditions.1,36 
Hence, under pathophysiological conditions constitutive activity of chemokine receptors 
might become apparent and therefore the use of inverse agonists beneficial. In order to 
study the relative efficacy of the non-peptidergic antagonists, we generated mutants of 
CXCR3, i.e. CXCR3 N3.35A, N3.35S, D3.39V and T2.56P, based on CAMs of chemokine 
receptors reported in literature.31-33 All generated mutants, except for CXCR3 D3.49V 
with a mutation in the conserved DRY motif at the cytoplasmatic end of TM3, displayed 
basal signaling. Mutation of the DRY motif of CXCR2 to VRY confers constitutive activity 
to CXCR2,31 while the same mutation for CXCR131 or CCR537 did not result in constitutive 
activity. Conversely, mutation of the VRY motif to DRY in the highly constitutively active 
chemokine receptor ORF74 encoded by Kaposi´s sarcoma-associated herpesvirus did not 
diminish its constitutive activity but even increased it.38 Therefore, mutation of D3.49 to 
Val does not appear to be a universal switch for constitutive activity in chemokine 
receptors. In the same way, mutation of T2.56 in the conserved TXP motif resulted in a 
CAM for CXCR3 (this study), CCR5 and CCR2 but not for CCR1, CCR3, CCR4, CXCR2 and 
CXCR4.33 Mutation of N3.35 in the N(L/F)Y motif in TM3 of CXC chemokine receptors 
resulted in CAMs for both CXCR3 (this study) and CXCR4.32 The non-peptidergic 
compounds acted as full inverse agonists at CXCR3 N3.35A, except for TAK-779, which 
only partially inhibited constitutive signaling at the highest concentration used (Figure 
7D). Since VUF10132 and TAK-779 have similar affinities for CXCR3 N3.35A (Table 2), it 
appears that TAK-779 lacks certain structural features needed for full inverse agonism at 
CXCR3. Interestingly, TAK-779 acts as a full inverse agonist at CCR5.37 As expected for a 
receptor in the active state,35 the affinities of the agonists CXCL10 and CXCL11 for 
CXCR3 N3.35A were increased compared to CXCR3 WT (Table 1). The full inverse 
agonists VUF10472, VUF10085, VUF5834 and VUF10132, which are predicted to have a 
higher affinity for an inactive receptor conformation,35 all showed reduced affinity for 
CXCR3 N3.35A compared to CXCR3 WT (Table 2). In contrast, the affinity of the weak 
partial inverse agonist TAK-779 did not change, indicating a different mode of interaction 
with CXCR3 compared to the other structural classes of compounds. 
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If antagonists are to be tested in animal models, detailed information on the interaction 
of the compound with the receptor of that specific species is required, since species 
differences may occur. We therefore tested the non-peptidergic antagonists on rhesus 
macaque CXCR3, which was cloned in this study, as well as on rat and mouse CXCR3. 
Human and rhesus macaque show 99% amino acid identity (Figure 3). Consistent with 
this high homology, no differences in affinity or potency of CXCL10 and CXCL11, or in the 
affinity of the non-peptidergic antagonists for the two receptors were found. Similarly, 
the protein sequences of rat and mouse CXCR3 are 96% identical and no significant 
differences in affinity of the endogenous agonists or the non-peptidergic compounds are 
observed between the CXCR3 of these rodent species. However, lower sequence identity 
is found when human and rhesus macaque CXCR3 are compared with rat and mouse 
CXCR3.  Approximately 85% identity exists between the primate (human and rhesus 
macaque) and rodent (rat and mouse) species (Figure 3). Nevertheless, the affinities of 
CXCL10 and CXCL11 found for rodent CXCR3 were comparable to the affinities found for 
primate CXCR3 (Table 1). While the affinities of CXCL10 and CXCL11 were comparable, 
the affinities of VUF10472, VUF10084, VUF5834 and VUF101032 were only about 4-fold 
lower for rodent CXCR3 than for primate CXCR3 (Table 2). Also their pKb values against 
hCXCL10/hCXCR3 and mCXCL10/mCXCR3 are comparable (Table 2, Figure 5B and 5F), 
indicating the usefulness of these compounds in mouse models. In contrast, the affinity 
of TAK-779 was equal for CXCR3 of all tested species, again indicating that TAK-779 
interacts with CXCR3 in another manner than the other antagonists. TAK-779, developed 
as a CCR5 antagonist, has been thoroughly investigated because of its potential use as a 
HIV-entry inhibitor. TAK-779 shows high affinity for human CCR5 and to a lesser extend 
for human CCR2b.15 Furthermore, TAK-779 was reported to bind mouse CCR5, as well as 
mouse CXCR3.16 Remarkably, TAK-779 shows a more than 100-fold higher affinity for 
human CCR5 than for mouse CCR5.15,16 This species selectivity of TAK-779 for CCR5 is 
not observed for human and mouse CXCR3, which both bind TAK-779 with affinities 
around 1 μM (Table 2). It appears that TAK-779 has nanomolar affinity for human CCR5 
and micromolar affinity for human CXCR3, whereas it has only micromolar affinity for 
mouse CCR5 and mouse CXCR3. This should be kept in mind when analyzing and 
extrapolating data from rodent models, since at a certain effective concentration of TAK-
779 different receptors will be occupied in humans and mice. While in mice the observed 
effects would likely be mediated by a combined blockage of CCR5 and CXCR3, in humans 
the effects of TAK-779 would be mostly through inhibition of CCR5 with low nanomolar 
affinity. The non-peptidergic CXCR3 antagonists investigated in this study only showed a 
3 to 4-fold species selectivity for CXCR3 of primates versus rodents in radioligand binding 
studies, whereas no species difference was observed in functional studies. When testing 
for selectivity against a small panel of GPCRs, VUF10132 inhibited CCR1-mediated 
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signaling and should therefore be optimized with respect to its affinity and specificity for 
CXCR3. In contrast, we observed that VUF10472, VUF10085 and VUF5834 are selective 
for CXCR3 amongst the GPCRs in the tested panel. In line with our findings, 
VUF10472/NBI-74330 has previously been reported not to affect chemotactic responses 
by human H9 T-cell lymphoma cells in response to CXCL12 and CCL19 and not to 
interfere with calcium mobilization induced by lysophosphatidic acid or radioligand 
binding to several GPCRs.22 
 
Conclusions 
 
In summary, we characterized representative examples of three classes of small non-
peptidergic and non-competitive CXCR3 antagonists at CXCR3 of four different species, 
with VUF10472 being the most potent compound at human, rhesus, rat and mouse 
CXCR3. The observed selectivity profile and relatively small differences in affinity 
observed between human and rodent CXCR3 imply that VUF10472/NBI-74330, 
VUF10085/AMG 487 and VUF5834 are useful in rodent models of CXCR3-mediated 
pathogenesis. Interestingly, it was found that the non-peptidergic antagonists act as 
inverse agonists at a constitutively active CXCR3 mutant.  
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Preliminary investigations into bivalent ligands for CXCR3  
 
 
Abstract 
 
The “bivalent ligand” approach can be used to probe dimers of 
GPCRs. Here, this approach is applied to the development of a new 
type of CXCR3 antagonists able to target possible CXCR3 dimers. 
Using the well known 3H-quinazolin-4-one and 3H-pyrido[2,3-
d]pyrimidin-4-one CXCR3 antagonists 3a-b and 4 as monomers, 
bivalent ligands with alkyl spacers have been synthesized. In 
comparison to 3a and 3b the bivalent analogues exhibit a decreased 
affinity and antagonistic activity at CXCR3 receptor. In the series of 
these bivalent analogue compounds, 1a showed the highest affinity 
whereas 1b showed the best antagonistic activity towards CXCR3. 
Owing to their interesting structures and pharmacological profiles, 
compounds 1a and 1b may be used as tools for CXCR3 dimerization 
studies. 
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Introduction 
 
Chemokine receptors, like the majority of cell surface receptors, belong to the 
superfamily of G-protein coupled receptors. They exert their activity through coupling to 
a heterotrimeric G protein which can initiate second messenger signaling cascades.1,2 
Although the classical literature routinely described GPCRs functioning as monomers 
signaling through downstream G-proteins in 1:1 stochiometric ratio, in the last decade 
the focus has shifted to the concept of GPCRs existing and potentially functioning as 
dimers/oligomers3,4. To date, several pharmacological studies as well as biochemical and 
biophysical techinques such as cross-linking,5,6 immunoprecipitation,7,8 
bioluminescence9,10 or fluorescence resonance energy transfer (FRET) studies11 have 
provided evidence for this new concept. Furthermore, in a study where infrared-laser 
atomic force microscopy was used to reveal the rodopsin arrangement in the native disc 
membranes,12 it has been shown that almost all rhodopsin molecules are present as rows 
of dimers. This appears consistent with the proposed dimeric form of GPCRs (Figure 1). 
 
Figure 1. Organization and topography of the cytoplasmic surface of rhodopsin. a, 
Topograph obtained using atomic-force microscopy, showing the arrangement of 
rhodopsin dimers in the native disc membrane. b, Angularly averaged powder-diffraction 
pattern. c, Magnification of a region of the topograph in a, showing rows of rhodopsin 
dimers, as well as individual dimers (inside dashed ellipse) and occasional rhodopsin 
monomers (arrowheads). Adapted from Fotiadis et al.12 
 
 
Interestingly, however, Whorton et al13 showed that when incorporating the 2-
adrenergic receptor in a high-density lipoprotein particle system, there is the possibility 
that the minimal GPCR functional unit required for signaling is simply a monomer. In 
fact, in this setting, where the 2-adrenergic receptor was not able to dimerize, agonist 
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treatment induced a rapid guanine-nucleotide exchange in G proteins. Therefore it might 
be speculated that even if the GPCRs exist as dimers/oligomers, the 
dimerization/oligomerization plays only a marginal role in the G protein activation.  
Nonetheless, in general all these important findings on GPCR dimers may collectively 
represent the basis for new pharmacological mechanisms of action and for new molecular 
designs that address a better ligand selectivity coupled to a lower incidence of side 
effects.14 Based on whether two of the same type of GPCR bind or two different types, 
one can distinguish homodimers or heterodimers. Both types can in principle be targeted 
by bivalent ligands. Bivalent (dimeric) ligands are defined as molecules containing two 
pharmacological recognition units (pharmacophores) linked covalently by a connecting 
unit (spacer). Bivalent ligands are generally thought to interact first via univalent binding 
which is then followed by a binding of a second pharmacophore to a second recognition 
site on an adjacent receptor15. In principle, this double binding event can increase affinity 
and selectivity toward the targeted receptor(s). Thus, bivalent ligands may be more 
effective than the respective monomeric ligands and their use may open the door to 
future development of potent, selective GPCR drugs. Figure 2 shows a cartoon depicting 
a bivalent ligand binding to a GPCR heterodimer. 
 
        bivalent ligand:  
 
 
 
   
 
Figure 2. Example of a bivalent ligand binding to a GPCR heterodimer. Adapted from 
Filizola.16 
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Besides being novel entries into drugs, bivalent ligands are expected to be valuable 
molecular probes for the study of GPCR dimerization. Particularly, studies in the opioid 
receptor area have shown that bivalent ligands can exhibit enhanced affinity compared to 
their monomeric analogues depending on the type and length of the spacer.17,18  
Moreover, in some studies the bivalent ligands showed improved selectivity for one of the 
receptor subtype over the others in the same family.19-23. These studies provided 
indications for the existence of several types of opioid receptor dimers. 
A few studies have shown that, like many GPCRs, some chemokines receptors are able to 
form homo- and heterodimers.24-27 Using different techniques such as the 
bioluminescence resonance energy transfer (BRET), homo- and heterodimerisation has 
been demonstrated for CCR2 and CCR5 receptors.24-26 Babcock et al used the BRET 
technique to show that CXCR4 is unable to heterodimerise with CCR5, but forms clusters 
(oligomers) of two or more CXCR4 monomers.27 
To date no evidence for CXCR3 homo- and/or heterodimerisation is available, nor are any 
specific studies on bivalent ligands for CXCR3 reported in the public domain. 
Interestingly, though, in the patent literature it has been claimed that certain 
aminoquinoline compounds, having the general structure shown in Figure 3, are effective 
in treating inflammatory and immuno diseases through their binding to CXCR3 
receptors.28 Also, a screen on natural binders turned up a dipyridinium salt (Figure 3, 
IC50=690 nM) as a CXCR3-binding hit.29 Both ligand classes bear some hallmarks of 
bivalent character, but neither study explicitly discusses receptor dimers as the targets. 
We were interested in studying whether bivalent analogues of known CXCR3 antagonists 
could increase the affinity for CXCR3 through a putative CXCR3 homodimer. Toward this 
end, some bivalent ligands derived from the validated CXCR3-pharmacophores of 3a
(VUF10085 / AMG 487), 3b and 430,31 (Figure 4) were designed and tested for their 
affinity and activity towards CXCR3. 
                            
Figure 3. (Left) General structure of aminoquinoline compounds as reported by Lin.28 
(Right) A natural product found on a screen on CXCR3.29 
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Figure 4. Structures of the reference compounds 3a-b and 4. R= nonyl
 
Chemistry 
Synthetic pathways for compounds 3a-b and 4 have been previously described30,31. As 
depicted in Scheme 1 and 2, final compounds 1a-c were obtained via alkylation of 
intermediates 530,31 and 631 with decanedioyl and dodecanedioyl dichloride, respectively. 
Incomplete conversion in the case of 1a-b yielded 2a-b in the same reaction and these 
compounds were also isolated. As outlined in Chapter 4, the used building blocks (e.g. 5) 
were racemic and this will hold true for the final compounds in this chapter as well. 
Pharmacology 
The affinity for the human CXCR3 of all compounds was determined by displacement of 
[125I]CXCL10 binding to membranes from HEK-293 cells stably expressing the human 
CXCR3 receptor. Functional activity was inspected by recording the effect of compounds 
on CXCL11-induced phospholipase C (PLC) activity. This was determined by measuring 
the production of [3H]-inositol phosphates ([3H]-IPx) in COS-7-CXCR3 cells.  
 
 
Results and discussion 
 
In this study, the bivalent ligand approach was used in order to investigate the behavior 
of bivalent molecules at CXCR3 and to probe putative CXCR3 dimers. The 
pharmacophores of previously reported CXCR3 antagonists (3a-b and 4) were selected 
as monomeric units on the basis of their affinities and antagonistic activities at human 
CXCR3 receptor.27,28 
Bivalent ligands were designed as duplication of the aforementioned ligands by linking 
the two monomeric units with a spacer length of eight (1a, 1c) or ten (1b) methylene 
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chains. The linkage of choice is an amide bond as this was already present in the parent 
compounds. Also, an alkyl spacer was selected because of its presence in reference 
compounds 3b and 4. The monomeric carboxylic products 2a and 2b were also tested 
for affinity and activities at human CXCR3. They function as important references to 
correct for any non-specific affinity effects induced by e.g. addition of extra bulk or 
hydrophobicity. 
 
 
Scheme 1. Synthetic Pathway for compounds 1a-b and 2a-b 
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Reagents and conditions. (i) Decanedioyl dichloride (a-series, n=8) or dodecanedioyl 
dichloride (b-series, n=10), Et3N, dioxane, rt, overnight.
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Scheme 2. Synthetic Pathway for compound 1c 
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Reagents and conditions. (i) Decanedioyl dichloride, Et3N, dioxane, rt, overnight.
 
 
Table 1. pKi and pIC50 values for hCXCR3 of the compounds 1a-c, 2a-b and 3a-b as 
determined by the displacement of [125I]CXCL10 binding and by the inhibition of CXCL11-
induced [3H]-IPx accumulation, respectively. 
compound
pKia
([125I]CXCL10) 
 
pIC50b
1a (VUF10091) 5.86 ± 0.10 6.04 ± 0.07 
1b (VUF10089) 5.71 ± 0.05 6.83 ± 0.09 
1c (VUF10143) 5.15 ± 0.13 5.17d 
2a (VUF10092) 5.15 ± 0.18 4.92 ± 0.09 
2b (VUF10090) 5.71 ± 0.13 5.61 ± 0.05 
3a 7.46 ± 0.10 7.36 ± 0.02 
3b 6.47 ± 0.09c nte 
a The binding experiments were carried out on cell membranes fractions from HEK-293 
cells stably expressing the human CXCR3 receptor. The compounds were tested for their 
ability to displace [125I]CXCL10 binding. The values are represented as the mean ± S.E.M 
of at least three independent experiments. 
b Experiments were performed on COS-7 cells transfected with cDNA encoding human 
CXCR3 and Gqi5. The compounds were tested for their ability to inhibit [3H]-IPx 
accumulation. Cells were stimulated with 10 nM CXCL11. The values are represented as 
the mean ± S.E.M of at least two independent experiments. 
c Data published.30 
d Tested only one time. 
e Not tested. 
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Figure 5. Effect of 
compounds 1a-b, 2a-b 
and 3a on CXCR3-
mediated PLC activity by 
CXCL11. PLC activity was 
measured by the 
production of [3H]IPx 
from radioactively labeled 
inositol in COS-7-CXCR3. 
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Reference compounds 3a-b, in accord to previous published data,30,31 showed the 
highest affinity values for CXCR3 (pKi 3a = 7.46 ± 0.10, pKi 3b = 6.47 ± 0.09). In 
comparison to the reference compounds 3a and 3b, their bivalent analogues 1a-b 
exhibit a decreased affinity and antagonistic activity at the human CXCR3 receptor (Table 
1). Indeed, the bivalent analogues with eight (1a) or ten (1b) methylene units in the 
spacer display a dramatic decrease in affinities when compared to 3a, and four (1a) and 
six (1b) times lower affinities when compared to 3b. Compound 1a is the best bivalent 
analogue in this small series, showing a pKi value of 5.86. 
The bivalent analogue of compound 4 (i.e. 1c) showed a decrease in affinity confirming 
the importance of the 3H-pyrido[2,3-d]pyrimidin-4-one scaffold properly substituted with 
e.g. pyridin-3-ylmethyl and p-ethoxy-phenyl moieties for the affinity at CXCR3 (4: IC50 = 
3.2 M, see Chapter 3). 
The monomeric carboxylic acid analogues (2a-b) of compounds 1a and 1b were also 
tested. Unexpectedly, 2b has an affinity value equal to that of its bivalent analogue 1b, 
whereas 2a has a lower affinity compared to 1a. This means that 1b may display non-
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specific binding effects resulting from e.g. addition of extra hydrophobic bulk by the 
spacer. 
In order to inspect functional activity, the effect of compounds 1a-c, 2a-b and 3a on 
CXCL11-induced PLC activity was determined (see Figure 5 for exemplary curves). All 
compounds showed the ability to inhibit the [3H]IPx accumulation. However, none of 
them was superior to 3a (pIC50 = 7.36 ± 0.02). Among the new compounds in the 
series, the best CXCR3 antagonistic activity is shown by the dimeric analogues (1a-b) 
especially when compared to their respective carboxylic momomeric analogues (2a-b). 
In fact, compounds 2a and 2b are more than ten times less potent than the bivalent 
counterparts (1a, 1b). The decyl-bivalent ligand (1b) showed the best activity, four 
times lower than reference compound 3a but six timer higher than its analogue with an 
eight-methylene spacer (1a).  
In general, most tested antagonists inhibited CXCL11-induced receptor activation with 
pIC50 values that qualitatively correlated with the measured affinity at CXCR3 (CXCL10). 
However, an apparent discrepancy in this trend can be observed when inspecting the 
affinity and activity of 1b (e.g. in contrast to 1a). The relevance of this is currently 
unclear. 
Conclusions 
 
In this first study on bivalent ligands for CXCR3, we identified two bivalent molecules 
(1a-b) displaying micromolar affinity and antagonistic activity towards the CXCR3 
receptor. The discussed bivalent ligands may be used as tools for further investigations 
into possible CXCR3 dimers. 
 
Experimental section 
General 
The solvents were dried according to standard procedures. All reactions were performed 
under an atmosphere of dry nitrogen. 1H NMR spectra were recorded on a Bruker AC-200 
(200 MHz) spectrometer. Flash column chromatography was carried out J. T. Baker silica 
gel was used for flash chromatography. HPLC-MS analyses were conducted using a 
Shimadzu LC-8A preparative liquid chromatograph pump system with a Shimadzu SPD-
10AV UV-Vis detector set at 254 nm, with the MS detection performed with a Shimadzu 
LCMS-2010 liquid chromatograph mass spectrometer. Conditions: Xbridge (C18) 5 μm 
column (100mm x 4.9 mm) with solvent A: 10% buffer pH 8- 90% H2O; solvent B: 10% 
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aqueous buffer pH8 - 90% acetonitrile (30% of B in A). The buffer pH 8 is prepared with 
ammonium bicarbonate in H2O (0.4 % w/v) adjusted to pH=8 with ammonium 
hydroxide. The total run time was 20 min. The synthesis of intermediates 5 and 6 has 
been described elsewhere30,31. 
N1,N10-bis(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-
yl)ethyl)-N1,N10-bis(pyridin-3-ylmethyl)decanediamide (1a) and 10-((1-(3-(4-
ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)(pyridin-3-
ylmethyl)amino)-10-oxodecanoic acid (2a) 
To a solution of compound 5 (0.12 g, 0.30 mmol) in 1,4-dioxane (20 mL), triethylamine 
(0.04 mL, 0.30 mmol) was added. After 30 min, decanedioyl dichloride (0.03 mL, 0.15 
mmol) was added. The solution was stirred overnight. HPLC-MS analysis on the crude 
material revealed two compounds corresponding to 1a (tR = min 7.40) and 2a (tR = min, 
4.53) which were isolated by flash column chromatography with butanol/acetic 
acid/water (14:5:1). This afforded 1a (0.03 g, 21%) and 2a (0.02 g, 23%) as pale 
yellow oils. 
1a: 1H NMR (CDCl3) : 0.82-1.57 (m, 12H), 1.57-1.98 (m, 8H), 2.05-2.44 (m, 2H), 3.92-
4.31 (m, 4.02H), 4.83-2.29 (m, 3.8H), 6.51-7.19 (m, 9H), 7.30-7.68 (m, 5H), 8.16-8.51 
(m, 6H), 8.88-8.97 (m, 2H) Peak splitting due to the presence of rotamers was observed. 
M/z = 485.5 [M+2/2]2+ 
2a: 1H NMR (CDCl3) : 0.87-1.21 (m, 21H), 2.12-2.36 (m, 4H), 4.06-4.41 (m, 2H), 5.03-
5.34 (m, 2H), 7.01-7.24 (m, 3H), 7.46-7.71 (m, 4H), 8.22-8.58 (m, 3H), 8.96-9.01 (m, 
1H). Peak splitting due to the presence of rotamers was observed. M/z = 586.2 [M+1]+. 
N1,N12-bis(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-
yl)ethyl)-N1,N12-bis(pyridin-3-ylmethyl)dodecanediamide (1b) and 12-((1-(3-
(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)(pyridin-
3-ylmethyl)amino)-12-oxododecanoic acid (2b) 
To a solution of compound 5 (0.36 g, 0.91 mmol) in 1,4-dioxane (20 mL), triethylamine 
(0.13 mL, 0.91 mmol) was added. After 30 min, dodecanedioyl dichloride (0.11 mL, 0.46 
mmol) was added. The solution was stirred overnight. HPLC-MS analysis on the crude 
material revealed two compounds corresponding to 1b (tR = min 10.38) and 2b (tR = 
min 7.53) which were isolated by flash column chromatography with butanol/acetic 
acid/water (14:5:1). This afforded 1b (0.01 g, 24%) and 2b (0.04 g, 14%) as pale 
yellow oils. 
1b: 1H NMR (CDCl3) : 0.82-1.63 (m, 30 H), 1.98-2.19 (m, 2H), 2.18-2.42 (m, 2H), 
3.91-4.41 (m, 3.7H), 4.72- 5.11 (m, 4.3H) 6.50-7.22 (m, 8H), 7.40-7.71 (m, 6H), 8.12-
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8.60 (m, 6H), 8.90-9.11 (m, 2H). Peak splitting due to the presence of rotamers was 
observed. M/z = 499.5 [M+2/2]2+.  
2b: 1H NMR (CDCl3) : 0.88-1.25 (m, 25H), 2.14-2.35 (m, 4H), 4.05-4.41 (m, 2.2H), 
5.01-5.36 (m, 1.8H), 7.02-7.24 (m, 3H), 7.45-7.68 (m, 4H), 8.27-8.61 (m, 3H), 8.98-
9.01 (m, 1H). Peak splitting due to the presence of rotamers was observed. M/z = 614.3 
[M+1]+ 
N1,N10-bis(2-(dimethylamino)ethyl)-N1,N10-bis(1-(3-(4-fluorophenyl)-4-oxo-
3,4-dihydroquinazolin-2-yl)ethyl)decanediamide (1c) 
Compound 6 (0.35 g, 1 mmol) and triethylamine (0.14 mL, 1 mmol) were dissolved in 
1,4-dioxane (10 mL). After 30 min, decanedioyl dichloride (0.10 mL, 0.5 mmol) was 
added and the solution was stirred overnight. The residue was dissolved in 
dichloromethane (30 mL) and washed with saturated aqueous Na2CO3 solution (30 mL), 
then twice with water (50 mL). The organic phases were dried over anhydrous Na2SO4, 
filtered and evaporated. The crude material was purified by flash chromatography on 
silica gel eluting with ethyl acetate/methanol (9:1) to afford the desired compound (0.09 
g, 21%) as white solid. 1H NMR (CDCl3) : 0.88-1.70 (m, 22H), 1.91-2.64 (m, 16H), 
3.21-3.59 (m, 4H), 4.73 (q, 0.6H), 5.21 (q, 1.4H), 6.99-7.81 (m, 14.5H), 7.89-8.31 (m, 
1.5H). Peak splitting due to the presence of rotamers was observed. 
 
 
Pharmacology 
 
Radioligand binding assay 
HEK293-CXCR3 cells were grown at 5% CO2 at 37°C in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum, 250 mg/mL G-418, 50 IU of 
penicillin per mL, and 50 mg of streptomycin per mL. These cells were seeded in poly-L-
Lysine-coated 48-well plates. After 24h, binding was performed on whole cells for 4h at 
4°C using approximately 70 pM [125I]-labelled CXCL10 (Perkin Elmer Life Science, 
Boston, USA) in binding buffer (50 mM HEPES [pH 7.4], 1 mM CaCl2, 5 mM MgCl2, 0.5% 
BSA) containing increasing concentrations of the indicated compounds. After incubation, 
cells were washed three times with ice-cold binding buffer supplemented with 0.5 M 
NaCl. Subsequently, cells were lysed and counted in a Wallac Compugamma counter. 
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[3H]Inositol phosphate production 
COS-7 cells were transfected with CXCR3 and Gqi5 chimeric protein.32 24 h after 
transfection cells were labeled overnight in inositol free medium (modified Eagle's 
medium with Earle's salts) supplemented with 2 mM L-glutamine, L-cysteine, L-leucine, 
L-methionine, L-arginine, glucose, 0.2% bovine serum albumin, and 2 Ci/mL myo-[2-
3H]inositol (Amersham Pharmacia Biotech, Roosendaal, The Netherlands). Subsequently, 
the labeling medium was aspirated, cells were washed for 10 min with Dulbecco's 
modified Eagle's medium containing 25 mM HEPES (pH 7.4) and 20 mM LiCl. Cells were 
preincubated for 10 minutes with/or without the indicated compounds and incubated for 
2 h in the same medium in the absence or presence of 10 nM CXCL11 or 30 nM CXCL10. 
The incubation was stopped by aspiration of the medium and addition of cold 10 mM 
formic acid. After 90 min of incubation on ice, inositol phosphates were isolated by anion 
exchange chromatography (Dowex AG1-X8 columns, Bio-Rad) and counted by liquid 
scintillation. 
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Summary
 Design, synthesis and pharmacological evaluation of non-
peptidergic ligands for the human CXCR3 receptor
The CXCR3 receptor belongs to the class of chemokine receptors, themselves the 
endogenous receptors for chemokine proteins and part of the superfamily of G protein-
coupled receptors (GPCRs). CXCR3 is thought to be involved in various diseases. Based 
on expression studies or knock-out models, CXCR3 has been shown to play a role in 
many inflammatory conditions, such as multiple sclerosis, rheumatoid arthritis and 
psoriasis. Much attention was also devoted to CXCR3 as a key factor in the rejection of 
donor organs after transplantation, although some controversy has emerged here in the 
last few years. Furthermore, CXCR3 appears to be involved in metastasis of melanoma 
and colon cancer cells to the lymph nodes and in metastasis of breast cancer cells to the 
lung. All this has led to CXCR3 being recognized as an interesting pharmacological target 
with potential therapeutic relevance. Toward this end, CXCR3 antagonists are believed to 
represent a means to capitalize on this therapeutic promise. 
The goal of the research described in this thesis was the development of various types of 
CXCR3 antagonists and the identification of structural requirements for antagonism at the 
human CXCR3 receptor. The thesis focuses on the design, synthesis and pharmacological 
evaluation of small non-peptidergic ligands for CXCR3.  
A review on small non-peptidergic CXCR3 ligands is presented in Chapter 1, in which the 
status concerning the medicinal chemistry on CXCR3 is described. It is shown how 
publications on CXCR3 antagonists did not start to emerge until 2006. The current set of 
CXCR3 antagonist classes display high chemical variability. However, only one compound 
(AMG 487) is known to have progressed to Phase II clinical trials where it showed a lack 
of efficacy, probably due to pharmacokinetic problems. 
The aim of the thesis is described in Chapter 2. The synthesis and pharmacological 
evaluation of novel ligands for CXCR3 can provide key information for better 
understanding the molecular features necessary for affinity and activity on CXCR3. This 
in turn will lead to a better understanding of ligand-receptor interactions and therefore to 
Summary
new insights and ideas for the generation of novel classes of CXCR3 ligands. This overall 
goal was pursued using medicinal chemistry approaches iniated from various angles. 
These are addressed in the different chapters. 
In Chapter 3, the synthesis and structure-activity relationships of a series of 3-phenyl-
3H-quinazolin-4-one derivatives are described. In this work, a compound reported in a 
patent was selected and SAR explorations involved removing the decanoyl chain and 
inspecting different 4-phenyl ring substituents. This approach enabled the identification 
of a compound (VUF 5834) which showed submicromolar affinity for CXCR3. Moreover, 
this compound effectively inhibits CXCR3-mediated IP3 production and calcium 
mobilization in cells expressing the human CXCR3. It also abrogates CXCR3-mediated 
actin polymerization and chemotaxis of human T cells. Therefore, it represents a valuable 
tool for future lead optimization programs. 
Deeper inspection of the active ligand described in Chapter 3 (VUF 5834) was pursued. 
Chapter 4 provides a detailed SAR-study of the 3H-quinazolin-4-one and 3H-pyrido[2,3-
d]pyrimidin-4-one series of CXCR3 antagonists, which allows linking VUF 5834 to the 
known AMG 487 antagonist. These studies revealed the importance of the (4-fluoro-3-
(trifluoromethyl)phenyl)acetyl and the 3-methylene-pyridine moieties in achieving high 
affinity. The superior affinities of AMG 487 and NBI-74330 were confirmed to be in the 
nanomolar range, therefore reinstating these compounds as valuable tools for targeting 
CXCR3 in various therapeutic areas. 
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Chapter 5 presents the results of a search for novel scaffolds using a pharmacophore 
model. Based on this model, the in-house database was screened. Unfortunately this 
approach did not identify any compound with encougaring affinity. However, a close 
inspection of the compounds possessing some affinity allowed the identification of the 
imidazole core as a common feature. The similarity of these imidazole compounds to 
some imidazolium derivatives from a patent application by Smithkline Beecham was 
observed. Based on this, the two compound classes were merged which led to a series of 
new imidazolium derivatives with CXCR3 affinity. The best compound of this series 
showed a submicromolar affinity for CXCR3 and bore an interesting dichloroaniline-unit. 
The molecular mechanism of action of diverse small molecule antagonists at the CXCR3 
receptor is addressed in Chapter 6. Five different non-peptidergic molecules, belonging to 
three different chemical classes including the ones described in Chapters 3-5, were used. 
The ligands were tested at rat and mouse CXCR3 as well as at CXCR3 from rhesus 
macaque. Except for TAK-779, all compounds display slightly lower affinity for rodent 
CXCR3 than for primate CXCR3. Additionally, the molecular mechanism of action of the 
various antagonists at the human CXCR3 receptor has been characterized, revealing that 
all tested compounds act as noncompetitive antagonists at CXCR3. Moreover, all 
compounds except one (TAK-779) showed inverse agonistic properties at a constitutively 
active mutant of CXCR3. This suggests a different mode of interaction at CXCR3 for some 
classes of compounds. 
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Chapter 7 deals with the first studies on “bivalent ligands” for CXCR3. This approach is 
based on linking two CXCR3 pharmacophores with the goal of targeting putative CXCR3 
dimers. This has the potential to afford more efficacious and selective ligands. Using the 
3H-quinazolin-4-one and 3H-pyrido[2,3-d]pyrimidin-4-one scaffolds described in 
Chapters 3 and 4, bivalent counterparts with amido-alkyl spacers were synthesized. This 
resulted in two bivalent molecules displaying micromolar affinity and antagonistic activity 
toward the CXCR3 receptor. The compounds in this chapter can be used as tools for 
further investigations into possible CXCR3 dimers. 
Taken together, this thesis describes the design and synthesis of small non-peptidergic 
ligands for CXCR3 by means of several conceptually different approaches, such as lead 
optimization, library screening, molecular design techniques and the use of ‘bivalent 
ligands’. The obtained ligands have provided more insights in the structural requirements 
that are important for binding and functional activity at CXCR3. Ultimately this knowledge 
will be helpful to develop compounds with an improved activity and selectivity profile at 
CXCR3. 
Samenvatting
Ontwerp, synthese en farmacologische evaluatie van non-
peptiderge liganden voor de menselijke CXCR3 receptor 
De CXCR3 receptor behoort tot de klasse van chemokine receptoren. Deze fungeren als 
de endogene receptoren voor chemokine signaaleiwitten en maken deel uit van de 
superfamilie van G eiwit-gekoppelde receptoren (GPCRs). CXCR3 lijkt bij verscheidene 
ziektes betrokken te zijn. Op basis van expressiestudies en/of knock-out modellen is 
bijvoorbeeld aangetoond dat CXCR3 een rol speelt bij vele ontstekingsgerelateerde 
aandoeningen zoals multiple sclerose, rheumatoide artritis and psoriasis. Ook heeft 
CXCR3 de aandacht getrokken door een mogelijke sleutelrol in de afstoting van 
donororganen door het lichaam. CXCR3 lijkt ook betrokken te zijn bij de metastase van 
huid- en darm-kankercellen naar de lymfeknopen en bij de metastase van 
borstkankercellen naar de longen. Dit heeft alles heeft ertoe geleid dat CXCR3 inmiddels 
wordt gezien als een farmacologisch interessant eiwit met duidelijke therapeutische 
relevantie. De ontwikkeling van CXCR3 blokkers (antagonisten) is één van de manieren 
om deze relevantie verder te bestuderen en hopelijk waar te maken. 
Het doel van het onderzoek dat beschreven staat in dit proefschrift is de ontwikkeling 
van verscheidene klassen van CXCR3 antagonisten en het identificeren van de 
moleculaire elementen die vereist zijn voor antagonisme op CXCR3. Het werk in dit 
proefschrift is in het bijzonder toegespitst op het ontwerpen, synthetiseren en 
farmacologisch evalueren van kleine, non-peptiderge liganden voor CXCR3. 
Hoofdstuk 1 beschrijft in het algemeen de medicinale chemie op de CXCR3 receptor en 
verschaft daarbij een overzicht van reeds bestaande non-peptiderge CXCR3 liganden. Het 
laat zien dat publicaties over CXCR3 liganden pas rond 2006 hun intrede deden. Getoond 
wordt hoe de reeds bekende klassen een grote variëteit aan chemische structuren aan de 
dag leggen. Toch is het zo dat, voor zover bekend, pas één verbinding (AMG487) het 
stadium van klinische studies heeft gehaald. Helaas viel deze verbinding in Fase 2 
klinisch onderzoek af door gebrek aan effectiviteit. Men vermoedt dat farmacokinetische 
problemen hieraan ten grondslag kunnen liggen. 
Samenvatting 
In Hoofdstuk 2 wordt het doel van dit proefschrift in meer detail beschreven. De beoogde 
synthese en farmacologische evaluatie van nieuwe liganden voor de CXCR3 receptor zal 
belangrijke informatie verschaffen over de moleculaire elementen die benodigd zijn voor 
affiniteit en activiteit op CXCR3. Dit zal weer leiden tot een beter begrip van de 
interacties die CXCR3 liganden aangaan met CXCR3 en tot optimaal beargumenteerde 
voorstellen voor nieuwe klassen van antagonisten. 
In het proefschrift wordt het algemene doel benaderd vanuit verschillende invalshoeken, 
zoals te lezen is in de verschillende hoofdstukken. 
Hoofdstuk 3 behandelt de synthese en structuur-activiteits relaties (SAR) van een serie 
3H-quinazolin-4-on derivaten. Een 3H-quinazolin-4-on dat gerapporteerd was in een 
octrooi werd gekozen als geschikt uitgangspunt. Vervolgens werden SAR studies 
uitgevoerd waarin de rollen van de decanoyl groep en phenyl substituenten verder 
bekeken werden. Deze studies leidden uiteindelijk tot de verbinding VUF5834 die 
submicromolaire affiniteit vertoont voor CXCR3. De verbinding is ook in staat om effectief 
CXCR3-geïnduceerde productie van IP3 alsmede calcium mobilisatie te remmen in cellen 
die de menselijke CXCR3 receptor tot expressie brengen. Ook bleek dat de stof 
polymerisatie van actine en de chemotaxis van menselijke T cellen reduceert. Bij beide 
processen speelt CXCR3 een belangrijke rol. Geconcludeerd kan worden dat VUF5834 een 
waardevolle lead is voor verdere studies. 
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Hoofdstuk 4 beschrijft een gedetailleerde SAR studie van twee klassen CXCR3 
antagonisten, namelijk die van de 3H-quinazolin-4-onen (e.g. VUF5834, Hoofdstuk 3) en 
die van de 3H-pyrido[2,3-d]pyrimidin-4-onen (waarvan AMG 487 een voorbeeld is). De 
SAR resultaten voor beide klassen werden in detail met elkaar vergeleken hetgeen 
resulteerde in een aantal gemeenschappelijke SAR trends. Zo bleek dat de (4-fluoro-3-
(trifluoromethyl)phenyl)acetyl en de 3-methylene-pyridine elementen in beide klassen 
belangrijk zijn om hoge affiniteit voor CXCR3 te bewerkstelligen. Deze studies 
bevestigden ook dat AMG 487 en NBI-74330 heel effectieve CXCR3 antagonisten zijn en 
dat het gebruik van deze twee als sleutelverbindingen in CXCR3 onderzoek dus 
gerechtvaardigd is.  
In Hoofdstuk 5 wordt een aanpak beschreven waarbij een farmacofoor model als de basis 
fungeerde voor het screenen van een in-house database. Helaas leidde dit vooralsnog 
niet tot nieuwe hits met hoge affiniteit. Wel werd opgemerkt dat veel van de matige hits 
een imidazool groep als gemeenschappelijk structuurelement bezaten en dat deze 
imidazool overeenkomsten vertoonde met een geoctrooieerde klasse antagonisten, 
namelijk die van imidazolium zouten. Uitgaande van deze interessante overeenkomst 
werd besloten om de structuren van de gevonden matige hits en die van de 
geoctrooieerde stoffen te combineren tot een nieuw chemotype imidazolium zouten. De 
beste verbinding uit deze nieuwe klasse bevatte een opmerkelijk dichloroaniline-element 
en vertoonde submicromolaire affiniteit voor CXCR3.   
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Samenvatting 
Het moleculaire werkingsmechanisme van diverse kleine CXCR3 antagonisten wordt 
behandeld in Hoofdstuk 6. Vijf verschillende non-peptiderge liganden uit drie 
verschillende klassen (inclusief diegene die in Hoofdstukken 3-5 zijn beschreven) zijn 
hierbij in detail bestudeerd. De liganden werden getest op rCXCR3 en mCXCR3 maar ook 
op CXCR3 van rhesus macaque. Met uitzondering van TAK-779 vertoonden alle 
verbindingen een ietwat lagere affiniteit voor CXCR3 van knaagdieren dan voor CXCR3 
van primaten. Ook werd het moleculaire werkingsmechanisme van de stoffen op 
menselijk CXCR3 bekeken. Hieruit volgde dat alle verbindingen fungeren als non-
competitieve antagonisten. Ook bleek dat, met uitzondering van TAK-779, de 
verbindingen zich als inverse agonisten gedroegen op een constitutief actieve CXCR3 
mutant. De verkregen resultaten suggereren dat verschillende klassen CXCR3 
antagonisten verschillende werkingsmechanismen op CXCR3 kunnen hebben. 
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Hoofdstuk 7 beschrijft verkennende studies naar het gebruik van “bivalente” liganden 
voor CXCR3. In deze aanpak worden twee bekende farmacoforen verbonden door een 
moleculaire linker. Het idee hierachter is dat, als CXCR3 uit dimeren zou bestaan, 
bivalente liganden efficiënt beide receptoren van zo’n dimeer kunnen binden. In het 
algemeen kan dit leiden tot efficiëntere en selectievere liganden. Gebaseerd op de 3H-
quinazolin-4-on and 3H-pyrido[2,3-d]pyrimidin-4-on chemotypes beschreven in 
Hoofdstukken 3 en 4 werd een aantal bivalente liganden gemaakt met amido-alkyl 
linkers. Farmacologische studies lieten zien dat twee van de gemaakte bivalente liganden  
micromolaire affiniteit voor CXCR3 bezaten en zich als antagonisten gedroegen in een 
functionele test. Deze twee liganden zijn dan ook geschikt voor vervolgstudies gericht op 
mogelijke CXCR3 dimeren. 
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Het gehele proefschrift in ogenschouw nemend kan gezien worden dat het ontwerpen en 
synthetiseren van non-peptiderge CXCR3 liganden is nagestreefd vanuit verschillende 
invalshoeken. Er is bijvoorbeeld gebruik gemaakt van lead optimalisatie, library 
screening, moleculaire modelling en bivalente liganden. De verkregen CXCR3 liganden 
verschaffen nieuwe inzichten in de moleculaire structuurelementen die belangrijk zijn 
voor binding en activiteit op CXCR3. Deze kennis zal uiteindelijk bijdragen aan de verdere 
ontwikkeling van liganden voor CXCR3.  
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